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ABSTRACT  
Infertility is becoming increasingly more common, affecting 1 in 6 couples in the UK and an 
estimated 48.5 million couples worldwide. Although there are a number of hormonal 
treatments, there has been very little advance in new treatments in the last decade. However, 
assisted reproductive therapies including in vitro fertilisation (IVF) are being more commonly 
used and in fact 2% of babies were conceived in the UK through IVF in 2012, although the 
average pregnancy rate per cycle has remained stable at only 20% for several years. Therefore, 
there is a huge scope for developing new treatments to help with the rising problem of 
infertility.  
Kisspeptin is a hypothalamic hormone that was associated for the first time with reproduction 
in 2003 and is now emerging as a possible novel future therapeutic for reproductive and fertility 
disorders. Kisspeptin signalling is vital for normal reproductive function and critically 
regulates GnRH secretion in response to metabolic and environmental cues. Previous research 
studies have shown that kisspeptin can be administered safely to humans with no side effects 
and therefore, my research builds on this previous work. I have focused on investigating how 
best to optimise the use of kisspeptin for future therapy, by firstly examining which isoform of 
kisspeptin is more potent and how this compares to GnRH (a current treatment modality). 
Secondly, I investigated whether continuous subcutaneous administration of kisspeptin would 
be a viable treatment modality, as in the future kisspeptin could be administered in a 
subcutaneous pump device and managed at home by the patient. I also investigate how baseline 
oestradiol levels may influence the gonadotrophin response to kisspeptin. Lastly, I investigate 
how kisspeptin interacts with two other neuropeptides to affect gonadotrophin secretion, by co-
administration of them in healthy males.   
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1.1 The reproductive axis 
Reproduction is regulated by a cascade of hormonal signals called the hypothalamic pituitary 
gonadal axis (HPG). This neuro-hormonal system encompasses three major areas; the 
hypothalamus, the pituitary gland and the gonads, which are connected by positive and negative 
feedback regulatory loops (Knobil 2005) (Figure 1.1).  
In humans, the hypothalamus is an almond sized gland situated rostral to the thalamus and 
caudal to the brain stem. It is bordered anteriorly by the optic chiasm, posteriorly by the 
mammillary body and laterally by the temporal lobes and optic tracts (Saper and Lowell 2014). 
There are three prominent areas of the hypothalamus, the anterior, middle and posterior regions 
containing several nuclei as shown in figure 1.2; 1) the supraoptic or anterior region is involved 
in autonomic function, circadian rhythm, vasopressin release and contains the preoptic area 
(POA); 2) the tuberal or middle region, contains several nuclei including the infundibular 
nucleus which is homologous to the arcuate nucleus (ARC) in animals, it has a predominant 
role in feeding and an endocrine role in secreting releasing hormones into the portal system 
which connects to the pituitary; 3) the mammillary or posterior region at the level of the 
mammillary bodies are thought to be involved in memory and through connections to the 
limbic system may be involved in regulating arousal and stress responses (Saper and Lowell 
2014). The median eminence (ME) forms the inferior border of the hypothalamus connecting 
it to the pituitary via the pituitary stalk (infundibulum).  
There are about 800-2000 hypothalamic gonadotrophin releasing hormone (GnRH) neurones 
distributed in the POA and adjacent sites in the rostral region of the hypothalamus (Lehman et 
al. 1986; Kawano and Daikoku 1981) which project to the ME where GnRH has been packed 
into vesicles and is released from nerve terminals (Silverman, Jhamandas, and Renaud 1987). 
In addition to this rostral area, a small number of GnRH neurons are located in the medial basal 
hypothalamus (MBH) (Lehman et al. 1986; Funabashi, Jinnai, and Kimura 1997; Silverman et 
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al. 1977). In certain areas of the brain the blood brain barrier (BBB) is diminished such that the 
peripheral and central circulation may communicate, two of these areas are associated with 
GnRH neurons principally the ME and the organum vasculosum of the lamina terminalis 
(OVLT). GnRH neurons terminate in the ME and secrete GnRH into the hypophyseal portal 
circulation connecting to the pituitary gland (Prevot et al. 2010) and also terminate at the OVLT 
(Herde et al. 2011), indicating that GnRH secretion can be influenced by peripheral factors.  
GnRH is secreted in a pulsatile manner and GnRH pulses correspond with LH pulses (Moenter 
et al. 1992). GnRH is a highly conserved decapeptide (Stevenson et al. 2012), which acts on 
GnRH receptors on gonadotrophs in the anterior pituitary gland (<10% of all pituitary cells) to 
secrete gonadotrophins – luteinizing hormone (LH) and follicle stimulating hormone (FSH) 
into the general circulation (Schally et al. 1971).  
LH and FSH act on the gonads to promote gametogenesis and sex steroid synthesis and release. 
In women, gonadotrophins stimulate ovarian granulosa cells to produce oestradiol as well as 
follicular growth and thus maintains regular menstrual cycles. In men, LH stimulates Leydig 
cells in the testes to secrete testosterone and FSH acts on Sertoli cells in seminiferous tubules 
to stimulate spermatogenesis. Inhibin is produced by ovarian granulosa cells in females and 
Sertoli cells in men (de Kretser et al. 2002), and together with the sex steroids exert negative 
feedback effects on gonadotrophin secretion at the level of the pituitary and hypothalamus.  
Negative feedback is such that sex steroids cause a reduction in further gonadotrophin secretion 
by acting at the hypothalamus and pituitary (Nakai et al. 1978; Akema, Tadokoro, and Kimura 
1984). In females oestradiol also exerts a positive feedback effect on gonadotrophin secretion 
at the time of the pre-ovulatory LH surge, where an elevation in oestradiol induces a surge of 
GnRH secretion leading to the LH surge (Xia et al. 1992; Clarke et al. 1989). Figure 1.3 details 
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the phases of the menstrual cycle in women and similarly female animals also undergo 
ovulatory cycles.   
 
Figure 1.1: The hypothalamic pituitary gonadal axis (HPG).  
Gonadotrophin releasing hormone (GnRH) neurons in the hypothalamus secrete GnRH into 
the portal circulation connecting to the pituitary. GnRH acts on the GnRH receptor (GnRH-R) 
on anterior pituitary gonadotroph cells to stimulate secretion of luteinizing hormone (LH) and 
follicle stimulating hormone (FSH) which both act on the gonads. FSH promotes 
spermatogenesis in men and ovarian follicular growth in women as well as inhibin production. 
LH promotes testosterone secretion in men and oestradiol secretion in women and together 
with inhibin negatively feedback onto the pituitary and hypothalamus to regulate further 
gonadotrophin secretion. Pre-ovulation oestradiol exerts positive feedback effects on the 
hypothalamus and pituitary resulting in an LH surge to trigger ovulation.  
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Figure 1.2: Structures of the hypothalamus in humans. The diagram below shows a mid-
sagittal section through the brain showing the hypothalamic nuclei above the pituitary 
surrounded by the optic chiasm, thalamus and mammillary body. The purple shaded areas and 
text are involved in GnRH and gonadotrophin secretion; GnRH neurons predominantly in the 
preoptic area (POA) project to the median eminence where they secrete GnRH into the 
hypophyseal circulation which reaches the anterior pituitary via the infundibulum. GnRH then 
acts on pituitary gonadotrophs to secrete gonadotrophins. The infundibular or arcuate nucleus 
is also involved in GnRH regulation and will be discussed later in the thesis.  
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Figure 1.3: Menstrual cycle.  
After menstruation (or menses) ovarian follicles develop and the predominant mature follicle 
is released at ovulation. Prior to ovulation there is a rise in oestradiol which induces a surge of 
LH which triggers ovulation of the ovum from the ovary. The remnant of the expelled follicle 
in the ovary (corpus luteum) regresses and produces progesterone to thicken and maintain the 
endometrium ready for implantation. However, if fertilisation of the ovum does not occur 
progesterone levels fall triggering menstruation once again. The cycle takes on average 28days.  
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1.2 The GnRH pulse generator  
GnRH secretion occurs as basal tonic secretion in pulses as well as a surge pre-ovulation. 
Pulsatile GnRH secretion at the right frequency is essential for coordinated pulsatile 
gonadotrophin secretion from pituitary gonadotrophs (Belchetz et al. 1978; Knobil et al. 1980; 
Santoro, Filicori, et al. 1986). Studies have shown that GnRH administered at 1h intervals to 
rhesus monkeys with hypothalamic lesions restored gonadotrophin secretion and long term 
replacement at this frequency restored menstrual cyclicity (Belchetz et al. 1978; Knobil et al. 
1980). However, studies where GnRH injections were given more or less frequently resulted 
in either suppression or reduction of LH secretion (Wildt et al. 1981; Pohl et al. 1983). 
Continuous infusion of GnRH also results in a decline of gonadotrophins most likely due to 
desensitisation and down regulation of pituitary GnRH receptors (Belchetz et al. 1978; Mason 
et al. 1994).   
The mechanism governing GnRH secretion has been the focus of much research over the last 
few decades. It has been proposed that either GnRH neurons themselves have the intrinsic 
ability to secrete GnRH in co-ordinated pulses or other neurons stimulate GnRH neurons and 
synchronise GnRH release (the GnRH pulse generator). GnRH secretion is dependent on many 
regulatory factors including sex steroid milieu and metabolic status and therefore, any pulse 
generator or the GnRH neurons themselves must be able to respond to these factors and regulate 
secretion appropriately.   
In vitro studies of GnRH neurons and foetal GnRH neurons taken from the olfactory placode 
before migration to the hypothalamus have shown their ability to release GnRH in synchronised 
bursts (Terasawa, Keen, et al. 1999; Terasawa, Schanhofer, et al. 1999; Richter, Keen, and 
Terasawa 2002). Immortalised GT-1 cells are a GnRH producing cell line that also show 
regular pulsatile GnRH release in vitro (Krsmanovic et al. 1992; Martinez de la Escalera, Choi, 
and Weiner 1992).  
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Neuroanatomical studies have shown that there are shared synapses between GnRH neurons as 
well as “dendro-dendritic bundling” or connections; all of which may contribute to 
synchronizing GnRH release in pulses (Campbell et al. 2009). GnRH fibres project to the ME 
and have characteristics of both axons and dendrites and are thus named dendrons (Herde et al. 
2013). 
In vitro studies of cultured MBH explants from guinea pigs show pulsatile GnRH secretion 
(Giri and Kaufman 1994), however, the MBH contains very few GnRH cell bodies in most 
animal species (Silverman et al. 1982; Silverman et al. 1977; Goldsmith et al. 1990), suggesting 
an alternate neuronal source of stimulation to GnRH neurons.   
Historic experiments using the Halasz knife technique involved deafferentation of the MBH 
from the rest of the brain but preserving its connection with the pituitary via the portal system. 
These experiments showed that deafferentation of the MBH did not affect pulsatile LH or the 
post castration rise of LH, but did prevent ovulation in rats, indicating the MBH is an important 
area in regulating pulsatile GnRH secretion but not necessarily directly involved in the pre-
ovulatory GnRH surge (Halasz and Pupp 1965; Blake and Sawyer 1974).  
Foetal MBH transplantation has been shown to stimulate ovarian activity in aged rats 
(Matsumoto et al. 1987), as well as restoring gonadotropin secretion after deafferentation of 
the anterior ARC from the MBH in rats (Ohkura, Tsukamura, and Maeda 1992), however, 
transplantation of foetal cortical tissue did not restore gonadotrophins, indicating that the ARC 
is a key area controlling GnRH secretion. Direct lesions of the ARC in female monkeys 
abolished gonadotrophin secretion (Plant et al. 1978), further indicating the importance of the 
ARC in GnRH secretion.  
Multiunit activity (MUA) is an electrophysiological method to record neuronal activity. MUA 
bursts termed MUA volleys in the MBH (containing the ARC) coincided with pulses of LH 
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secretion in monkeys (O'Byrne and Knobil 1993; Cardenas et al. 1993), rats (Kawakami, 
Uemura, and Hayashi 1982; Kinsey-Jones et al. 2008) and goats (Mori et al. 1991; Tanaka, 
Mori, and Hoshino 1992; Ohkura, Takase, et al. 2009). These studies suggest that neurons in 
the MBH govern pulsatile release of GnRH secretion. Interestingly, the administration of sex 
steroids to gonadectomised animals resulted in a reduction of MUA in the MBH indicating that 
sex steroid negative feedback is likely to be mediated via the MBH to affect GnRH secretion 
(Wakabayashi et al. 2010). One weakness of MUA recording is that only neuronal activity is 
recorded, but does not indicate the cellular source, therefore, these studies cannot isolate 
specific neurons involved, but only anatomical areas.  
Basal tonic GnRH secretion is negatively affected by sex steroid feedback (Karsch et al. 1987; 
Smith, Dungan, et al. 2005; Smith, Clifton, and Steiner 2006), however, GnRH neurons are 
unable to respond to sex steroids directly as they lack the essential oestradiol receptor (ERα) 
involved in negative feedback (Hrabovszky et al. 2000; Hrabovszky et al. 2001).  Some GnRH 
neurons express another form of oestradiol receptor, ERβ (Hrabovszky et al. 2001), however 
this receptor is unlikely to be involved in regulating GnRH secretion since ERβ knockout mice 
show normal fertility (Krege et al. 1998). Therefore, it is likely that GnRH release is controlled 
by other neurons that can respond to sex steroids and then regulate GnRH secretion 
accordingly.  
Post-menopausal and ovariectomy studies have reported hypertrophy in the ARC on sex steroid 
withdrawal, implicating this area of the hypothalamus in mediating sex steroid negative 
feedback actions on GnRH release (Rometo et al. 2007; Alcin et al. 2013). This further 
strengthens the evidence that the GnRH pulse generator is contained within the ARC.  
Deafferentation experiments of the MBH did not impair ovulation despite disruption to 
pulsatile LH secretion and therefore, it is likely that the pre-ovulation GnRH surge resulting in 
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the LH surge to trigger ovulation is not governed by the MBH pulse generator but by another 
area of the hypothalamus. MUA recordings in the MBH during the pre-ovulatory or oestradiol 
induced LH surge did not show a rise in MUA volleys despite the rise in LH (O'Byrne et al. 
1991; Tanaka, Mori, and Hoshino 1992), suggesting that the GnRH surge was not generated in 
the MBH.  
 
1.3 GnRH and pubertal delay 
In highly evolved primates, through infancy and the juvenile period there is a quiescent 
hypogonadotrophic period of low GnRH pulse generator activity, before being reactivated to 
trigger puberty (Plant 2006).  The activation of pulsatile hypothalamic GnRH secretion, 
followed by increased gonadotrophin secretion, is thought to be the key event for the onset of 
puberty (Plant 2002), although this trigger to activation is still yet to be elucidated.   
During embryo development, GnRH neurons migrate with olfactory neurons from the olfactory 
placode to the hypothalamus and the olfactory neurons to the olfactory bulb (Schwanzel-
Fukuda and Pfaff 1989; Wierman et al. 2004). Any disruption to this migration or to GnRH 
secretion in intact GnRH neurons can lead to hypogonadotrophic hypogonadism (HH) and thus 
the failure to produce the necessary gonadotrophins for reproductive function. Less than 20% 
of mutations in patients with isolated HH have been identified (Trarbach, Silveira, and 
Latronico 2007). In 2003, a new genetic mutation resulting in pubertal failure, sexual 
immaturity and HH was identified in two separate consanguineous families who had a mutation 
of the kisspeptin receptor (KISS1R) gene (de Roux et al. 2003; Seminara et al. 2003).  
Kisspeptin is a peptide that had never before been associated with reproduction and since 2003 
a tremendous amount of research has investigated the actions of kisspeptin on the reproductive 
pathway. As explained above the site of the GnRH pulse generator has been implicated in the 
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ARC and a large proportion of kisspeptin expressing neurons which are oestradiol receptor 
positive are located in the ARC, thus indicating that kisspeptin could be the missing link which 
forms part of the GnRH pulse generator and mediates sex steroid feedback effects on GnRH 
secretion.  
 
1.4 Kisspeptin the product of the KISS1 gene 
The kisspeptin gene (KISS1) was discovered in 1996 in Hershey, Pennsylvania and was 
subsequently named after the famous Hershey chocolate kisses (Lee et al. 1996). It was first 
identified as having anti metastatic potential as KISS1 mRNA was highly expressed in 
melanoma tumour cell lines with low tumour cell invasiveness (Lee et al. 1996), and when 
transfected into breast carcinoma cells, expression of KISS-1 correlated with reduced 
metastatic potential (Lee and Welch 1997b), thus it was initially named metastin (Ohtaki et al. 
2001).  
The KISS1 gene encodes a 145 amino acid protein which is part of the RF-amide group. It is 
cleaved into shorter peptides known as kisspeptin-54, 14, 13 and 10 (denoting their number of 
amino acids) (Ohtaki et al. 2001; Kotani et al. 2001) shown in Figure 1.4. All kisspeptins share 
a common C-terminal decapeptide region distinctive of the RF-amide peptide superfamily and 
this is critical for their biological activity (Ohtaki et al. 2001; Muir et al. 2001; Kotani et al. 
2001). There is some uncertainty as to whether the smaller peptides in mammals are in fact the 
degradation of the major product rather than specifically derived.  
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Figure 1.4: Kisspeptin isoforms. Schematic diagram showing the precursor kisspeptin-145 
and its cleavage points for truncation to smaller fragments which all share the same 10 amino 
acid carboxyl-terminus. Adapted from Roseweir and Millar, Hum. Reprod. Update 2009 
(Roseweir and Millar 2009).   
 
 
1.5 KISS1 gene expression  
1.5.1 CNS distribution    
The majority of KISS1 expression in the mammalian brain is found within the hypothalamus 
with predominantly two distinct populations, one in the caudal medial basal hypothalamus 
(MBH) and the second in the rostral POA or anteroventral periventricular nucleus (AVPV).  
The most consistent and largest population of kisspeptin expressing neurons across species is 
found within the MBH particularly the arcuate nucleus (ARC) or infundibular nucleus in 
humans (Lehman et al. 2010). The rostral population is more varied between species, in rodents 
the predominant area is the rostral periventricular area of the 3rd ventricle (RP3V) which 
includes the AVPV and periventricular regions and in non-rodents the POA contains a large 
population of kisspeptin expressing neurons (Gottsch et al. 2004; Smith, Dungan, et al. 2005; 
 
 
29 
 
Smith, Cunningham, et al. 2005; Shahab et al. 2005; Franceschini et al. 2006; Estrada et al. 
2006; Clarkson and Herbison 2006; Adachi et al. 2007; Smith et al. 2007; Kauffman et al. 
2007; Ramaswamy et al. 2008; Rometo et al. 2007; Hrabovszky et al. 2010; Tomikawa et al. 
2010). Immunohistochemistry was used to confirm kisspeptin production in the AVPV and 
ARC of mice (Clarkson and Herbison 2006; Clarkson et al. 2009) and rats (Adachi et al. 2007).  
Other areas of the hypothalamus that contain fewer numbers of kisspeptin cells include the ME, 
infundibular stalk, the dorsomedial nucleus of the hypothalamus and the ventromedial 
hypothalamic nucleus (Clarkson et al. 2009; Lehman, Hileman, and Goodman 2013). 
Kisspeptin expression has also been found in cortical areas and the brain stem as well as areas 
of the limbic system: medial amygdala, bed nucleus of the stria terminalis, dentate gyrus of the 
hippocampus and basal ganglia (Kim et al. 2011; Goodman and Lehman 2012; Lehman, 
Hileman, and Goodman 2013).  
Kisspeptin mRNA and protein have also been isolated in the anterior pituitary in rats and 
primates (Gutierrez-Pascual et al. 2007; Richard et al. 2008; Ramaswamy, Gibbs, and Plant 
2009).  
 
1.5.2 Kisspeptin fibres  
Although KISS1 cell bodies are only found in a few regions of the brain, fibres positive for 
kisspeptin immunoreactivity (kisspeptin-IR) are much more widespread throughout the brain. 
Kisspeptin fibres in rodents and sheep have been isolated in the POA, ARC, MBH, 
paraventricular nucleus and the internal zone of the ME with only a few kisspeptin positive 
fibres in the external zone of the ME (Franceschini et al. 2006; Clarkson and Herbison 2006; 
Clarkson et al. 2009; Lehman, Hileman, and Goodman 2013). ARC kisspeptin neurons project 
to other hypothalamic areas including the POA as well as to limbic areas, whereas kisspeptin 
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neurons in the AVPV project mostly to other hypothalamic nuclei including the ARC (Yeo and 
Herbison 2011). 
 
1.5.3 Peripheral distribution    
KISS1 expression has also been found in a number of non-neural tissues: pancreas, kidneys, 
gonads, adipose tissue and extremely high levels in the placenta; kisspeptin protein also 
circulates at high levels during pregnancy (Lee et al. 1996; Ohtaki et al. 2001; Muir et al. 2001; 
Kotani et al. 2001; Terao et al. 2004; Torricelli et al. 2008). However, the role of kisspeptin in 
the majority of these tissues remains to be determined.  
 
1.6 The kisspeptin receptor (KISS1R) 
1.6.1 Description 
The kisspeptin receptor (KISS1R) gene is located on chromosome 19, was previously known 
as the orphan G-protein-coupled receptor 54 (GPR54), AXOR12 or hOT7T175, but it was not 
until 2001 that kisspeptin was found to cause agonist activity of this receptor (Lee et al. 1999; 
Muir et al. 2001; Ohtaki et al. 2001). All isoforms of kisspeptin (-54, -14, -13, -10) bind and 
stimulate KISS1R (Kotani et al. 2001). It is a seven transmembrane domain receptor and once 
stimulated activates a phospholipase C/calcium dependent pathway which regulates multiple 
ion channels, activating protein kinase C and subsequently, extracellular regulated kinase 
(ERK) (Castellano, Navarro, Fernandez-Fernandez, Castano, et al. 2006; Liu, Lee, and 
Herbison 2008).  
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1.6.2 Receptor expression 
KISS1R is highly expressed in the hypothalamus and limbic system of several species 
including rodents, sheep and monkeys (Lee et al. 1999; Shahab et al. 2005; Kinoshita et al. 
2005; Yamada et al. 2007; Kim et al. 2009; Quennell et al. 2010; Smith et al. 2011). Although 
it may not be expressed on kisspeptin neurons themselves as kisspeptin neurons in the ARC 
and POA of sheep did not contain the KISS1R (Smith et al. 2011).  
KISS1R is expressed on GnRH neurons, however, studies have shown only a proportion (50-
95%) of GnRH neurons express KISS1R (Irwig et al. 2004; Han et al. 2005; Messager et al. 
2005; Herbison et al. 2010; Smith et al. 2011; Li et al. 2012). Expression is also evident in the 
basal ganglia and substantia nigra (Muir et al. 2001; Ohtaki et al. 2001). 
KISS1R is also expressed in the placenta, pituitary, spinal cord, pancreas, stomach, small 
intestine, kidney, liver, thymus, lung and testis (Kotani et al. 2001). KISS1R expression in the 
pituitary has been particularly investigated in several species including humans (Kotani et al. 
2001), sheep (Bellingham et al. 2009),  pigs (Li et al. 2008) and rats (Gutierrez-Pascual et al. 
2007; Richard et al. 2008).  
 
1.7 Pubertal effects of KISS1/KISS1R gene mutations  
The first association of kisspeptin with the reproductive axis was the discovery of deactivating 
mutations of KISS1R resulting in patients presenting with pubertal failure and sexual 
immaturity (de Roux et al. 2003; Seminara et al. 2003). Since then further reports of KISS1R 
mutations causing HH have emerged (Lanfranco et al. 2005; Semple et al. 2005; Cerrato et al. 
2006; Tenenbaum-Rakover et al. 2007; Teles et al. 2010; Nimri et al. 2011) and activating 
mutations resulting in precocious puberty (Teles et al. 2008).  
 
 
32 
 
Loss of function mutations of the kisspeptin gene (KISS1) resulting in HH have also been 
reported (Topaloglu et al. 2012) as well as mutations associated with a form of kisspeptin that 
had a higher resistance to degradation found in three patients with  precocious puberty (Silveira 
et al. 2010), indicating that kisspeptin is critical for normal reproduction. Rhie et al, showed 
that there is an increase in kisspeptin levels in patients with precocious puberty and the levels 
reduced post treatment (Rhie et al. 2011; Demirbilek et al. 2012). 
KISS1R knockout mice have very similar phenotypes to humans with KISS1R mutations, of 
sexual immaturity, low gonadotrophins, small gonads, HH and infertility (Seminara et al. 2003; 
Funes et al. 2003; Lapatto et al. 2007), although they have normal levels of hypothalamic 
GnRH content, suggesting that this mutation has affected the secretion of GnRH (Seminara et 
al. 2003; Funes et al. 2003). KISS1 knockout mice have shown normal GnRH neuronal 
migration into the hypothalamus, with normal connections to the ME and normal hypothalamic 
GnRH content (d'Anglemont de Tassigny et al. 2007), which again suggests a likely error of 
GnRH secretion.  
Mice with KISS1 gene disruption also have similar phenotype to humans with KISS1/KISS1R 
mutations with HH (d'Anglemont de Tassigny et al. 2007; Lapatto et al. 2007), although there 
is a more severe phenotype in KISS1R knockout mice (Lapatto et al. 2007; Mei et al. 2011), 
suggesting that there may be further endogenous ligands for KISS1R yet to be discovered.  
Both KISS1 and KISS1R knockout mice show some degree of residual GnRH activity as a 
they show partial sexual maturation with almost all female mutants eventually entering 
oestrous although delayed and some males able to produce mature sperm (Lapatto et al. 2007; 
Chan et al. 2009; Mei et al. 2011). This was disrupted with further lowering of gonadal weights 
by administration of a GnRH antagonist acyline, indicating kisspeptin independent 
mechanisms to secrete low levels of GnRH activity (Chan et al. 2009). In KISS1 knockout 
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mice the LH was not consistently lower than wild type, although FSH was generally lower 
(Lapatto et al. 2007; Chan et al. 2009).  
Interestingly, embryonic genetic ablation of KISS1 or KISS1R containing neurons does not 
result in a delay in puberty or disruption of ovulation, however, similar ablation in adults 
resulted in a complete disruption of ovarian cycles (Mayer and Boehm 2011), suggesting 
compensatory mechanisms may become activated during development to overcome the loss of 
KISS1 and KISS1R expressing neurons. It is also possible that small numbers of kisspeptin 
neurons may have remained after ablation and these were sufficient for reproduction and sexual 
maturity. Popa et al, showed that even with only 5% of kisspeptin expressing neurons 
remaining after ablation, males still had normal sized litters, although females required much 
higher levels for normal fertility (Popa et al. 2013). 
 
1.8 Kisspeptin and GnRH secretion 
 
1.8.1 Kisspeptin neurons are closely associated with GnRH neurons and terminals 
Hypothalamic kisspeptin neurons are anatomically closely associated with GnRH neurons 
suggesting their interaction. Kisspeptin axons in the AVPV and ARC of rodents send 
projections to GnRH cell bodies and dendrites in the POA (Clarkson and Herbison 2006; 
Lehman et al. 2010; Yeo and Herbison 2011). Fewer ARC kisspeptin neurons project to GnRH 
cell bodies compared to the AVPV (Yeo and Herbison 2011).  
Kisspeptin fibres have been shown to closely appose GnRH neurons in mice (Clarkson and 
Herbison 2006), sheep (Smith, Coolen, et al. 2008) and monkeys (Ramaswamy et al. 2008).  
In the ME, electron microscopy has shown direct membrane contact of kisspeptin and GnRH 
neuron axons in sheep (Lehman et al. 2010), goats (Matsuyama et al. 2011), rats (Kinoshita et 
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al. 2005; Uenoyama et al. 2011) and mice (d'Anglemont de Tassigny et al. 2008). In the 
external zone of the ME, kisspeptin fibres have been located near GnRH terminals in sheep 
(Smith et al. 2009) monkeys (Ramaswamy et al. 2008) and rodents (Clarkson and Herbison 
2006; Clarkson et al. 2009; Adachi et al. 2007). ARC kisspeptin neuron fibres have also been 
shown in close apposition to GnRH fibres in the ME projecting to the portal vessels 
(Ramaswamy et al. 2008). 
 
1.8.2 Kisspeptin stimulates GnRH release 
A large proportion of GnRH neurons in the hypothalamus express KISS1R (50-95%) in rats 
(Irwig et al. 2004), mice (Han et al. 2005; Messager et al. 2005; Herbison et al. 2010), cichlid 
fish (Parhar, Ogawa, and Sakuma 2004) and sheep (Smith et al. 2009; Smith et al. 2011; Li et 
al. 2012).  
Electrophysiology studies in mice have shown that kisspeptin evokes depolarisation of GnRH 
neurons (Han et al. 2005; Pielecka-Fortuna, Chu, and Moenter 2008) and kisspeptin 
administered to rodents causes an increase in c-Fos expression in GnRH neurons, which is an 
early gene product indicating cellular activity (Irwig et al. 2004; Matsui et al. 2004).   
In sheep kisspeptin has been shown to stimulate GnRH release into the portal circulation (Smith 
et al. 2011) and when infused into the third ventricle of sheep increased levels of GnRH in the 
cerebrospinal fluid (CSF) (Messager et al. 2005; Caraty et al. 2007).  
In mice and monkeys it has been shown that the stimulation of gonadotrophin secretion by 
kisspeptin was inhibited by a GnRH receptor antagonist suggesting that kisspeptin is working 
via GnRH release to then stimulate gonadotrophin release (Gottsch et al. 2004; Shahab et al. 
2005).  
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Kisspeptin secretion is pulsatile leading to pulsatile GnRH secretion; in female pubertal 
monkeys, kisspeptin-54 release in the stalk-median eminence was pulsatile with an interpulse 
interval of 60 min and approximately 75% of kisspeptin pulses correlated with GnRH pulses 
(Keen et al. 2008). Han et al used selective optogenetics in mice to show that synchronised 
stimulation of ARC kisspeptin neurons resulted in LH pulses. However, this effect was absent 
in KISS1R knockout mice, indicating that KISS1R is critical to kisspeptin’s ability to generate 
LH pulses (Han et al. 2015). 
GnRH specific KISS1R knockout mice fail to go through puberty and are infertile (Kirilov et 
al. 2013; Novaira et al. 2014), however, this can be rescued via selective reinsertion of KISS1R 
into GnRH neurons (Kirilov et al. 2013). In global KISS1R knockout mice with selective 
reinsertion of KISS1R on GnRH neurons despite being fertile they still have abnormal gonad 
structure and altered responses in gonadotrophin negative feedback withdrawal indicating that 
although kisspeptin stimulation of GnRH neurons is required for fertility, there are other 
reproductive actions of kisspeptin which may be GnRH independent (Leon et al. 2016).  
 
1.8.3 Exogenous kisspeptin acts at GnRH nerve terminals 
It is interesting to consider that not only central administration but peripheral administration of 
kisspeptin stimulates gonadotrophin secretion (via GnRH secretion). The BBB separates the 
brain from the peripheral circulation, however, there are some areas where contact is possible, 
in the ME and vascular organ of lamina terminalis (OVLT). Kisspeptin has been shown to 
stimulate GnRH neurons in the OVLT (Herde et al. 2011) and the ME and therefore, presents 
a likely mechanism by which peripheral exogenous kisspeptin can stimulate gonadotrophin 
release (via GnRH release).  
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A kisspeptin antagonist peptide infusion into the stalk/median eminence of pubertal female 
rhesus monkeys supressed GnRH and GnRH pulses, which returned to normal on terminating 
the infusion (Roseweir et al. 2009), indicating a likely site of kisspeptin action on GnRH nerve 
terminals in the ME.  
Intravenous (IV) kisspeptin administered to ovariectomised ewes showed no induction of c-
Fos in GnRH cells and microinjections of kisspeptin into the ME of ewes elicited an LH pulse 
suggesting that KP acts on GnRH terminals in the ME to cause pulsatile GnRH secretion 
(Ezzat, Pereira, and Clarke 2015). Also, peripheral injections of kisspeptin to KISS1 knockout 
mice resulted in a rise of LH however, there was no induction of c-Fos in GnRH neurons, again 
suggesting that kisspeptin acts at the level of GnRH secretory terminals (d'Anglemont de 
Tassigny et al. 2010). IV injections of kisspeptin rapidly causes the release of GnRH into 
hypophyseal portal blood within 2 min, suggesting that the most likely site of action is at the 
ME outside the BBB near GnRH neurosecretory terminals (Caraty et al. 2013).  
Using IV horseradish peroxidase (which is unable to cross the BBB), GnRH neurons and 
dendrites in the OVLT were determined to be outside the BBB. Kisspeptin stimulated these 
GnRH neuron dendrites after direct administration, indicating another site of action of 
peripheral kisspeptin (Herde et al. 2011).  
1.8.4 Kisspeptin and puberty 
As previously discussed mutations in the KISS1 or KISS1R genes results in failure of puberty. 
Animal studies have shown that kisspeptin secretion increases towards puberty with increasing 
KISS1R expression on GnRH neurons and increasing kisspeptin induced GnRH neuron 
depolarisation.    
Blood sampling from the ME in monkeys in the juvenile period revealed low amplitude pulses 
of kisspeptin, which increased in amplitude and frequency at puberty (Keen et al. 2008; 
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Guerriero et al. 2012). In lambs there is also higher frequency of LH pulses and increased 
number of KISS1 neurons at puberty (Redmond et al. 2011).  
There is also an increase in hypothalamic expression of KISS1 mRNA at the time of puberty 
in rats (Navarro, Castellano, et al. 2004). ARC kisspeptin expression has shown to increase 
during puberty in monkeys (Shahab et al. 2005; Keen et al. 2008), sheep (Redmond et al. 2011; 
Nestor et al. 2012) and rats (Takase et al. 2009; Bentsen et al. 2010; Takumi, Iijima, and Ozawa 
2011). 
Pre-pubertal monkeys displayed similar GnRH responses to kisspeptin after being 
ovariectomised. However, in puberty, after ovariectomy there was no GnRH response to 
kisspeptin and this was only partially restored with oestradiol replacement (Guerriero et al. 
2012), indicating that in the primate pre-pubertal changes to kisspeptin expression are 
independent of sex steroids, however, during puberty sex steroids have a predominant action 
on kisspeptin expression and action.  
In mice, there is an increase in kisspeptin expression in the rostral hypothalamic populations 
until puberty (Han et al. 2005; Clarkson and Herbison 2006; Clarkson et al. 2009; Mayer et al. 
2010; Gill et al. 2010), and this increase was dependent on sex steroids (Clarkson et al. 2009; 
Mayer et al. 2010).  
There is an increase in kisspeptin-IR fibres and in the close association of kisspeptin and GnRH 
neurons in the POA and ME of mice during puberty (Clarkson and Herbison 2006; Clarkson 
et al. 2009; Gill et al. 2010). KISS1R expression on GnRH neurons also increases towards 
puberty, in mice one study showed 40% of GnRH neurons in the POA after birth express 
KISS1R and this increases to 70% in adulthood (Herbison et al. 2010). 
The increasing KISS1R expression towards puberty leads to an increase in GnRH neuron 
depolarisation in response to exogenous kisspeptin. In juvenile mice 27% of GnRH neurons 
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depolarize with exogenous kisspeptin, 45% in pre-pubertal mice and 90% in the adult (Han et 
al. 2005). Both increasing KISS1R numbers and sensitivity are likely to contribute to the 
greater GnRH response to kisspeptin that is seen in pubertal monkeys compared with pre-
pubertal monkeys (Guerriero et al. 2012).  
Repetitive kisspeptin administration to rats and primates showed an advance in puberty 
(vaginal opening and increased uterine weight) with elevated levels of gonadotrophins to that 
of adults in rats (Navarro, Fernandez-Fernandez, et al. 2004) and primates (Plant and Witchel 
2006). Conversely, central KISS1R antagonist administration for 7 days to pubertal female rats 
showed delayed vaginal opening and reduced uterine and ovarian weights (Pineda et al. 2010).  
Taken together this evidence shows a developing and maturing kisspeptin system towards 
puberty in order to produce the GnRH secretion required to induce puberty. The trigger to 
activation of kisspeptin after a quiescent and low activity phase in the juvenile period still needs 
to be determined, however, is likely to involve a variety of metabolic and physical signals 
which converge to initiate puberty (Plant 2015), and kisspeptin as a component of the pulse 
generator is upregulated accordingly.   
 
1.9 Effects of kisspeptin administration in animals 
GnRH secretion into the hypophyseal portal blood supply is difficult to measure in view of its 
anatomical inaccessibility but also the short half-life of GnRH (2-4min), therefore, GnRH 
levels are inferred from examining LH secretion in the peripheral circulation.  
Exogenous kisspeptin potently stimulates the secretion of the pituitary gonadotrophin 
hormones, LH and FSH in numerous mammalian species including mice (Gottsch et al. 2004; 
Messager et al. 2005), rats (Irwig et al. 2004; Matsui et al. 2004; Navarro, Castellano, et al. 
2004; Thompson et al. 2004), sheep (Messager et al. 2005; Caraty et al. 2007), cows 
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(Kadokawa, Suzuki, and Hashizume 2008) and monkeys (Shahab et al. 2005; Seminara et al. 
2006; Plant, Ramaswamy, and Dipietro 2006). 
Kisspeptin can stimulate gonadotrophin secretion when administered in a number of different 
routes: subcutaneous (SC), intramuscular (IM), intraperitoneal (IP), intravenous (IV) and 
intracerebroventricular (ICV) (Abbara et al. 2013), although there are differences in peak 
concentrations and duration of circulating kisspeptin levels. Endogenous kisspeptin acts 
centrally on GnRH neurons to stimulate GnRH release, however, when exogenous kisspeptin 
is administered peripherally the rise in gonadotrophins is likely to be due to stimulation of 
GnRH neurons at the OVLT and ME as discussed above (Herde et al. 2011; Caraty et al. 2013; 
Ezzat, Pereira, and Clarke 2015). 
Different isoforms of kisspeptin have also been studied, mostly kisspeptin-10, kisspeptin-52 
(murine form of kisspeptin-54) and kisspeptin-54 and all have been found to stimulate 
gonadotrophins. Kisspeptin-10 contains the minimum amino acid sequence that is required for 
KISS1R activation and is common to all isoforms.  
In general the stimulatory effect of kisspeptin is greater on LH release than FSH release. In 
male rats kisspeptin caused a rapid increase in LH to 8 times baseline within 15 min and 
although FSH levels did rise to 2 times baseline levels this was delayed from 30 min onwards 
(Navarro, Castellano, Fernandez-Fernandez, Tovar, Roa, Mayen, Barreiro, et al. 2005). The 
same study also showed that the dose of kisspeptin-10 required to stimulate FSH secretion was 
up to 200 fold higher than was required to stimulate LH secretion (Navarro, Castellano, 
Fernandez-Fernandez, Tovar, Roa, Mayen, Barreiro, et al. 2005), indicating that FSH secretion 
may not be as responsive to kisspeptin stimulation as LH. The lower fold rise in FSH with 
kisspeptin administration compared with LH secretion has also been demonstrated in humans 
(Dhillo et al. 2005; Dhillo et al. 2007). LH is preferentially secreted in response to high 
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frequency GnRH pulses, whereas FSH secretion is favoured by low frequency GnRH pulses 
(Dalkin et al. 1989), therefore, as exogenous kisspeptin is likely to stimulate a high frequency 
of GnRH pulses shown by the robust rise in LH it is likely that LH is secreted preferentially.  
 
1.10 Effects of kisspeptin administration in humans 
1.10.1 Gonadotrophin response, isoforms and route of administration  
Kisspeptin stimulates gonadotrophin secretion in healthy participants and those with 
reproductive disorders without any reported side effects (Dhillo et al. 2005; Dhillo et al. 2007; 
Jayasena et al. 2009; Jayasena et al. 2010; George et al. 2011; Chan et al. 2011; Chan et al. 
2012; Young et al. 2013).  
In view of the difficulty measuring GnRH pulsatility, LH pulsatility has been used as a 
surrogate marker. As such kisspeptin has been shown to increase LH pulse amplitude and 
frequency in men (George et al. 2011) and women (Jayasena, Comninos, Veldhuis, et al. 2013). 
In reproductive disorders, such as women with hypothalamic amenorrhoea (HA) and 
hypogonadal men with type 2 diabetes, kisspeptin has also been shown to increase LH 
pulsatility (George et al. 2013; Jayasena, Abbara, Veldhuis, et al. 2014).  
Chan et al compared the LH responses from healthy men administered kisspeptin with HH men 
administered GnRH and suggested that an IV bolus of 0.24nmol/kg kisspeptin-10 produced 17 
min of sustained GnRH release(Chan et al. 2011), which was very similar to ex vivo 
experiments in rodents (Han et al. 2005; Pielecka-Fortuna, Chu, and Moenter 2008). They also 
found that the kisspeptin induced GnRH pulse delayed the next endogenous LH pulse, thereby 
resetting the GnRH pulse generator (Chan et al. 2011). This could not be replicated in women 
at any stage of the menstrual cycle (Chan et al. 2012), suggesting differences in the pulse 
generator between men and women. However, women show a differing response to kisspeptin 
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during different phases of the menstrual cycle compared with men and will be further discussed 
in the next section on sexual dimorphism (section 1.10.2).  
Kisspeptin has also been shown to consistently increase FSH albeit to a lesser degree than LH, 
(Dhillo et al. 2005; Dhillo et al. 2007; George et al. 2011; Jayasena et al. 2011; Chan et al. 
2012; George, Anderson, and Millar 2012), which has been similarly seen in rodents and 
explained above (Navarro, Castellano, Fernandez-Fernandez, Tovar, Roa, Mayen, Barreiro, et 
al. 2005). Dhillo et al, observed that the peak serum LH during a 90 min IV infusion of 
kisspeptin-54 was 10.2 IU/L (12pmol/kg/min kisspeptin-54), but serum FSH was only 3.7 IU/L 
at this dose (Dhillo et al. 2005) and other researchers have found similar results (Chan et al. 
2011; George et al. 2011).  
One challenge in interpreting the clinical outcomes of human studies has been due to different 
isoforms of kisspeptin being studied, namely kisspetpin-10 and kisspeptin-54. We are unable 
to directly compare the clinical results as it has not been established how the different doses of 
the isoforms compare. Interestingly, when SC kisspeptin-54 was administered to women in the 
follicular phase of the menstrual cycle even doses as low as 0.4nmol/kg stimulated 
gonadotrophin release (Dhillo et al. 2007), however, a SC bolus of kisspeptin-10 at doses up 
to 32nmol/kg were not able to stimulate LH (Jayasena et al. 2011).  
Kisspeptin-54 may have a greater potency than kisspeptin-10 in view of its in vivo half-life of 
28 min for kisspeptin-54 (Dhillo et al. 2005) and 4 min for kisspeptin-10 (Jayasena et al. 2011). 
Therefore, I will investigate this further in chapter 2 by comparing the effects of kisspeptin-10, 
-54 and GnRH at the same doses on gonadotrophin secretion in healthy male volunteers. This 
will allow for direct comparisons to be made between human studies and establish which 
peptide produces the optimum gonadotrophin response. Also, by comparing them to GnRH at 
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the same dose I will be able to compare the hypothalamic response to kisspeptin with the 
pituitary response to GnRH at the same dose on gonadotrophin secretion.  
Clinical studies have also used differing routes of administration (Skorupskaite, George, and 
Anderson 2014) and therefore, comparing the outcomes is also difficult. IV and SC 
administration have been studied in humans and result in a rise of gonadotrophins in men, 
although women vary their response depending on the phase of the menstrual cycle. If 
kisspeptin may be used as a therapeutic in the future it is important to administer this in a 
convenient way at home and SC administration would be favoured. Although studies have 
administered kisspeptin in SC injections twice daily or twice weekly to women (Jayasena et al. 
2009; Jayasena et al. 2010), pump administration (SC infusion) offers another treatment 
modality in the future. Insulin pump treatment used in the management of diabetes is well 
tolerated (Pickup 2012b) and in view of the long term treatment needed for reproductive 
disorders may be more acceptable than SC injections. However, no previous studies have 
administered kisspeptin via SC infusion to humans and therefore, in chapter 3, I investigate 
this further, by comparing whether SC administration is able to potently stimulate 
gonadotrophins in order to establish whether kisspeptin pump administration would a viable 
treatment modality for the future.   
Prolonged exposure to kisspeptin can lead to tachyphylaxis (similar to GnRH receptor 
desensitisation) and thus a reduction in the rise of LH in men (Dhillo et al. 2005) and women 
with hypothalamic amenorrhoea (Jayasena et al. 2009) and will be discussed further in section 
1.15.   
1.10.2 Sexual dimorphism 
There appears to be complex differences in response to kisspeptin between males and females 
(sexual dimorphism). Studies have shown men to be responsive to exogenous kisspeptin, 
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however, in women the phase of the menstrual cycle appears to be the greatest determinant in 
their response to kisspeptin. Administration of kisspeptin-10 can stimulate LH in men and 
women during the pre-ovulatory phase of the menstrual cycle, but not in women in the follicular 
phase (Jayasena et al. 2011). The half-life of kisspeptin-10 was similar in men and women and 
therefore, it is unlikely that metabolic differences such as body fat content and clearance of the 
peptide have contributed to the lower responsiveness of women in the follicular phase 
(Jayasena et al. 2011). Studies have consistently shown that women are less responsive to 
kisspeptin in the follicular phase of the menstrual cycle and markedly more responsive in the 
pre-ovulatory phase (Dhillo et al. 2007; Chan et al. 2012).  
The frequency and amplitude of LH pulses varies over the menstrual cycle (Rahe et al. 1980; 
Sollenberger et al. 1990) despite no difference in the total daily LH secretion or the half-life of 
LH (Sollenberger et al. 1990). Chan et al, showed that endogenous LH pulses in the follicular 
phase of the menstrual cycle could be replicated by administering an IV bolus of 0.24nmol/kg 
kisspeptin-10 to women in the follicular phase, however in other phases of the menstrual cycle 
this dose produced much larger LH pulses, indicating a reduced capacity to respond to 
exogenous kisspeptin administration in the follicular phase (Chan et al. 2012). This may be a 
protective mechanism to avoid overstimulation especially in the follicular phase as higher 
levels of GnRH and subsequently higher FSH may result in multiple ovarian follicles and the 
risk of multiple pregnancy. This is one possible explanation as to why women are least 
responsive to exogenous kisspeptin during follicular phase.  
Oestradiol levels also change over the menstrual cycle with generally lower levels in the 
follicular phase and higher in the pre-ovulatory phase, raising the possibility that oestradiol 
could be influencing the gonadotrophin response to kisspeptin. Animal studies have also shown 
that females are more responsive to kisspeptin administration in the pre-ovulatory phase of the 
oestrous cycle when oestradiol levels are high in rats (Roa et al. 2006) and sheep (Smith et al. 
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2009; Smith et al. 2011). Maximal gonadotrophin responses to kisspeptin in ovariectomised 
mice were only seen after oestradiol replacement (Roa et al. 2006). Thus oestradiol levels seem 
to be an important determinant of gonadotrophin response to kisspeptin.  
Therefore, in chapter 3, I will further investigate the role of oestradiol in the LH response to 
kisspeptin in healthy women in the follicular phase of the menstrual cycle where oestradiol 
levels are at their lowest in the cycle. This is important because if kisspeptin is to be considered 
as a therapeutic in the future it may be important to optimise oestradiol levels first in order to 
achieve a potent gonadotrophin response to kisspeptin.  
Sex steroids are an important regulatory factor for GnRH secretion in men and women and is 
discussed below. 
 
1.11 Sex steroid feedback effects on GnRH secretion  
1.11.1 General overview 
The HPG axis is under constant regulation by sex steroids, governing both the negative and 
positive feedback control of GnRH secretion. There are two types of oestrogen receptor – alpha 
(ERα) and beta (ERβ). ERα is essential in reproduction as ERα knockout mice are infertile, 
with altered gonadal and breast tissue development (Korach et al. 1996; Lubahn et al. 1993). 
However, ERβ knockout mice are fertile, questioning the importance in this receptor in 
reproduction (Krege et al. 1998), although GnRH neurons only express ERβ but not ERα 
(Hrabovszky et al. 2000; Hrabovszky et al. 2001; Skinner and Dufourny 2005). ERα knockout 
mice do show some oestradiol binding in the brain, suggesting that ERβ may be implicated in 
mediating the effects of oestradiol in these areas (Shughrue et al. 1997), however further work 
is needed to investigate the function of ERβ.  
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Kisspeptin neurons in the ARC and AVPV express both oestradiol receptors, although a higher 
proportion of ERα than ERβ, as well as the progesterone receptor and the androgen receptor 
(AR) (Smith, Dungan, et al. 2005; Clarkson et al. 2012; Smith, Cunningham, et al. 2005; 
Franceschini et al. 2006; Adachi et al. 2007; Clarkson et al. 2008).   
Blockade of ERα in female rats reduced the gonadotrophin response to kisspeptin (Roa, Vigo, 
Castellano, et al. 2008). Also, ovariectomised ERα knockout mice do not show the normal rise 
in ARC KISS1 mRNA expression after sex steroid withdrawal (Smith, Cunningham, et al. 
2005), indicating that oestradiol works via the ERα to exert its negative feedback effects on 
KISS1 expression in the hypothalamus. In mice with a targeted deletion of ERα in kisspeptin 
neurons (KERKO mice), there are high levels of gonadotrophins and females usually develop 
precocious puberty onset (Mayer et al. 2010), likely due to a chronic lack of negative feedback 
resulting in sustained GnRH and gonadotrophin secretion.  
The ERβ knockout mouse is able to regulate KISS1 mRNA after ovariectomy and oestradiol 
replacement (Smith, Cunningham, et al. 2005), indicating a non-significant role of ERβ in sex 
steroid negative feedback.  
Oestradiol has been shown to down regulate KISS1 expression in the ARC/infundibular 
nucleus and up regulate KISS1 expression in the POA/AVPV in mice (Smith, Cunningham, et 
al. 2005; Smith, Dungan, et al. 2005), rats (Adachi et al. 2007) and ewes (Franceschini et al. 
2006; Goodman et al. 2007; Smith et al. 2007). In rodents after ovariectomy, the removal of 
sex steroids results in an increase in KISS1 mRNA in the ARC and a reduction in the AVPV 
(Smith, Cunningham, et al. 2005; Smith, Popa, et al. 2006). Therefore, it is now clear that the 
two populations of kisspeptin neurons respond differently to sex steroids; the ARC population 
is involved in sex steroid negative feedback as well as positive feedback in some species, and 
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the AVPV population in rodents is responsible for positive feedback effects resulting in the 
GnRH surge pre-ovulation. 
 
1.11.2. Sex steroid negative feedback 
Kisspeptin neurons in the ARC are the predominant site of the sex steroid negative feedback 
regulation of GnRH secretion. In ovariectomised females or castrated males there was 
increased ARC KISS1 mRNA in mice (Smith, Cunningham, et al. 2005; Smith, Dungan, et al. 
2005), sheep (Pompolo et al. 2006; Smith et al. 2007; Smith, Coolen, et al. 2008), rhesus 
monkeys (Rometo et al. 2007) and post-menopausal women (Rometo et al. 2007), suggesting 
that by removing sex steroids and their negative feedback effect on KISS1 expression in the 
ARC, KISS1 expression was allowed to increase. On replacement of sex steroids to 
gonadectomised male and female mice, KISS1 mRNA levels reduced to control levels (Smith 
et al. 2007; Smith, Clifton, and Steiner 2006; Smith, Cunningham, et al. 2005). Also, chronic 
treatment with oestrogen reduces c-Fos in ARC kisspeptin cells of ovariectomised ewes (Smith 
et al. 2009).  
MUA activity in the ARC where a large number of kisspeptin neuron cell bodies reside showed 
regular increases in MUA activity associated with LH pulses in gonadectomised males and 
females (Ohkura, Uenoyama, et al. 2009), and oestradiol treatment in the ovariectomised goat 
reduced the MUA frequency (Wakabayashi et al. 2010), indicating that oestradiol acting in the 
ARC negatively influences kisspeptin neuron activity.  
The post castration rise in LH was absent in KISS1R knockout mice (Chan et al. 2009). KISS1R 
antagonists inhibited the post castration rise in gonadotrophins in rodents (Roseweir et al. 2009) 
and inhibited episodic LH secretion in ovariectomised ewes (Millar et al. 2010; Guerriero et 
al. 2012), further indicating that kisspeptin is essential in the negative feedback action of sex 
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steroids on GnRH secretion. Interestingly, KISS1R antagonists do not inhibit LH 
concentrations in gonadally intact rodents (Roseweir et al. 2009), indicating some inherent 
kisspeptin independent GnRH release. This can also been seen in KISS1 and KISS1R knockout 
mice who have further reductions in gonadal weights and gonadotrophins on GnRH antagonist 
administration. 
 
1.11.3 Sex steroid positive feedback and pre-ovulatory LH surge 
The pre-ovulatory surge of GnRH and then LH, stimulates ovulation and is triggered by an 
elevation in oestradiol. Kisspeptin has been implicated in facilitating the LH surge via 
mediating the positive feedback effects of oestradiol; KISS1R antagonists or use of a 
monoclonal antibody to kisspeptin in rats and sheep diminished or prevented the LH surge 
(Kinoshita et al. 2005; Caraty et al. 2007; Clarkson et al. 2008; Pineda et al. 2010; Smith et al. 
2011). Kisspeptin antiserum has also been shown to abolish the pre-ovulatory LH surge 
(Kinoshita et al. 2005).  
The hypothalamic kisspeptin neuronal population responsible for mediating the positive 
feedback effects of oestradiol are not as consistent as for the negative feedback site of the ARC. 
Oestradiol has been shown to up regulate KISS1 mRNA in the POA/AVPV of rodents and the 
ARC of sheep and primates at the time of the pre-ovulatory LH surge to trigger ovulation 
(Smith, Cunningham, et al. 2005; Estrada et al. 2006; Adachi et al. 2007). Therefore, these 
species are considered separately below.  
 
1.11.3.1 Rodents 
The expression of KISS1 mRNA increases in the AVPV at the time of the GnRH surge when 
oestradiol levels are high (Smith, Popa, et al. 2006; Adachi et al. 2007; Clarkson et al. 2008; 
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Clarkson et al. 2009), with c-Fos induction indicating transcriptional activation (Smith, Popa, 
et al. 2006; Adachi et al. 2007; Clarkson et al. 2008). Pre-ovulatory and oestrogen induced LH 
surges are blocked by local infusion of kisspeptin antibody into the POA (Kinoshita et al. 2005; 
Adachi et al. 2007). KISS1R knockout mice despite LH surge oestradiol levels are unable to 
produce the LH surge (Clarkson et al. 2008), although a report suggested this may not be the 
case (Dungan et al. 2007).    
There is also an upregulation of KISS1 expression in AVPV neurons with oestradiol 
replacement (Smith, Cunningham, et al. 2005; Adachi et al. 2007; Dungan et al. 2007). 
However, there was no stimulatory effect of oestradiol on KISS1 expression in the AVPV of 
ERα knockout mice, but ERβ knockout mice showed the normal stimulatory effect on 
kisspeptin neurons in the AVPV (Smith, Cunningham, et al. 2005), indicating again the 
importance of ERα in mediating sex steroid effects on kisspeptin neurons. Mice with a specific 
ERα deletion on kisspeptin neurons (KERKO mice) showed no LH surge in post-pubertal 
females (Mayer et al. 2010). 
Taken together this indicates that AVPV KISS1 expression is important for the pre-ovulatory 
LH surge and ovulation in rodents and thus must mediate the positive feedback of oestradiol.  
 
1.11.3.2 Non-rodent species 
Evidence suggests that the MBH/ARC is important for the LH surge in sheep (Caraty et al. 
1998; Smith 2009) and monkeys (Hess et al. 1977; Plant et al. 1978; Smith et al. 2010). In 
sheep there are more kisspeptin expressing cells in the ARC in females compared with males 
(Cheng et al. 2010), which likely indicates its role in sex steroid positive feedback in 
stimulating the GnRH surge. There is a rise in KISS1 expression in the ARC prior to the LH 
surge (Estrada et al. 2006; Smith et al. 2009). Also, ovariectomised ewes treated with surge 
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inducing levels of oestradiol show c-Fos expression indicating transcriptional activation in the 
mid-caudal ARC (Smith et al. 2009). Interestingly, after ovariectomy only half the kisspeptin 
cells in the caudal ARC that were activated by high oestradiol levels showed c-Fos expression, 
indicating that some cells in the ARC are able to both mediate negative and positive feedback 
actions of sex steroids on GnRH regulation (Smith et al. 2009) in sheep.  
Oestradiol also increases KISS1 mRNA expression in the POA of sheep (Smith et al. 2007) 
similar to in the rodent AVPV. There is also an increase in KISS1 expression in the ovine POA 
prior to the LH surge (Smith et al. 2009) as well as c-Fos expression in POA kisspeptin neurons 
(Hoffman et al. 2011). In monkeys there is also a rise in POA KISS1 expression pre-ovulation 
(Smith et al. 2010), suggesting that the POA may also be of relevance in positive feedback. 
However, it is not clear how the POA population in sheep and monkeys may mediate the 
positive feedback actions of oestradiol as only about 50% of kisspeptin neurons express ERα 
here (Franceschini et al. 2006). Although the predominant site for positive feedback is the ARC 
(Caraty et al. 1998) the POA may be involved to a lesser degree. 
Taken together kisspeptin is ideally placed to mediate both the negative and positive feedback 
effects of sex steroids on GnRH secretion.  
 
1.12 Kisspeptin neuron sexual dimorphism 
As discussed above in the sexual dimorphism section (1.10.2), there are clear differences in 
kisspeptin response between men and women. However, there are also clear gender differences 
in kisspeptin neuronal expression which may be related to these areas mediating oestradiol 
positive feedback to generate the GnRH surge which only occurs in females (Kauffman 2009). 
This has been predominantly investigated in rodents where positive feedback actions are via 
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the AVPV, in non-rodents there does not appear to be such a striking difference between the 
sexes but will be discussed below.   
In the rodent AVPV, females express more kisspeptin-IR neurons and KISS1 mRNA than 
males and up to 10 times more kisspeptin neurons have been found in the RP3V of females 
(Clarkson and Herbison 2006; Smith, Popa, et al. 2006; Kauffman et al. 2007; Kauffman 2010). 
This difference was not due to differences in sex hormone  milieu as both intact and 
gonadectomised males and females showed this sex difference as well as those replaced with 
sex steroids post gonadectomy (Adachi et al. 2007; Kauffman et al. 2007). Interestingly, the 
ARC of mice shows no sex difference in kisspeptin-IR neuronal expression (Clarkson and 
Herbison 2006; Kauffman 2009; Gill et al. 2010) and in fact even despite maximal levels of 
oestradiol, ARC kisspeptin neurons are greater in number than in the AVPV, indicating that 
the ARC population is of particular importance (Lehman et al. 2010) in both sexes as it 
mediates sex steroid negative feedback of GnRH secretion. 
In sheep and humans, females express greater numbers of kisspeptin expressing cells in the 
ARC and infundibular nucleus compared with males (Cheng et al. 2010; Hrabovszky et al. 
2010; Nestor et al. 2012). In humans there is also a preponderance of kisspeptin-IR neurons in 
the POA of females compared with males (Hrabovszky et al. 2010), however, this has not been 
reported in the POA of sheep or monkeys.  
Taken together this evidence shows species differences in kisspeptin neuronal populations and 
clear sexual dimorphism in rodents in the AVPV (the site of sex steroid positive feedback in 
rodents). In non-rodents the site mediating sex steroid positive feedback is likely to be the ARC 
and possibly the POA and accordingly greater numbers of ARC kisspeptin neurons have been 
demonstrated in females of some species. It is unclear how some ARC kisspeptin neurons in 
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non-rodent species can mediate both positive and negative feedback effects of sex steroids in 
females, which remains to be further investigated.  
 
1.13 Kisspeptin neurons form part of the GnRH pulse generator 
Kisspeptin neurons are ideally situated to form part of the GnRH pulse generator in the ARC, 
not only in location also by being able to mediate sex steroid feedback on GnRH secretion. 
Although the peptide kisspeptin itself is unlikely to be involved in the regulation of the ARC 
kisspeptin neurons because they do not express the KISS1R (Herbison et al. 2010); peripheral 
kisspeptin-10 administration which stimulated LH, did not induce MUA activity in the ARC 
of goats (Ohkura, Takase, et al. 2009) and rats (Kinsey-Jones et al. 2008).  
Kisspeptin may not work alone, but in combination with other neuropeptides in the ARC to 
regulate GnRH secretion. Animal studies have shown that ARC kisspeptin neurons co-express 
two other neuropeptides, neurokinin B (NKB) and dynorphin, termed KNDy neurons (Cheng 
et al. 2010) which independently have been shown to affect LH secretion and therefore, may 
work together to regulate GnRH secretion and possibly represents the elusive GnRH pulse 
generator in the ARC.  
 
1.14 KNDy neurons  
1.14.1 Co-localisation and neuronal projections  
NKB is a member of the tachykinin family and in humans is encoded by the tachykinin-3 gene 
(TAC3) and acts at the neurokinin-3 receptor (NK3R) encoded by the tachykinin-3 receptor 
(TAC3R) gene. Dynorphin is an opioid that acts at the kappa opioid receptor (KOR).  
The peptides kisspeptin, NKB and dynorphin are found throughout the brain, however, they 
are co-localised in a subpopulation of neurons in the ARC in mice (Navarro et al. 2009), goats 
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(Wakabayashi et al. 2010), sheep (Foradori et al. 2006; Goodman et al. 2007; Cheng et al. 
2010), rats (Burke et al. 2006; True, Kirigiti, Ciofi, et al. 2011) and monkeys (Ramaswamy et 
al. 2010), termed KNDy neurons and giving rise to an anatomical basis for their interaction 
(Cheng et al. 2010).  
In humans, Hrabovszky et al, showed that in post mortem samples of the infundibular nucleus 
taken from men that there was dual immuno labelling of kisspeptin and NKB perikarya but that 
only a few dynorphin immune reactive cell bodies were visualised in the infundibular nucleus 
(Hrabovszky et al. 2012). There could have possibly been a loss of antigen post mortem or 
perhaps this may be due to male specimens being examined. Hrabovszky et al, two years 
earlier, found that there was marked differences in the numbers of ARC KNDy peptide 
expressing neurons between the sexes, particularly of note in men there were much less 
kisspeptin containing cells than women. Thus perhaps the low levels of dynorphin co-
localisation could be in part due to less kisspeptin expressing cells in the first place 
(Hrabovszky et al. 2010).  
KNDy neurons have been shown to form a dense neuronal network of interconnecting KNDy 
neurons which synapse at cell bodies and dendrites (Burke et al. 2006; Foradori et al. 2006; 
Krajewski et al. 2010; Wakabayashi et al. 2013).  KNDy neurons project to GnRH neurons 
(Navarro et al. 2009; Lehman, Coolen, and Goodman 2010; Ramaswamy et al. 2010; 
Wakabayashi et al. 2010) and are in close appositions to GnRH terminals in the median 
eminence (Krajewski et al. 2005; Burke et al. 2006; Krajewski et al. 2010). Krajewski et al, 
showed that NKB ARC neurons also project to the medial POA (site of GnRH perikarya) and 
AVPV (Krajewski et al. 2010). Taken together suggests that KNDy neurons from the ARC 
modulate GnRH secretion via widespread projections, dense interconnected networks and 
multiple neural pathways.  
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1.14.2 Neurokinin B (NKB)   
The tachykinin family include the peptides substance P, neurokinin A and neurokinin B (Page 
2005). They are 10-11 amino acids and share a common C terminus (Almeida et al. 2004). The 
TAC3 gene in humans and TAC2 gene in rodents encodes the NKB peptide. There is 
widespread expression of NKB mRNA in rodents and humans with predominant areas 
including the infundibular nucleus, anterior hypothalamus, and amygdala (Marksteiner, Sperk, 
and Krause 1992; Chawla et al. 1997). Although it only co-localises with kisspeptin and 
dynorphin expressing neurons in the ARC.  
The tachykinins bind the G protein coupled receptors, neurokinin receptor 1, 2 and 3 (NK1R, 
NK2R, NK3R) with varying affinities. NKB has the highest affinity for NK3R encoded by the 
TACR3 gene. Senktide used in the studies described below is a highly selective NK3R agonist 
(Almeida et al. 2004). NK3R is widespread throughout the brain and spinal cord (Krajewski et 
al. 2005; Navarro, Castellano, et al. 2011).  
Mutations in the genes encoding for NKB and its receptor  (TAC3 and TAC3R) result in HH 
(Topaloglu et al. 2009; Guran et al. 2009; Young et al. 2010; Francou et al. 2011), indicating 
that NKB is critical for normal GnRH secretion in humans and subsequent puberty and 
reproduction. There may be species differences as knockout mice for NK3R show a variable 
reproductive phenotype with pubertal development and fertility (Yang et al. 2012).  
TAC3R is not found on GnRH neurons (Amstalden et al. 2010; Navarro, Gottsch, et al. 2011) 
but is expressed on KNDy neurons (Burke et al. 2006; Navarro et al. 2009; Amstalden et al. 
2010; Navarro, Castellano, et al. 2011). It is therefore, generally accepted that NKB works on 
NK3R in the ARC to stimulate KNDy neurons (Amstalden et al. 2010). Wakabayashi et al, 
showed in goats that senktide (a NK3R agonist) increased MUA activity near KNDy neurons 
in the ARC (Wakabayashi et al. 2010) and ICV senktide induced c-Fos in KNDy neurons 
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(Navarro, Castellano, et al. 2011; Sakamoto et al. 2012). NKB also depolarised KISS1 neurons 
in the ARC likely via the NK3R (Navarro, Gottsch, et al. 2011).  
This being said, administration of NKB or senktide has shown some conflicting results in 
animal studies resulting in either stimulation or inhibition of GnRH release and a subsequent 
rise or fall in gonadotrophins. Research has shown the NKB effects depend on sex steroid 
milieu, development status and gender (Ruiz-Pino et al. 2015).  
Senktide has been shown to increase LH in mice (Navarro et al. 2009; Garcia-Galiano et al. 
2012), rats (Navarro, Castellano, et al. 2011; Navarro, Gottsch, et al. 2011; Grachev, Li, Lin, 
et al. 2012), goats (Wakabayashi et al. 2010), ewes (Billings et al. 2010; Goodman et al. 2013) 
and monkeys (Ramaswamy et al. 2010; Ramaswamy, Seminara, and Plant 2011). However, in 
states of low sex steroids NKB seems to inhibit LH secretion. Senktide has been shown to 
lower or suppress LH levels when administered to ovariectomised rodents with or without low 
oestradiol replacement (Sandoval-Guzman and Rance 2004; Navarro et al. 2009; Navarro, 
Castellano, et al. 2011; Grachev, Li, Kinsey-Jones, et al. 2012; Kinsey-Jones et al. 2012). 
Whereas when senktide is administered to ovariectomised rodents with high levels of oestradiol 
replacement this increases LH levels (Navarro, Castellano, et al. 2011). Billings et al, also 
showed a rise in LH with ICV senktide when administered to follicular phase ewes (high 
oestradiol levels) and no effect on LH in the luteal phase with lower oestradiol levels (Billings 
et al. 2010).  
Pubertal status and gender are also important considerations when evaluating the response to 
senktide; ICV senktide in pre-pubertal male and female rats caused a rise in gonadotrophins, 
where as in adult females only a rise in LH was seen and in adult males there was no change 
in gonadotrophins (Ruiz-Pino et al. 2015). IV NKB has shown no effect when given 
peripherally in both men and women (Jayasena, Comninos, De Silva, et al. 2014). 
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Other tachykinins have been found to affect LH secretion and ICV administration of NK1R 
and NK2R agonists increase gonadotrophins in pre-pubertal male and female rats, although in 
adults only the NK2R agonist increased LH in both sexes (Ruiz-Pino et al. 2015). Therefore, 
this may account for some differences between studies using NKB that can act partially at all 
the receptors and senktide which is selective for NK3R. deCroft et al, showed that in GFP-
labelled ARC kisspeptin neurons that NKB and senktide resulted in electrical stimulatory 
action in 95% of neurons, however, NK3R antagonists only blocked the effects of senktide, but 
not the stimulatory effects of NKB (de Croft, Boehm, and Herbison 2013). Only a combination 
of the three tachykinin receptor antagonists (NK1-3) blocked the stimulatory effects of NKB, 
thus indicating that NKB may work to stimulate all three tachykinin receptors (de Croft, 
Boehm, and Herbison 2013).  
 
1.14.3 Dynorphin 
Historically, it has been shown that endogenous opioids such as dynorphin have an inhibitory 
role on GnRH secretion and subsequently LH secretion. Dynorphin has been shown to act at 
its receptor the kappa opioid receptor (KOR) (Chavkin, James, and Goldstein 1982). Gallo et 
al, showed that in pregnant rats, ICV naloxone (a non-specific opioid receptor antagonist) 
caused a rise in pulsatile LH secretion, however, only the specific KOR antagonist and not the 
antagonists of mu and delta opioid receptors caused a rise in LH secretion; thus concluding that 
the kappa opioid receptor and thus dynorphin (its ligand) was responsible for the rise in LH 
(Gallo 1990).  
Dynorphin and KOR agonists have been shown to inhibit LH secretion (Kinoshita et al. 1982; 
Navarro et al. 2009; Wakabayashi et al. 2010) and inhibit MUA in the MBH (Wakabayashi et 
al. 2010). Ex-vivo experiments using murine hypothalamic slices showed that KOR agonists 
caused a reduction in firing of GFP labelled ARC kisspeptin and NKB neurons (de Croft, 
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Boehm, and Herbison 2013; Ruka, Burger, and Moenter 2013), further suggesting that 
dynorphin may act in the ARC. 
KOR antagonists have been shown to cause a rise in LH in ewes (Goodman et al. 2013). 
Naloxone administered to ovariectomised rats caused a dramatic rise in MUA volley frequency 
in the ARC/ME and rise in LH (Kimura et al. 1991). Dynorphin and KOR knockout mice have 
a compromised rise in LH post ovariectomy (Navarro et al. 2009). One mechanism of action is 
by mediating the inhibitory feedback control of progesterone on GnRH secretion (Goodman et 
al. 2004), as progesterone has been shown to supress GnRH secretion. KNDy neurons express 
the progesterone receptor (Foradori et al. 2002; Smith et al. 2007), and progesterone has been 
shown to increase the expression of dynorphin (Foradori et al. 2005). Therefore, it has been 
suggested that progesterone may potentiate the inhibitory actions of dynorphin. The inhibitory 
action of progesterone on LH secretion can be reversed by disruption of dynorphin signalling 
(Gallo 1990; Goodman et al. 2004).  
There are small numbers of KOR on GnRH neurons (Mitchell et al. 1997; Sannella and 
Petersen 1997) and thus the inhibitory action of dynorphin must be acting elsewhere. There are 
also very few KOR expressed on KNDy neurons; 20% KOR mRNA co-localised kisspeptin 
neurons in the ARC of female mice (Navarro et al. 2009) and 6% of Oprk1 mRNA which 
encodes KOR co-localised with kisspeptin neurons of male mice (Navarro, Gottsch, et al. 
2011), thus suggesting that there may be intermediary neurons that are stimulated by the 
dynorphin secreted from KNDy neurons to cause the GnRH pulse to cease.  
Ovariectomy reduces the expression of pro-dynorphin gene transcription in the ARC of ewes 
(Foradori et al. 2005), compared with increases seen with kisspeptin and NKB (Rometo and 
Rance 2008). Post mortem hypothalami of pre and post-menopausal women were compared 
using in situ hybridisation and found in post-menopausal women a reduction in dynorphin gene 
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expression on neurons in the infundibular nucleus and POA/anterior hypothalamus. 
Interestingly only in the infundibular nucleus was there hypertrophy of dynorphin expressing 
cells, although the overall gene expression was reduced (Rometo and Rance 2008). There were 
no other differences in dynorphin expression elsewhere in the hypothalamus between the two 
groups. As dynorphin has inhibitory effects, the reduction in endogenous dynorphin expression 
in neurons of the infundibular, POA and anterior hypothalamus after menopause may represent 
a reduction in the inhibition to gonadotrophin secretion, thus allowing the rise in 
gonadotrophins seen post-menopause.  
In post-menopausal and ovariectomised young women naloxone had no effect on LH secretion 
(Melis et al. 1984; Casper and Alapin-Rubillovitz 1985; Shoupe, Montz, and Lobo 1985; 
Dawood, Khan-Dawood, and Ramos 1986), however, after sex steroid replacement this 
restored their ability to respond to naloxone and caused a rise in LH (Melis et al. 1984; Casper 
and Alapin-Rubillovitz 1985; Shoupe, Montz, and Lobo 1985). This suggests that the loss of 
opioid tone after oophorectomy and menopause is due to the removal of sex steroids, and this 
can be restored with sex steroid treatment.   
 
1.14.4 Kisspeptin  
KISS1R is not expressed on KNDy neurons in the ARC (Herbison et al. 2010; Smith et al. 
2011) and therefore, it is unlikely that kisspeptin has any direct action on KNDy neurons. 
Kisspeptin release from activated KNDy neurons acts at KISS1R on GnRH neurons to 
stimulate GnRH release (Irwig et al. 2004; Han et al. 2005; Messager et al. 2005).  
In rats, kisspeptin injections into the POA and ARC did not stimulate LH secretion, however, 
administration of a kisspeptin antagonist to the ARC resulted in a reduction of LH pulse 
frequency (Li et al. 2009). Intra-ARC implants of KISS1R antagonist in ewes inhibited LH 
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secretion (Goodman et al. 2013), thus suggesting that kisspeptin may act on non-KNDy 
KISS1R positive neurons in the ARC to exert effects on LH secretion.  
 
1.14.5 Involvement in sex steroid negative feedback 
KNDy neurons have been implicated in sex steroid negative feedback; virtually all KNDy 
neurons express the ERα and progesterone receptor in females (Foradori et al. 2002; Burke et 
al. 2006; Smith et al. 2007; Maeda et al. 2010) and the ERα and androgen receptor in males 
(Smith, Dungan, et al. 2005). Sex steroids exert a negative feedback effect on GnRH secretion 
likely mediated through ARC KNDy neurons. Ablation of KNDy neurons in rats results in 
complete abolishment of the negative feedback action of oestradiol on LH secretion (Yeo and 
Herbison 2014).  
 
In ovariectomised animals and post-menopausal women without oestradiol replacement there 
is hypertrophy in the ARC with increased expression of kisspeptin and NKB (Rance and Young 
1991; Rance and Bruce 1994; Smith, Cunningham, et al. 2005; Smith, Dungan, et al. 2005; 
Rometo et al. 2007; Smith et al. 2007; Rance 2009) and a reduction in dynorphin mRNA 
(Foradori et al. 2005) and fewer dynorphin cell numbers (Rometo and Rance 2008).  
 
Oestradiol reduced the MUA volley frequency in the ARC as well as LH secretion (Kesner et 
al. 1987; Nishihara, Sano, and Kimura 1994; Wakabayashi et al. 2010), in keeping with 
negative feedback effects of sex steroids. Oestradiol also induces a decline in NKB mRNA in 
the ARC of sheep and monkeys (Abel, Voytko, and Rance 1999; Pillon et al. 2003). There is 
also a reduction in NKB, NK3R and KISS1 expression in the ARC during the pre-ovulatory 
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phase when oestradiol is high (Navarro, Castellano, et al. 2004; Smith, Popa, et al. 2006; 
Navarro, Castellano, et al. 2011).  
Taken together the evidence suggests that KNDy neurons in the ARC mediate the negative 
feedback effects of sex steroids on GnRH secretion.   
 
1.14.6 KNDy neuron hypothesis of GnRH pulse generation  
KNDy neurons are not only anatomically ideally located to be part of the GnRH pulse 
generator, but they are able to mediate sex steroid negative feedback and stimulate GnRH 
release. MUAs recorded in the vicinity of KNDy neurons in the ARC of goats have been shown 
to correlate with LH pulses (Ohkura, Takase, et al. 2009) and are synchronised (Wakabayashi 
et al. 2013).   
The mechanism by which KNDy neurons work to stimulate GnRH secretion is still yet to be 
fully elucidated. NKB has no direct effect on GnRH neurons and therefore, is thought to work 
in the ARC on KNDy neurons that express its receptor, NK3R (Navarro, Gottsch, et al. 2011). 
Senktide (NK3R agonist) and NKB have been shown to induce c-Fos expression in KISS1 
neurons in the ARC of rats (Navarro, Castellano, et al. 2011) and sheep (Sakamoto et al. 2012). 
NKB also has been shown to cause depolarisation in KISS1 neurons, which was significantly 
reduced by a NK3R antagonist (Navarro, Gottsch, et al. 2011).  NK3R antagonist 
administration to KISS1 neuron brain slices taken from male mice resulted in a reduction in 
NKB activation suggesting that NKB works on NK3R expressed on KISS1 neurons (Navarro, 
Gottsch, et al. 2011) to cause kisspeptin release.  
In pre-pubertal rats administration of a kisspeptin receptor antagonist blocked senktide induced 
LH pulses (Grachev, Li, Lin, et al. 2012), suggesting that kisspeptin acts downstream of NKB. 
Also, in humans with TAC3 and TAC3R mutations, kisspeptin can restore pulsatile LH 
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secretion (Young et al. 2013) and KISSR knockout mice show no response to senktide or KOR 
antagonists (Garcia-Galiano et al. 2012). Collectively indicating that NKB must work upstream 
of kisspeptin in the pathway that stimulates LH release.  
 
Furthermore, senktide administered to castrated juvenile male macaque monkeys resulted in a 
rise in LH which was abolished with a GnRH receptor antagonist and a NK3R antagonist 
(Ramaswamy et al. 2010). Despite the NK3R antagonist, there was still a rise in LH with IV 
kisspeptin-10, again suggesting that NKB works upstream of kisspeptin and GnRH 
(Ramaswamy et al. 2010). Interestingly, the NKB and kisspeptin systems both show evidence 
of tachyphylaxis; in agonadal juvenile male monkeys, a continuous IV infusion of kisspeptin-
10 over 99h resulted in likely desensitisation of the KISS1R with no further LH response to 
kisspeptin but also with no response to senktide (Ramaswamy, Seminara, and Plant 2011). 
Although the monkeys remained responsive to GnRH. An IV infusion of senktide for 48h 
desensitised the NK3R such that in the last 3h there was no further response to senktide, 
however there was response to kisspeptin-10 (Ramaswamy, Seminara, and Plant 2011). 
Similarly, in KISS1R knockout mice the stimulatory actions of NKB in wild type mice are not 
seen (Garcia-Galiano et al. 2012). Taken together the evidence above demonstrates that NKB 
likely works upstream of kisspeptin, and in view of continued response to GnRH despite 
KISS1R desensitization that kisspeptin must work upstream of GnRH.    
 
Therefore, a currently accepted model of KNDy neuron action is that NKB secreted by KNDy 
neurons in the ARC acts autosynaptically and via branches of interconnecting cell bodies and 
dendrites to activate NK3R on other KNDy neurons to stimulate kisspeptin release.  
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Kisspeptin then activates KISS1R on GnRH neurons which stimulates them to secrete GnRH 
and stimulate the rest of the HPG axis. Dynorphin has an inhibitory role and is thought to be 
secreted by KNDy neurons to cease kisspeptin release and subsequent GnRH release. As only 
6-20% of KNDy neurons express KOR receptors, it is suggested that the mechanism for this is 
via the interconnecting network of other neurons (Navarro et al. 2009; Navarro, Gottsch, et al. 
2011). 
 
NKB may work with dynorphin to inhibit the GnRH pulse; a KOR antagonist blocked the 
senktide induced suppression of pulsatile LH in ovariectomised rats with or without low 
oestradiol replacement (Grachev, Li, Kinsey-Jones, et al. 2012), indicating that intact 
dynorphin signalling is required for NKB to act in low steroid states. Although, in ex vivo 
experiments examining ARC neurons from intact and castrated male mice, pre-treatment with 
dynorphin reduced the ability of KNDy neurons to respond to senktide only in the intact group, 
suggesting that dynorphin is important in regulating the response to senktide in sex steroid 
replete states as well (Ruka, Burger, and Moenter 2013).  
 
ICV senktide suppressed LH pulses and intra-ARC MUA in both ovariectomised and 
ovariectomised oestradiol replaced rats (Grachev, Li, Kinsey-Jones, et al. 2012; Kinsey-Jones 
et al. 2012), also a reduction in the expression of genes for KISS1R and GnRH but not KISS1 
in the POA was seen (Grachev, Li, Kinsey-Jones, et al. 2012). However, pre-treatment with a 
KOR antagonist removed the senktide induced inhibition of LH, thus suggesting that NKB 
suppresses the frequency of the GnRH secretion in a dynorphin and kappa opioid receptor 
dependent fashion and may regulate KISS1R and GnRH neuron gene expression (Grachev, Li, 
Kinsey-Jones, et al. 2012; Kinsey-Jones et al. 2012). Although in intact pre-pubertal rats, 
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senktide caused a rise in LH and pre-treatment with a KOR antagonist did affect the senktide 
induced LH pulses (Grachev, Li, Lin, et al. 2012).  
 
There may be gender differences in the response to dynorphin and senktide, in female rats 
senktide increased LH release and no change was seen with pre-treatment using a KOR 
antagonist. In  male rats no change in gonadotrophins was seen with senktide. However, pre-
treatment with a KOR antagonist then resulted in a gonadotrophin rise with senktide (Ruiz-
Pino et al. 2015).  One explanation could be that there is a higher dynorphin inhibitory tone in 
males so when blocked by the KOR antagonist the stimulatory effects of senktide are now seen.  
As highlighted there are lots of conflicting studies in different animal models with regards to 
NKB effects and NKB and dynorphin/KOR antagonist interactions. However, a hypothesis for 
how the KNDy peptides interact has been developed and figure 1.5 shows a pictorial 
representation. KNDy neurons form collaterals and a dense network of interconnecting neurons 
which then project to GnRH terminals in the ME. NKB stimulates KNDy neurons at the NK3R 
and the interconnecting network as well as autosynaptic activation then initiates a synchronised 
burst of kisspeptin which is released in a pulse at the ME. Kisspeptin at the ME acts on GnRH 
neurons/nerve terminals at KISS1R to stimulate GnRH secretion into the hypophyseal portal 
circulation. Dynorphin then acts to reduce the frequency of this burst, either by direct action 
on KNDy neurons although there are very few KOR isolated on KNDy neurons or through 
other intermediary neurons. Dynorphin inhibition then ceases prior to the next stimulatory burst 
induced by NKB through currently unidentified processes.  
 
Sex steroids negatively feedback onto KNDy neurons in the ARC; in females oestradiol acting 
at the ERα and in males testosterone aromatised to oestradiol acting at the ERα and androgen 
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receptor (Smith 2013). KNDy neuron ablation resulted in the loss of sex steroid feedback 
(Mittelman-Smith et al. 2012).  
Kisspeptin neurons express several other receptors and have been shown to closely interact 
with metabolic neuropeptides to mediate and regulate GnRH secretion which is further 
discussed in section 1.20.  
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Figure 1.5: KNDy neuron hypothesis of GnRH secretion.  
Pictorial representation of the KNDy neuron hypothesis of GnRH secretion. KNDy neurons 
located in the ARC/infundibular nucleus project to the median eminence where they secrete 
kisspeptin which acts at the KISS1R on GnRH nerve terminals to secrete pulsatile GnRH which 
acts on pituitary gonadotrophs to secrete LH and FSH. Once sufficient GnRH has been 
secreted, the KNDy neuron secretes dynorphin which act at the kappa opioid receptor (KOR) 
on yet to be identified intermediary neurons which project back onto the KNDy neurons to 
inhibit neuronal activity and terminate the GnRH pulse. NKB secreted by the KNDy neuron 
acts autosynaptically and on other KNDy neurons at the NK3R to stimulate kisspeptin 
secretion. However, in certain animal models studied NKB can also suppress GnRH and 
gonadotrophin secretion and this may be via a KOR dependent pathway although the exact 
mechanism of suppression is yet to be determined.  
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However, this is a tentative hypothesis and questions still remain including the mechanism by 
which NKB initiates and dynorphin ceases the GnRH pulse. Although it has been suggested 
that these neurons may possess pacemaker function. Clearly this pathway needs to be further 
investigated, however, manipulation of these peptides may offer a novel therapeutic avenue in 
the future. Therefore, in order to investigate this relationship further in humans I investigated 
(chapter four) the effects of co-administering kisspeptin-54, NKB and an opioid receptor 
antagonist, naltrexone on LH pulsatility (surrogate marker for GnRH pulsatility in humans) 
and gonadotrophin release in humans.  
 
1.15 Chronic kisspeptin administration and tachyphylaxis 
Kisspeptin causes a dose-dependent stimulation of LH secretion, which is more marked than 
its effects on FSH or testosterone secretion. However, prolonged administration causes 
desensitisation to these effects, resulting in a lower LH response. This phenomenon is called 
tachyphylaxis. The KISS1R, like other G-protein coupled receptors undergo ligand induced 
receptor desensitisation due to uncoupling of the receptor from its signalling pathway and 
receptor internalisation (Bianco et al. 2011). Internalisation is usually mediated by arrestin, 
which is present on the membrane and binds phosphorylated receptors, preventing further 
coupling, signalling and then triggers receptor internalisation (Drake, Shenoy, and Lefkowitz 
2006). Receptor internalisation was shown in KISS1R using fluorescence microscopy 
(Pampillo et al. 2009; Bianco et al. 2011). 
Animal studies have shown that continuous administration of kisspeptin results in a reduction 
in biological effect within 3hrs (Seminara et al. 2006; Thompson et al. 2006; Caraty et al. 2007; 
Ramaswamy et al. 2007; Roa, Vigo, Garcia-Galiano, et al. 2008; Thompson et al. 2009), 
although they were still responsive to GnRH (Seminara et al. 2006; Roa, Vigo, Garcia-Galiano, 
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et al. 2008).  Interestingly, adult female rats showed tachyphylaxis after continued kisspeptin 
infusion, however, the onset of this was delayed in underfed animals (Roa, Vigo, Garcia-
Galiano, et al. 2008). Also, in pubertal females gonadotrophin levels remained elevated after 
the 7 day infusion of kisspeptin and the levels in underfed pubertal animals were higher (Roa, 
Vigo, Garcia-Galiano, et al. 2008). Thus kisspeptin actions and receptor desensitization is 
likely to depend also on pubertal and metabolic status.   
Tachyphylaxis has also been demonstrated in human studies where higher doses or more 
frequent administration of kisspeptin has resulted in a lower rise of LH (Dhillo et al. 2005; 
Jayasena et al. 2009). However, George et al, showed that continuous infusion of kisspeptin-
10 over 22.5h in men resulted in a continued rise in LH without tachyphylaxis (George et al. 
2011), although they administered a dose of 0.69nmol/kg/h which was likely to be below the 
dose required for tachyphylaxis. Dhillo et al, administered IV infusions of kisspeptin-54 and 
found that at doses above 0.72nmol/kg/h tachyphylaxis occurred (Dhillo et al. 2005). However, 
different isoforms have been used and therefore, it is difficult to compare these outcomes and 
doses used directly.  
In women with HA twice daily injections of kisspeptin initially increased gonadotrophins, 
however, this was not maintained and resulted in tachyphylaxis (Jayasena et al. 2009). 
Therefore, if kisspeptin is to be used therapeutically in the future then important consideration 
must be taken with regards to the dose and timing of injections. Also in view of tachyphylaxis, 
kisspeptin has the potential to be used therapeutically in the future to down regulate the HPG 
axis to treat hormone sensitive cancers or even as a form of contraception and this is further 
discussed in section 1.17 regarding kisspeptin antagonists.  
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1.16 Therapeutic applications of kisspeptin to stimulate the HPG axis 
1.16.1 General overview  
The HPG axis is tightly regulated and therefore, any changes or disturbances to any part of the 
pathway could result in disruption and ultimately infertility. Hypogonadism refers to low 
circulating levels of sex steroids and ineffective spermatogenesis or ovarian follicular growth, 
caused by primary or secondary causes. Primary hypogonadism directly affects the gonads and 
their sex steroid production, and due to the loss of sex steroid negative feedback on the 
hypothalamus and pituitary, gonadotrophins are increased to try and increase sex steroid 
production from the gonads, resulting in high LH and FSH levels.  In secondary hypogonadism 
there is inadequate gonadotrophin signalling to the gonads resulting in low gonadotrophin 
levels.  
Secondary hypogonadism is also referred to as hypogonadotrophic hypogonadism (HH), since 
the gonadotrophin levels and the sex steroids are both low. There are a number of causes of 
secondary hypogonadism all resulting in the reduction of pituitary gonadotrophin secretion. 
For kisspeptin to be used as a therapeutic, it requires intact and functioning GnRH neurons as 
it acts directly on KISS1R on GnRH neurons, therefore, the disruption to the HPG axis must 
be above the level of GnRH neurons. There must also be functioning gonads that can respond 
to gonadotrophins after kisspeptin stimulation of the HPG axis. As such any congenital 
conditions affecting hypothalamic stimulation of the HPG axis can be successfully treated with 
kisspeptin as well as acquired conditions such as hypothalamic amenorrhoea due to low body 
weight as described below.  
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1.16.2 GnRH deficiency 
Any defect in the hypothalamic signalling to GnRH neurons can result in HH. KISS1 and 
KISS1R mutations resulting in HH can be successfully treated with kisspeptin to induce 
puberty and sexual maturation, as well as reproduction (Pallais et al. 2006). Also mutations of 
the NKB gene or its receptor (TAC3 and TACR3) can result in HH (Topaloglu et al. 2009), 
and although knockout mice have shown variable reproductive phenotype, in humans these 
result in HH. Young et al, showed that these patients had low amplitude LH pulses which 
increased in amplitude and frequency on kisspeptin administration (Young et al. 2013). 
 
1.16.3 Hypothalamic amenorrhea 
Women with functional hypothalamic amenorrhoea (HA) (i.e. HH due to low body weight, 
with low circulating gonadotrophins and oestradiol and no structural hypothalamic or pituitary 
lesion), are able to respond to kisspeptin and increase their gonadotrophin levels. Women with 
HA are in fact much more responsive to exogenous kisspeptin than healthy females in the 
follicular phase of the menstrual cycle (when they normally have their lowest levels of 
oestradiol) resulting in a four times greater response in LH (Jayasena et al. 2009). This could 
represent enhanced responsiveness of KISS1R to kisspeptin in HA women. This rise in 
gonadotrophins was partially sustained during twice weekly kisspeptin administration, 
however, twice daily administration led to a desensitisation and lower LH compared to twice 
weekly administration  (Jayasena et al. 2010). Thus indicating that the dose and frequency of 
treatment is particularly important in this cohort of patients who are extremely sensitive to 
kisspeptin.  
Similarly, in animals subjected to undernutrition, there is suppression of reproductive activity 
and exogenous kisspeptin can stimulate LH secretion (Castellano et al. 2005), indicating that 
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downstream pathways are intact and the stress resulted in kisspeptin suppression. These 
animals had a reduction in hypothalamic KISS1R mRNA and in particular a suppression of 
kisspeptin expression in the ARC (Castellano et al. 2005; Kinsey-Jones et al. 2009). Therefore, 
it is likely women with HA also have a reduction in hypothalamic kisspeptin expression which 
reduces HPG functioning.  
 
1.16.4 Hyperprolactinaemia 
High prolactin levels suppress the HPG axis resulting in low gonadotrophins as seen in 
physiological states such as lactation but also in pathological conditions such as pituitary 
adenomas which secrete prolactin. The prolactin receptor is also expressed on ARC kisspeptin 
neurons but minimally on GnRH neurons (Kokay, Petersen, and Grattan 2011; Li et al. 2011). 
Ovariectomised rats with elevated levels of prolactin had reduced levels of ARC kisspeptin 
expression and low LH (Araujo-Lopes et al. 2014), indicating that prolactin may be acting on 
kisspeptin neurons in the ARC to negatively affect GnRH secretion. In patients with 
hyperprolactinaemia, the primary aim is to reduce the high prolactin which should improve the 
suppressive reproductive effects, however, 11-24% of patients fail to achieve a normal 
prolactin with current treatments (Molitch 2003) or are unable to tolerate the treatment due to 
side effects. Therefore, in this sub group of patients with amenorrhoea kisspeptin could 
potentially be used to stimulate the HPG axis and restore menstrual cyclicity.  
 
1.16.5 In vitro fertilisation (IVF) 
As described above, the pre-ovulatory GnRH surge stimulated by the positive feedback of 
oestradiol mediated through the actions of kisspeptin neurons in the AVPV of rodents and the 
ARC and possibly POA in other species is important in achieving the GnRH and subsequent 
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LH surge to trigger ovulation. In vitro fertilisation (IVF) treatment artificially replicates the 
ovarian cycle using exogenous gonadotrophins as well as GnRH antagonists to prevent an early 
GnRH surge. In vivo the LH surge stimulates follicle maturation and then ovulation and in IVF 
treatment, human chorionic gonadotrophin (hCG) is used to replicate LH. Unfortunately, hCG 
has a long duration of action and thus women are at risk of over stimulating the ovaries and 
developing the potentially life-threatening condition ovarian hyper stimulation syndrome 
(OHSS). This is the most common complication of IVF treatment (Kawwass et al. 2015) and 
can occur in 1 in 3 IVF cycles, although symptoms may be mild, severe symptoms are found 
in 1 in 10 IVF cycles (Delvigne and Rozenberg 2002) and consist of ovarian enlargement and 
fluid imbalance with ascites, hydrothorax, renal failure, acute respiratory distress syndrome 
and even death (Delvigne and Rozenberg 2002). Women with polycystic ovarian syndrome 
(PCOS) have a five times greater risk of developing OHSS with IVF (Wada et al. 1993). 
Therefore, kisspeptin offers an alternative to hCG treatment to trigger egg maturation. The rise 
in LH after kisspeptin is shorter than with hCG and therefore, reduces the risk of 
overstimulating the ovary. In fact kisspeptin has been successfully used in IVF with similar 
pregnancy rates to the conventional hCG trigger, however, with no complications of OHSS 
(Jayasena, Abbara, Comninos, et al. 2014). Kisspeptin was then used in women with PCOS 
and thus were at higher risk women of OHSS and found that there were no cases of moderate 
to severe OHSS in this group (Abbara et al. 2015).  
 
1.16.6 Kisspeptin analogues 
Although kisspeptin is ideally placed to act as a therapeutic for infertility and reproductive 
disorders, there are difficulties, such as the potential of tachyphylaxis. Thus kisspeptin 
analogues may be able to overcome this hurdle or even be used to suppress the HPG axis in 
hormone sensitive cancers (MacLean et al. 2014; Matsui et al. 2014) as explained below.  
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1.17 Therapeutic applications of kisspeptin to inhibit the HPG axis  
Kisspeptin signalling is limited by tachyphylaxis therefore, over stimulation cannot occur. This 
feature can be utilised to down regulate the HPG axis in conditions such as hormone sensitive 
cancers where suppression of the HPG axis is required. Kisspeptin receptor antagonists have 
been developed and may have the ability to cross the blood brain barrier (Roseweir et al. 2009).  
Administration of a kisspeptin antagonist to the stalk/median eminence of pubertal female 
rhesus monkeys suppressed GnRH secretion and GnRH pulses, which ceased after the 
antagonist infusion was stopped (Roseweir et al. 2009). Kisspeptin antagonists also delay 
vaginal opening and reduce gonadal weights in female rats (Pineda et al. 2010), thus delaying 
puberty.  
Kisspeptin antagonists can affect sex steroid feedback; ICV administration of kisspeptin 
antagonists inhibited the post castration rise in gonadotrophins in male mice and rats (Roseweir 
et al. 2009), indicating inhibition of sex steroid negative feedback on GnRH secretion. ICV 
pump delivery of a kisspeptin antagonist pre-oestrus resulted in a failure of the LH surge 
(Pineda et al. 2010), indicating inhibition of sex steroid positive feedback on the GnRH surge.  
Interestingly, the use of kisspeptin antagonists have not shown any disruption of basal GnRH 
secretion and does not reduce LH as much as GnRH antagonists, indicating a kisspeptin 
independent mechanism for GnRH secretion (Roseweir et al. 2009).  Although this may be 
seen as an advantage in some clinical situations where complete suppression of the GnRH is 
not required such as in endometriosis and benign prostatic hypertrophy. Polycystic ovarian 
syndrome may also be a likely clinical application but needs to be further investigated, as it 
could reduce follicular growth and oestradiol. Pineda et al, showed inhibition of the pre-
ovulatory LH surge after administration of a kisspeptin antagonist in rats, but no change to 
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basal LH (Pineda et al. 2010), suggesting that this could even be used as a novel contraceptive 
without the need for high levels of sex steroids as used in current contraceptive agents.  
Treating hormone sensitive cancers generally requires reduction in gonadotrophins to 
castration levels, which can be achieved with GnRH agonists (through desensitisation of the 
GnRH receptor) and antagonists, although side effects are possible of hot flushes, bone loss, 
low lean body weight. 
 
1.18 Extra hypothalamic functions of kisspeptin in reproduction  
1.18.1 Pituitary  
In view of KISS1R expression in the pituitary it has been questioned whether there could be 
direct pituitary stimulation by kisspeptin to secrete gonadotrophins. There have been some 
varied results across the species. Pituitary cells taken from rats, baboons, pigs, sheep and cows 
cultured with kisspeptin resulted in LH secretion although some studies required sex steroid 
incubation in order to stimulate LH secretion (Navarro, Castellano, Fernandez-Fernandez, 
Tovar, Roa, Mayen, Nogueiras, et al. 2005; Smith et al. 2007; Suzuki, Kadokawa, and 
Hashizume 2008; Ezzat et al. 2010; Luque et al. 2011). However, in rats there have been 
conflicting reports, some studies show no gonadotrophin secretion from pituitary cell cultures 
when incubated with kisspeptin-10 (Thompson et al. 2004), however, this discrepancy may be 
related to adult rats being studied here as opposed to the pubertal rats above which were able 
to respond to kisspeptin (Navarro, Castellano, Fernandez-Fernandez, Tovar, Roa, Mayen, 
Nogueiras, et al. 2005).  In vivo studies in sheep however, using the hypothalamo-pituitary 
disconnection (HPD) model, whereby the pituitary is cut off from the median eminence and is 
thus not able to receive GnRH, did not show any direct pituitary effect of kisspeptin in 
ovariectomised ewes replaced with GnRH (Smith et al. 2007).  
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Interestingly, Thompson et al, who found no LH secretion from rat pituitary cell cultures 
incubated with kisspeptin had used 100 times the dose of kisspeptin required to stimulate 
hypothalamic explants to secrete GnRH (Thompson et al. 2004). Thus although there may be 
some direct pituitary stimulation by kisspeptin, although not consistently shown, this is likely 
to be a very small effect in comparison with the effect of kisspeptin on the hypothalamus to 
secrete GnRH. On pre-administering GnRH receptor antagonists to rodents and monkeys there 
is an inhibition of the stimulatory effects of kisspeptin on gonadotrophin secretion (Gottsch et 
al. 2004; Shahab et al. 2005; Roseweir et al. 2009), indicating that direct kisspeptin effects on 
the pituitary to secrete gonadotrophins is minimal.   
 
1.18.2 Pregnancy and implantation 
The highest circulating levels of kisspeptin in humans have been found during pregnancy with 
increasing levels throughout gestation up to 7000 times greater than in non-pregnant females 
(Horikoshi et al. 2003; Jayasena, Abbara, Izzi-Engbeaya, et al. 2014). This is likely to be as a 
result of kisspeptin secretion from the placenta, where syncytiotrophoblast cells have shown to 
express the highest peripheral levels of kisspeptin (Bilban et al. 2004). KISS1R is also 
expressed in placental tissue (Janneau et al. 2002). In gestational trophoblastic neoplasia, there 
is a malignant increase in placental invasion and hypertrophy with high levels of plasma 
kisspeptin-IR which fall after chemotherapy treatment, indicating that the placenta highly 
secretes kisspeptin (Dhillo et al. 2006).  
Kisspeptin actions in the placenta need to be further elucidated, however, it may be involved 
in trophoblast invasion and angiogenesis in the early part of pregnancy in order to create a 
viable placenta (Horikoshi et al. 2003; Bilban et al. 2004; Terao et al. 2004), after which it is 
likely that kisspeptin inhibits migration and proliferation further into the endometrium (Bilban 
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et al. 2004; Hiden et al. 2007). Bilban et al, reported that actually in the first trimester when 
placental invasion is key to a successful pregnancy there are higher levels of KISS1/KISS1R 
in the placenta compared with term (Bilban et al. 2004), although this is in contrast to the 
maternal circulatory kisspeptin levels that rise with gestation (Horikoshi et al. 2003). The 
syncytiotrophoblast is in close association with the maternal bloodstream and thus allows 
kisspeptin to enter the circulation from the placenta. More research is needed to investigate the 
role of kisspeptin after implantation.  
Women with a lower kisspeptin level in the first trimester had a greater risk of miscarriage 
(Jayasena, Abbara, Izzi-Engbeaya, et al. 2014), thus kisspeptin levels may correlate with 
pregnancy complications, including pre-eclampsia (Logie et al. 2012) and intrauterine growth 
retardation (Smets et al. 2008). Lower kisspeptin levels were found in pregnant women with 
type 1 diabetes, gestational diabetes, hypertension, pulmonary embolus and placental 
dysfunction compared with normal pregnant women, indicating that kisspeptin may be affected 
by a number of factors (Cetkovic et al. 2012). Therefore, kisspeptin may be used in the future 
as a prognostic indicator of better pregnancy outcomes with lower complication rates.  
 
1.18.3 Gonads 
KISS1 and KISS1R expression have been found in the ovary (Ohtaki et al. 2001; Castellano, 
Navarro, Fernandez-Fernandez, Roa, et al. 2006; Gaytan et al. 2009; Shahed and Young 2009) 
and testes (Ohtaki et al. 2001) of number of species, although the majority of studies have been 
conducted on ovarian tissue. As such it would be plausible that kisspeptin could act directly on 
the gonads.  
KISS1 expression in the ovary varies over the oestrous cycle with greatest expression before 
ovulation in rats and Siberian hamsters (Castellano, Navarro, Fernandez-Fernandez, Roa, et al. 
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2006; Shahed and Young 2009), although KISS1R mRNA levels remained stable throughout 
(Castellano, Navarro, Fernandez-Fernandez, Roa, et al. 2006). Interestingly, on blocking the 
pre-ovulatory LH surge in rats, this eliminated the rise in KISS1 expression in the ovary, 
indicating that gonadotrophins may regulate KISS1 expression in the ovary (Gaytan et al. 
2009). Inhibition of prostaglandin synthesis has been implicated in regulating gonadotrophin 
induced KISS1 expression in the ovary (Gaytan et al. 2009). However, local kisspeptin action 
at the ovary is unlikely to affect ovulation as shown by KISS1R mutants who were able to 
ovulate with gonadotrophin treatment (Seminara et al. 2003; Pallais et al. 2006).  
There is a paucity of data regarding kisspeptin effects on the testes, however, kisspeptin 
expression has been investigated in sperm; kisspeptin-IR has been found in human spermatozoa 
(Pinto et al. 2012) and on kisspeptin administration calcium responses were seen in sperm as 
well as a change in motility (Pinto et al. 2012). However, further work is needed on determine 
kisspeptin effects on the testes and sperm.  
 
1.19 Other regulators of GnRH secretion may interact with kisspeptin 
GnRH secretion is regulated by a dynamic balance between excitatory and inhibitory signals 
that are yet to be fully understood; internal and external signals are likely to regulate GnRH 
secretion and may act via kisspeptin signalling.  
Internal signals include:- 
 Gonadal steroids and stress hormones (Kinsey-Jones et al. 2009; Li, Knox, and 
O'Byrne 2010).  
 Nutrient and metabolic signals, including the neuropeptides leptin, neuropeptide Y 
(NPY), melanocortins, ghrelin and insulin (Woller et al. 1992; Fernandez-Fernandez 
et al. 2006; Martini et al. 2006; Tena-Sempere 2007; Pralong 2010; Pinilla et al. 2012). 
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 Inflammatory state (Tomaszewska-Zaremba and Herman 2009; Castellano et al. 2010).  
 Other neuropeptides including  
o Other RF-amide superfamily peptides e.g. gonadotrophin inhibiting hormone 
and RF-releasing peptides (Navarro et al. 2006; Smith and Clarke 2010). 
o Noradrenaline (Gore and Terasawa 1991). 
o Glutamate (Ezzat, Pereira, and Clarke 2015). 
o Gamma-aminobutyric acid (GABA) (Cheong et al. 2015). 
o Opioids (Gallo 1990; Kimura et al. 1991; Kinsey-Jones et al. 2008; Mostari et 
al. 2013).   
External signals:-  
 Environmental factors such as social cues 
 Photoperiod (day length) in seasonal breeders (Simonneaux et al. 2009).  
 
Glutamate, noradrenergic and NPY signalling have been associated with an excitatory role on 
GnRH neurons (Gore and Terasawa 1991; Woller et al. 1992; Ezzat, Pereira, and Clarke 2015). 
Whilst GABA and opioids an inhibitory role (Herbison and Moenter 2011).  
The ARC kisspeptin population are predominantly glutamatergic and the RP3V population 
GABAergic (Cravo et al. 2011). Interestingly, kisspeptin has been shown to mediate the 
inhibitory action of GABA on GnRH, by using a GABA antagonist in monkeys, which resulted 
in GnRH secretion and an advancement in menarche which was inhibited by a kisspeptin 
antagonist (Kurian et al. 2012).  
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1.20 Kisspeptin and the metabolic regulation of GnRH secretion 
 
1.20.1 Kisspeptin may mediate metabolic effects on GnRH secretion 
Reproduction is a heavily consumptive process and thus adequate metabolic conditions must 
be in place to sustain reproduction. Therefore, metabolic regulatory signals must be able to 
influence GnRH secretion. There is a reduction in the expression of hypothalamic KISS1 
mRNA and gonadotrophin secretion in rats that have been fasted (Castellano et al. 2005), 
specifically in some studies a reduction of KISS1 mRNA in the AVPV (Kalamatianos et al. 
2008) or the ARC (Backholer et al. 2010) or both (True, Kirigiti, Kievit, et al. 2011). In pre-
pubertal rats with chronic undernutrition, kisspeptin administration can increase 
gonadotrophins, sex steroids and restore delayed vaginal opening (Navarro, Fernandez-
Fernandez, et al. 2004; Castellano et al. 2005). Interestingly, there is also a reduction in TAC3R 
and TAC2 in the ARC of pubertal female rats after fasting (Navarro et al. 2012).   
Obesity also affects kisspeptin signalling and in overfed mice with low levels of testosterone, 
there were normal levels of KISS1 mRNA in the hypothalamus rather than the increased levels 
that may have been expected given the low sex steroids (Garcia-Galiano, Pinilla, and Tena-
Sempere 2012). Obese mice have shown a reduction in KISS1 mRNA levels in the AVPV and 
ARC (Quennell et al. 2011), although some studies have also shown that obesity is associated 
with increased hypothalamic KISS1 mRNA levels and advanced vaginal opening (Castellano 
et al. 2011).  
KISS1R knockout mice not only have impaired reproductive function but they also have 
striking effects on body composition, weight and glucose metabolism. Compared with the wild 
type, KISS1R knockout mice have increased fat mass and a reduction in lean mass, however, 
females also display impaired glucose tolerance, increased body mass, reduced food intake, 
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reduced locomotion and energy expenditure (Tolson et al. 2014). Suggesting sexual 
dimorphism of kisspeptin signalling and metabolic regulation.  
As oestradiol deficiency is also associated with obesity in females (Butera, Wojcik, and Clough 
2010; Eckel 2011), ovariectomised KISS1R knockout mice continued to display reduced 
energy expenditure, increased weight gain, increased fat mass and impaired glucose tolerance 
compared to ovariectomised controls (Tolson et al. 2014), thus indicating the effects in the 
mutant mouse were independent of oestradiol. However, gonadectomised KISS1R knockout 
males showed no differences in body weight compared with high fat diet fed gonadectomised 
wild type and had normal glucose homeostasis (Tolson et al. 2014).   
Taken together this suggests that kisspeptin signalling may mediate metabolic regulatory 
effects on GnRH secretion in a sexually dimorphic manner.  
 
1.20.2 Leptin 
 
1.20.2.1 Leptin an important regulator of GnRH secretion 
Fat stores are an important indicator of metabolic status and readiness for impending 
reproduction. Leptin is a peptide hormone secreted from adipocytes and is proportional to body 
fat stores (Zhang et al. 1994; Maffei et al. 1995). It acts on the leptin receptor in the 
hypothalamus to regulate appetite pathways resulting in a reduction in food intake. 
Leptin deficient mice have HH, delayed puberty and are infertile, which can be restored with 
leptin administration (Chehab, Lim, and Lu 1996; Mounzih, Lu, and Chehab 1997). Leptin has 
even been shown to advance puberty in normal mice (Ahima et al. 1997), indicating that leptin 
can induce GnRH secretion sufficient to stimulate the HPG axis. In humans, mutations in the 
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leptin gene or its receptor result in HH and obesity (Montague et al. 1997), which can be treated 
with leptin replacement (Farooqi et al. 1999).  
Therefore, it was proposed that leptin could relay nutritional status to the reproductive axis. 
However, the leptin receptor (LepRb) is not found on GnRH neurons (Finn et al. 1998; 
Quennell et al. 2009) but is expressed in a proportion of kisspeptin neurons in the ARC (Smith, 
Acohido, et al. 2006; Cravo et al. 2011). Thus kisspeptin neurons are ideally placed to mediate 
the effects of leptin on GnRH secretion.  
Gonadectomised leptin knockout mice (Ob/Ob) have a reduction in ARC KISS1 mRNA 
expression and this can be partially upregulated by leptin administration with a rise in 
gonadotrophins (Smith, Acohido, et al. 2006). Kisspeptin administered to leptin deficient pre-
pubertal rats and those with a mutation in the leptin receptor causing a hyperleptinaemic state, 
showed puberty and maturation of the reproductive system (Navarro, Fernandez-Fernandez, et 
al. 2004), suggesting a lack of kisspeptin in these mutant mice, which on replacement 
stimulated the HPG axis. 
Leptin has been shown to depolarise ARC kisspeptin neurons in guinea pigs (Qiu et al. 2011). 
Interestingly, mice with a selective deletion of the leptin receptor on kisspeptin neurons or with 
over 95% of their kisspeptin neurons ablated, had normal pubertal development and 
reproduction (Donato et al. 2011; Mayer and Boehm 2011), suggesting that leptin signalling in 
kisspeptin neurons is not essential for reproductive development. Although a developmental 
compensatory mechanism cannot be ruled out. However, it seems from recent work by Popa et 
al, that only a small amount of functioning kisspeptin neurons is required to go through puberty 
(as low as 5% in males) (Popa et al. 2013). Leptin may also work via GnRH independent 
mechanisms as leptin was able to induce ovulation in GnRH deficient mice (Barkan et al. 
2005).  
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Leptin receptor-deficient mice treated with LH surge levels of oestradiol did not show c-Fos 
activation of GnRH or RP3V kisspeptin neurons compared with activation seen in wild type 
mice, suggesting that leptin may work upstream of kisspeptin neurons to affect GnRH secretion 
(Quennell et al. 2011). 
Other areas of the hypothalamus express the leptin receptor, particularly in the POA, AVPV 
and ARC and these areas also contain a population of kisspeptin expressing neurons (Louis et 
al. 2011), although other areas not containing kisspeptin neurons such as the ventral 
premammillary nucleus (PMV) also express the leptin receptor suggesting that there may be 
intermediary pathways or pathways independent of kisspeptin that may regulate GnRH 
(Donato et al. 2011).  
 
1.20.2.2 Undernutrition 
Some disease states such as anorexia nervosa or low body weight result in abnormal 
functioning of the reproductive pathway. Leptin replacement is able to restore menstrual 
cyclicity in animal models of under nutrition and in women with hypothalamic amenorrhoea 
(Welt et al. 2004; Chou et al. 2011; Backholer et al. 2010). Hypogonadotrophic lean sheep had 
lower levels of kisspeptin expression in the ARC and POA which was partially restored on 
administering ICV leptin (Backholer et al. 2010), suggesting that low leptin in view of the low 
body weight could negatively affect kisspeptin expression and suppress the HPG axis to avoid 
reproduction in nutritionally deficient states.  
This is also evident in under fed rats during lactation, resulting in reduced weight and delayed 
vaginal opening, with low leptin levels and reduced hypothalamic KISS1 mRNA expression at 
puberty (Castellano et al. 2011).  
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1.20.2.3 Obesity 
Obesity affects the HPG axis and mice treated with a high-fat diet (HFD) are prone to infertility 
(Quennell et al. 2011). These mice were obese and leptin resistant but also had markedly 
reduced kisspeptin gene expression, particularly in the ARC and RP3V, indicating that 
kisspeptin may be regulated by increased body weight (Quennell et al. 2011). Postnatal over 
feeding resulting in heavier rats showed precocious puberty, with high leptin levels and 
hypothalamic KISS1 mRNA levels (Castellano et al. 2011). 
 
1.20.3 Neuropeptide Y (NPY) 
Neurons that express NPY are found throughout the brain. In the ARC the majority co-express 
agouti-related peptide (AgRP); secretion of NPY or AgRP from these neurons stimulates food 
intake (Schwartz et al. 2000). It is well placed to influence GnRH section although studies have 
shown varied results depending on the animal model studied (Kalra and Crowley 1992; Pralong 
2010). Kisspeptin and NPY neurons are in close apposition in the ARC and kisspeptin has been 
shown to induce NPY secretion (Backholer et al. 2010). Also NPY knockout mice express 
lower levels of KISS1 mRNA (Luque, Kineman, and Tena-Sempere 2007), thus suggesting 
that NPY may interact with kisspeptin in order to relay nutritional information although more 
research is needed to elucidate the interaction further.  
 
1.20.4 Melanocortins 
Proopiomelanocortin (POMC) expressing neurons in the ARC secrete POMC which is a pre-
cursor of melanocortins including alpha melanocyte stimulating hormone (α-MSH) which have 
an anorectic effect on food intake. POMC and NPY neurons work closely together to regulate 
food intake through the actions of leptin (Schwartz et al. 2000) and may mediate the effects of 
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leptin in reproduction (Backholer, Smith, and Clarke 2009; Backholer et al. 2010).  POMC and 
KISS1 neurons have close apposition in the ARC (Backholer et al. 2010) and a melanocortin 
agonist increased LH and KISS1 mRNA in the POA, however, showed a reduction in the ARC 
(Backholer, Smith, and Clarke 2009). Studies have shown that kisspeptin can either inhibit or 
stimulate ARC POMC expression (Backholer et al. 2010; Fu and van den Pol 2010), thus the 
interaction with kisspeptin is complex and yet to be fully elucidated.   
 
1.20.5 Mammalian target of rapamycin protein (mTOR) 
mTOR is involved in regulating energy homeostasis and in undernutrition has a role in reducing 
cell growth (Schmelzle and Hall 2000). An mTOR antagonist suppressed kisspeptin expression 
in the ARC with low LH levels and delayed puberty (Roa et al. 2009), without disrupting the 
gonadotrophin response to exogenous kisspeptin, indicating a possible indirect link between 
kisspeptin and mTOR. Further work is needed to determine the effects of mTOR on GnRH 
secretion via kisspeptin  
 
1.20.6 Ghrelin 
This is a hormone secreted by the gastric mucosa with an orexigenic effect. Levels increase 
before meals and could be considered as a leptin antagonist as levels are inversely proportional 
to BMI (Tena-Sempere 2008). Ghrelin has also been shown to negatively affect gonadotrophin 
secretion and when administered to pre-pubertal male rats delayed puberty although this was 
not seen in females (Fernandez-Fernandez et al. 2005; Tena-Sempere 2008), as well as 
inhibiting  KISS1 mRNA expression in the POA of rats (Forbes et al. 2009). Thus taken 
together ghrelin may work to suppress GnRH secretion via kisspeptin signalling in times of 
 
 
83 
 
fasting when ghrelin levels are high in order to prevent reproduction. This association with 
kisspeptin and GnRH regulation needs to be further determined. 
  
1.20.7 Insulin 
Inactivation of the insulin receptor within the brain resulted in metabolic changes such as 
increased food intake and obesity with increased body fat and higher leptin levels, but also 
impaired ovarian follicular development and spermatogenesis (Bruning et al. 2000), suggesting 
that insulin may be another metabolic influence on GnRH secretion. A small proportion (5%) 
of ARC kisspeptin neurons express the insulin receptor (Evans et al. 2014), although insulin 
administration did not alter kisspeptin cell activation. Kisspeptin-specific insulin receptor 
knockout mice (KIRKO mice) showed no changes to puberty or reproduction (Evans et al. 
2014). However specific deletion of the insulin receptors on kisspeptin neurons resulted in 
delayed puberty with eventual normal fertility (Qiu et al. 2013), indicating that insulin is also 
an important influence in puberty but does not ultimately affect adult fertility.  
 
1.21 Non reproductive effects of kisspeptin 
1.21.1 Cancer 
Kisspeptin was discovered in melanoma cells with low tumour invasiveness (Lee et al. 1996) 
and since then kisspeptin has been associated with the anti-metastatic nature of several cancer 
cell lines including breast (Lee and Welch 1997b), endometrial (Jiang et al. 2005) and 
pancreatic (Masui et al. 2004) cancers. A decline in KISS1 expression has also been associated 
with metastasis and tumour progression in a number of cancers including, non-small cell lung 
(Zheng et al. 2010), gastric (Dhar et al. 2004) and oesophageal squamous cell carcinomas 
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(Ikeguchi, Yamaguchi, and Kaibara 2004) as well as bladder (Sanchez-Carbayo, Capodieci, 
and Cordon-Cardo 2003) and pancreatic (Nagai et al. 2009) cancer.   
The use of kisspeptin as a therapeutic here has been questioned as circulating levels of 
kisspeptin in non-metastatic cancers was similar to advanced cancers and therefore, it is likely 
that the kisspeptin content of the tumour is the important indicator of tumour invasiveness 
(Katagiri et al. 2009; Karapanagiotou et al. 2011). Therefore, kisspeptin could be used as a 
prognostic indicator rather than as a treatment to prevent metastasis and tumour progression. 
Although the reverse has been found in oestrogen sensitive breast cancers where a high 
expression of KISS1 and KISS1R have been associated with a poorer prognosis (Marot et al. 
2007), although further investigation is needed in these cancers which already have a close 
relationship with oestradiol and the kisspeptin system.  
 
1.21.2 Neuroendocrine  
KISS1R mRNA expressed in ovine pituitary somatotroph cell fractions (Smith, Rao, et al. 
2008), raised the possibility that kisspeptin could directly affect non-reproductive pituitary 
hormones. In vitro studies have shown that kisspeptin can stimulate growth hormone (GH) 
release from bovine pituitary cell cultures (Kadokawa, Suzuki, and Hashizume 2008; Ezzat 
Ahmed et al. 2011). However, in vivo studies have shown a discrepancy in that kisspeptin can 
either stimulate GH secretion in cows (Kadokawa et al. 2008; Whitlock et al. 2010) and 
monkeys (Luque et al. 2011) or have no effect in goats (Hashizume et al. 2010), gilts (Lents et 
al. 2008), monkeys (Ramaswamy, Gibbs, and Plant 2009) and calves (Ezzat Ahmed et al. 
2009). There have also been contradictory reports of inhibition and stimulation of prolactin 
after kisspeptin administration in rats (Navarro, Castellano, et al. 2004; Szawka et al. 2010), 
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however, kisspeptin was shown to stimulate bovine pituitary cell cultures to secrete prolactin 
(Ezzat et al. 2010).  
In humans, we did not find any change in any non-gonadotrophin pituitary hormone after 
kisspeptin administration both acutely and chronically in healthy females (Jayasena, 
Comninos, Narayanaswamy, et al. 2014).  
Kisspeptin has been shown to stimulate oxytocin neurons in the supraoptic nucleus and 
subsequent oxytocin release (Kotani et al. 2001; Scott and Brown 2011), which is likely to be 
important in lactation but needs further investigation.  
 
1.21.3 Metabolic tissues 
KISS1/KISS1R expression has been shown in pancreatic islet cells particularly the alpha and 
beta cells but not the exocrine pancreas (Hauge-Evans et al. 2006). However, the exact function 
in these tissues remains to be elucidated. In vitro studies have shown contradictory effects of 
kisspeptin on insulin secretion in response to glucose (Hauge-Evans et al. 2006; Silvestre et al. 
2008; Bowe et al. 2009; Vikman and Ahren 2009). Perifusion of isolated islet cells from 
humans, pigs and mice with kisspeptin in the presence of glucose, increased insulin secretion 
(Bowe et al. 2012). In vivo studies have also demonstrated a rise in glucose induced insulin 
secretion after kisspeptin administration in rats and monkeys (Bowe et al. 2009; Wahab, Riaz, 
and Shahab 2011). However, it has also been shown to reduce glucose induced insulin secretion 
in mice (Song et al. 2014). Interestingly, specific hepatic kisspeptin knockdown in diabetic 
mice improved insulin secretion in response to glucose and thus glycaemic control (Song et al. 
2014), suggesting that kisspeptin may have direct effects on pancreatic insulin secretion 
although this needs to be further investigated.  
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A streptozotocin induced diabetic rat model resulted in HH with reduced hypothalamic KISS1 
mRNA levels, which could be corrected with kisspeptin (Castellano, Navarro, Fernandez-
Fernandez, Roa, et al. 2006), suggesting that kisspeptin may mediate the metabolic effects of 
insulin on the reproductive system.  
 
1.21.4 Cardiovascular system 
KISS1/KISS1R expression has been shown in atherosclerotic plaques in the coronary artery, 
as well as in the smooth muscle cells of the aorta and coronary arteries (Mead et al. 2007), 
raising the possibility that kisspeptin could have potential vasoconstrictor actions in these 
vessels. In mice kisspeptin was able to stimulate constriction of peripheral vasculature (Sawyer 
et al. 2011). Interestingly, kisspeptin has also been implicated in inhibiting angiogenesis of 
placental vessels and endothelial cells (Ramaesh et al. 2010), although the significance of this 
needs further investigation.  
KISS1R expression has been shown in myocytes and intra-myocardial blood vessels and 
kisspeptin administration resulted in inotropic effects (Maguire et al. 2011). However, from all 
the human clinical studies conducted by our team we have never seen any rise in heart rate or 
blood pressure even at doses that cause a robust rise in gonadotrophins, suggesting that the in 
vivo effects of kisspeptin on the cardiovascular system are minimal.  
 
1.21.5 Other roles of kisspeptin in the central nervous system  
KISS1 and KISS1R are expressed in many regions of the brain and spinal cord, however, their 
functions in most of these regions are largely undetermined. The limbic system is an area of 
high KISS1/KISS1R expression and therefore may associate kisspeptin with sexual behaviour. 
KISS1 expression in the medial amygdala is under the influence of sex steroids (Kim et al. 
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2011) and as this area has been associated with pheromone control of sexual behaviour 
(Newman 1999) as well as neuroendocrine function (Beltramino and Taleisnik 1978), 
kisspeptin may have a role in sexual behaviour however, this needs to be further investigated.  
 
1.22 Summary 
Since kisspeptin was discovered to be critical for puberty and reproduction in 2003 there has 
been an enormous amount of research investigating its mechanisms of action. In doing so 
researchers have uncovered a complex network of excitatory and inhibitory signals governing 
GnRH secretion and kisspeptin is likely to mediate many of these factors as well as directly 
stimulating GnRH secretion.  
It is extraordinary that the decapeptide GnRH is so highly conserved amongst species and is 
the key hypothalamic output to the pituitary. Thus the mechanisms governing GnRH secretion 
have been the subject of much scrutiny. GnRH is secreted in regular pulses as well as a surge 
pre-ovulation in women. Pituitary gonadotrophs are sensitive to the frequency of pulsatile 
GnRH secretion and this has led to the hypothesis of the GnRH pulse generator.  
Neuronal activity of the ARC closely correlates with the secretion of LH pulses and thus is 
likely to be involved in GnRH pulse generation. As there is a preponderance of kisspeptin 
neurons in the ARC, it is likely that kisspeptin neurons are involved. In the ARC, kisspeptin 
neurons co-localise with two other neuropeptides (NKB and dynorphin) and are termed KNDy 
neurons. All three KNDy neuropeptides when investigated in isolation affect LH secretion and 
thus much research has focused on their interaction to generate the GnRH pulse. This has not 
proven to be straightforward with regards to NKB as it has differing effects depending on the 
animal model studied and there are also very few dynorphin receptors on KNDy neurons. 
Which only reflects the tremendous complexity of GnRH pulse generation.  
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Kisspeptin has proven to be the final output of the KNDy neuron and has little direct effect on 
KNDy neurons themselves. Kisspeptin neuronal activity can be affected by a number of other 
regulators of GnRH such as metabolic signals like leptin. It seems likely that kisspeptin 
mediates the effects of this complex network of regulatory signals in order to govern GnRH 
release.  
The mechanisms regulating this activation of KNDy neurons are still yet to be determined fully. 
It is not clear how NKB and dynorphin are able to stimulate and suppress KNDy neuronal 
activity respectively at the correct times, whether these neurons have pacemaker qualities or 
are regulated by other mechanisms remains to be discovered.  
Kisspeptin and its receptor are expressed throughout the body and although I have focused on 
reproductive effects it is not clear what the function of this expression is in other tissues. 
Kisspeptin function in the placenta and association with cancer have been largely investigated 
although many questions remain. Kisspeptin may be used in the future as a positive predictor 
of better pregnancy outcomes and less invasive cancers, although oestradiol positive cancers 
seem to show the reverse.  
Kisspeptin is now being used in clinical IVF trials with reduced complication rates. However, 
it has the potential to be used in treating reproductive disorders currently treated with 
gonadotrophin injections. In contrast to gonadotrophins, kisspeptin acts by releasing 
endogenous GnRH and thus represents a more physiological way of stimulating the HPG axis.   
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1.23 Aims and hypotheses of the thesis 
1.23.1 Aims 
My research focusses on improving our understanding of kisspeptin with a view to therapeutic 
use in the future. Many questions still remain regarding which isoform of kisspeptin is optimal, 
which route of administration could be used in treatment and how the manipulation of the 
KNDy system could further optimise the effects on the HPG axis.  
Specifically this research aims to:-  
1. identify whether there is a difference in gonadotrophin stimulation in healthy men when 
infused with kisspeptin-10, -54 and GnRH at 3 different doses. 
2. determine whether subcutaneous infusion of kisspeptin could be a viable mode of 
administration and whether baseline oestradiol correlates with gonadotrophin response 
to kisspeptin. 
3. investigate the KNDy (kisspeptin, neurokinin B (NKB) and dynorphin) hypothesis in 
humans by assessing the LH pulsatility and gonadotrophic effects of co-administration 
of kisspeptin, NKB and an opioid receptor antagonist, naltrexone, in men.  
 
1.23.2 Hypotheses 
Overall Hypothesis: Kisspeptin is a therapeutic agent to treat reproductive and fertility 
disorders.  
Specific hypotheses:- 
1. Kisspeptin-54 is more potent at stimulating gonadotrophins than kisspeptin-10 and 
GnRH is more potent than both kisspeptin isoforms.   
2. Subcutaneous infusion of kisspeptin-54 is a viable mode of administration to stimulate 
a rise in gonadotrophins.  
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3. Co-administration of naltrexone with kisspeptin or NKB will remove opioid inhibition 
resulting in a rise of gonadotrophins above that seen with either kisspeptin or NKB 
alone.  
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CHAPTER 2: THE EFFECTS OF KISSPEPTIN-10, 
-54 AND GnRH ON GONADOTROPHIN 
RELEASE IN HEALTHY MEN  
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2.1 Introduction 
The kisspeptin signalling system governing GnRH release is fundamental for normal puberty 
and reproduction (de Roux et al. 2003; Seminara et al. 2003) and as such it is being evaluated 
as a potential novel therapy for disorders involving failure of GnRH release. As kisspeptin 
stimulates endogenous GnRH release, this may represent a more physiological way of 
stimulating GnRH release compared to current treatments.  
Members of the kisspeptin family share a common binding site to the kisspeptin receptor, 
KISS1R and are denoted by amino acid length (Ohtaki et al. 2001). Unfortunately, early human 
studies investigating the effect of kisspeptin on the reproductive system have either used 
kisspeptin-10 or kisspeptin-54, but not both isoforms. This is problematic, since clinically 
important differences are likely to exist between kisspeptin-10 and -54. Firstly, kisspeptin-54 
has been observed to stimulate gonadotrophin secretion when administered through the 
subcutaneous (SC) or intravenous (IV) routes in all subject groups tested (Dhillo et al. 2005; 
Dhillo et al. 2007; Jayasena et al. 2009; Jayasena et al. 2010).  However, kisspeptin-10 
stimulates gonadotrophin secretion when administered IV (Jayasena et al. 2011; George et al. 
2011; Chan et al. 2011), but showed no rise in gonadotrophins when administered as a SC bolus 
injection to women in the follicular phase of the menstrual cycle (Jayasena et al. 2011). 
Although women are less responsive to exogenous kisspeptin in the follicular phase, SC 
kisspeptin-54 was able to stimulate gonadotrophin release when administered in the same phase 
(Dhillo et al. 2007).  
Therefore, differences in the effects of the kisspeptin isoforms may be related to the plasma 
half-life of kisspeptin-10 which is approximately 6-fold shorter than for kisspeptin-54 (4 min 
vs 28 min) (Dhillo et al. 2005; Jayasena et al. 2011). In addition, the shorter amino acid 
sequence of kisspeptin-10 makes it far less expensive to synthesize when compared with 
kisspeptin-54 and therefore may be more cost effective to produce as a therapeutic. Various 
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dosing regimens and human models have been evaluated during previous clinical studies and 
therefore, establishing the potencies of kisspeptin hormones is important for comparing studies 
and for the future development of kisspeptin based therapies.   
Furthermore, it is not known how potently kisspeptin-10 and -54 stimulate gonadotrophin 
secretion in humans when compared with GnRH, which itself may be used to treat patients 
with infertility. In the UK GnRH is mostly used as a test of anterior pituitary gonadotroph 
function and is administered at supraphysiological doses. It would be interesting to compare 
gonadotrophin effects from kisspeptin induced GnRH release with those from direct pituitary 
stimulation by exogenous GnRH at the same doses. Thereby investigating the hypothalamic 
response to kisspeptin and the pituitary response to GnRH in the same individual.  
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2.2 Aims and hypothesis  
Kisspeptin-54 was first administered to healthy men in 2005 and subsequent studies have 
investigated the effects of both kisspeptin-10 and kisspeptin-54 in men and women as well as 
those with reproductive disorders (Dhillo et al. 2005; Dhillo et al. 2007; Jayasena et al. 2009; 
Chan et al. 2011; George et al. 2011; Chan et al. 2012; Jayasena, Comninos, Nijher, et al. 2013). 
If kisspeptin is to be used a future therapeutic it is important to establish which kisspeptin 
isoform would be preferable for administration, as kisspeptin-10 is cheaper to produce and thus 
may be more cost effective to administer than kisspeptin-54. This chapter investigates for the 
first time the effects of both kisspeptin isoforms and GnRH on gonadotrophin secretion in the 
same individuals. As GnRH acts on the pituitary and kisspeptin at the hypothalamus this will 
also allow for direct comparison of GnRH and kisspeptin on gonadotrophin release in the same 
participants.  
 
2.2.1 Aim 
To identify whether there is a difference in gonadotrophin secretion in healthy men when 
infused with kisspeptin-10, -54 and GnRH at 3 different doses. 
 
2.2.2 Hypothesis  
I hypothesise that kisspeptin-54 will be more potent in stimulating gonadotrophin secretion 
than kisspeptin-10 and that GnRH will be more potent than either isoform of kisspeptin when 
administered at the same doses.  
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2.3 Materials and methods 
 
2.3.1 Ethical approval  
Ethical approval was granted by the Local Ethics Research Committee (registration: 
12LO/0507). Written informed consent was obtained from all subjects. This study was 
performed in accordance with the Declaration of Helsinki. 
 
2.3.2 Subjects 
Five participants were recruited to each dosing group, however, in view of the total blood loss 
not all volunteers were able to receive all three doses and therefore, ten healthy male volunteers 
were recruited through advertisements in local newspapers and received either one or two 
dosing groups. Responders to adverts were evaluated with a detailed medical history, clinical 
examination, electrocardiogram and blood tests as follows: full blood count; renal profile; liver 
profile; bone profile; random glucose; thyroid profile; LH; FSH; testosterone; sex hormone 
binding globulin (SHBG). Participants were included within the study if they fulfilled the 
following criteria: age between 18 and 45 years; absence of significant systemic disease co-
morbidity; absence of therapeutic or recreational drug use; normal clinical and biochemical 
reproductive function; absence of blood donation in the preceding three months. Ten subjects 
participated in the study, with a summary of baseline characteristics provided in Table 2.1.  
 
2.3.3 Peptides 
Human kisspeptin-10 was synthesised by Bachem (Liverpool, UK) and human kisspeptin-54 
was synthesized by the Advanced Biotechnology Centre, Imperial College London. Both were 
purified by reverse phase high performance liquid chromatography (HPLC) and confirmed by 
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electrospray mass spectroscopy and amino acid analysis. No endotoxin was detected when 
tested with the Limulus amoebocyte lysate assay (Associates of Cape Cod, Liverpool). The 
peptides were sterile when cultured by the department of microbiology at Hammersmith 
Hospital, London. Bioactivity was confirmed by stimulation of LH release in female mice 
(Jayasena et al. 2010). Vials of freeze-dried kisspeptin-10 and -54 were stored at -20 degrees 
and then reconstituted with 0.9% saline when required.  
Gonadorelin 100µg (GnRH) was purchased from Intrapharm laboratories Ltd. (Maidenhead, 
Berks, UK). It was reconstituted with the sterile solvent supplied containing 2% benzyl alcohol 
and water for injection.  
 
Table 2.1: Baseline Characteristics of study volunteers 
 
Participant 
no. 
Age 
(years) 
Weight 
(kg) 
BMI 
(kg/m2) 
LH 
(IU/L) 
FSH 
(IU/L) 
Testosterone 
(nmol/L) 
1 25 75.9 26.5 4.40 2.21 18.78 
2 23 82.7 24.1 4.69 2.67 31.40 
3 34 73.1 23.9 5.16 4.25 16.05 
4 20 68.4 23.6 2.11 1.85 23.97 
5 28 88.4 25.7 4.03 3.16 12.29 
6 43 66.3 19.8 2.01 2.55 22.91 
7 30 68.7 25.2 3.10 2.09 13.65 
8 30 62.2 20.2 1.78 1.66 29.75 
9 26 71.3 23.4 2.61 2.84 17.05 
10 30 83.9 23.7 5.30 1.74 20.52 
 
Mean 
±SEM 
 
28.9 
±2.02 
 
74.10 
±2.69 
 
23.61  
±0.68 
 
3.52 
±0.43 
 
2.50 
±0.25 
 
20.60 ±2.03  
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2.3.4 Study protocol 
Participants attended our clinical investigation unit in the morning and were asked to lay supine 
(see Figure 2.1 for protocol summary). Two experienced investigators were present at all times. 
Subjects were asked to refrain from strenuous exercise, sexual activity and alcohol 
consumption for the 24h period preceding each study visit. Participants had their blood pressure 
and pulse recorded on arrival and at regular intervals throughout the study. Three doses were 
chosen to be investigated; 0.1, 0.3 and 1nmol/kg/h. These doses were selected based on 
previous studies that have demonstrated an LH rise during IV infusion of kisspeptin-54 in 
healthy men (Dhillo et al. 2005).  
On arrival, the participant had two cannulas inserted, one into each forearm. Blood samples 
were taken via cannula 1 and cannula 2 was used to infuse the kisspeptin, GnRH or vehicle 
(gelofusin (5% vol/vol) B.Braun Medical Sheffield, UK) via a pump controlling the rate of 
flow.  
Baseline blood sampling was performed at 10min intervals between 0 and 60 in. A single-
blinded 3h continuous intravenous infusion of gelofusin (vehicle), kisspeptin-10 (0.10, 0.30 or 
1.00nmol/kg/h), kisspeptin-54 (0.10, 0.30 or 1.00nmol/kg/h) or GnRH (0.10, 0.30 or 
1.00nmol/kg/h), was commenced at time 60min, and continued until 240min (n=5 subjects per 
group; see Table 2 for dose allocation of subjects). A participant was allocated a dose and 
received all three peptides at that dose at least a week apart and in random order. However, it 
was not possible for the same volunteers to participate in all dosing groups due to ethical 
restrictions on total blood loss.   
The infusion was made up into a 50ml syringe, after initial priming of the syringe and giving 
set with gelofusin (5% vol/vol, B.Braun Medical, Sheffield, UK). Kisspeptin or GnRH was 
made up from frozen or refrigerated vials (respectively). Kisspeptin was reconstituted in 0.9% 
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saline and GnRH with the solvent supplied (2% Benzyl Alcohol in water for injection). A set 
amount of the peptide solution was transferred into the 50ml syringe containing the gelofusin. 
10ml of solution would then be expelled through the giving set in order to prime the giving set 
with the peptide solution. The rate of infusion was calculated as per the weight and commenced 
at 60min.  
A two-fold higher infusion rate was administered during the first 30min of each infusion, in 
order to achieve steady state plasma levels (Edwards et al. 1999). Therefore, total doses of 0.35, 
1.05 or 3.50nmol/kg peptide were administered during 3h infusions with maintenance 
administration rates of 0.10, 0.30 or 1.00nmol/kg/h, respectively.  
Regular blood samples were taken to measure gonadotrophin and testosterone levels. A 3ml 
blood sample was collected in plain serum vacutainer tubes and allowed to clot prior to 
centrifugation and separation of the serum. The samples were centrifuged at 3000 rpm for 
10min, separated and then frozen at -20 degrees centigrade until analysed. A further 3ml blood 
sample was also taken for plasma kisspeptin immunoreactivity (kisspeptin-IR) at t= 0, 60, 70, 
80, 90, 120, 180, and 240min. For the kisspeptin samples, the blood was put into lithium 
heparin tubes (LIP, Cambridge, UK) containing 5000 kallikrein inhibitor units of aprotinin 
(0.2ml Trasylol; Bayer, Newbury, UK) and centrifuged immediately at 4000 rpm for 4min. The 
plasma was separated and frozen at -20 degrees centigrade and analysed via a 
radioimmunoassay (RIA) described briefly below in the analytical methods section and in more 
detail in appendix 1.   
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Figure 2.1: Protocol diagram for the study. 
IV infusions of GnRH, kisspeptin-54, kisspeptin-10 or vehicle were administered to healthy 
men at a rate of 0.1, 0.3 and 1.0nmol/kg/h (n=5/group).  Each participant underwent 1h of 
baseline blood sampling prior to the peptide infusion or vehicle. The IV infusion started at 1h 
into the study and the infusion rate was halved 30min after commencement, to achieve a steady-
state concentration of peptide during the infusion period. The infusion was continued until the 
end of the study 3h later. Blood samples were taken every 10min (upward arrows) for the 
duration of the 4h study to measure LH, FSH and testosterone. Blood pressure and heart rate 
were recorded at regular intervals throughout the study and two experienced physicians were 
in attendance at all times.  
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Table 2.2: Allocation of healthy men to infusion treatment groups.  
Ten different 3h IV infusions were administered in healthy men: vehicle; 0.1, 0.3 or 
1.0nmol/kg/h kisspeptin-10; 0.1, 0.3 or 1.0nmol/kg/h kisspeptin-54; 0.1, 0.3 or 1.0nmol/kg/h 
GnRH. In order to directly compare the effects of equimolar doses of kisspeptin-10, kisspeptin-
54 and GnRH, the same combination of subjects (numbered 1-10) received the same dose of 
each of peptide. Study visits for individual patients were scheduled a minimum of a week apart 
and performed in random order. 
 
Treatment group Dose Subject number 
 
Vehicle 
 
- 2 3 9 10 8 
 
Kisspeptin-10,-54 or GnRH 
 
0.1nmol/kg/h 1 4 5 6 7 
 
Kisspeptin-10,-54 or GnRH 
 
0.3nmol/kg/h 1 4 7 8 10 
 
Kisspeptin-10,-54 or GnRH 
 
1.0nmol/kg/h 2 3 5 6 9 
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2.3.5 Analytical methods 
2.3.5.1 Hormone analysis 
Serum LH, FSH and testosterone were measured using automated chemiluminescent 
immunoassays (Abbott Diagnostics, Maidenhead, UK). Reference ranges for males were as 
follows: LH, 4–14 IU/l; FSH, 1.5–8 IU/l; testosterone, 10–28 nmol/l. The respective intra-assay 
and inter-assay coefficients of variation for each assay were: 4.1 and 3.4% (LH); 4.1 and 3.5% 
(FSH); 4.2 and 2.8% (total testosterone). Analytical sensitivities were: 0.5 IU/L (LH), 0.05 
IU/L (FSH); 2 nmol/L (total testosterone). Limits of detectability for each assay were as 
follows: LH, 0.07 IU/L; FSH, 0.05 IU/L; testosterone, 4.9 nmol/l.  
 
2.3.5.2 Kisspeptin immunoreactivity (kisspeptin-IR) 
Measurement of plasma kisspeptin-IR was performed using an established radioimmunoassay 
(Dhillo et al. 2005; Dhillo et al. 2007). Briefly, the radioimmunoassay is based on a GQ2 
antibody raised in sheep immunised to synthetic human kisspeptin-54 (Advanced 
Biotechnology Centre, Imperial College London, UK). The antibody cross-reacted 100% with 
human kisspeptin-54, kisspeptin-14 and kisspeptin-10 and less than 0.01% with other RF amide 
related peptides. The 125I-kisspeptin-54 label was prepared using the iodogen method and 
purified by reverse-phase HPLC.  The assay was performed in duplicate using neat plasma in 
0.06 m phosphate buffer (pH 7.2) containing 0.3% BSA and incubated for 3days at 4 degrees 
centigrade. Free and antibody-bound label were then separated by charcoal absorption. The 
proportion of radiolabel present in the two fractions enables direct measurement of the amount 
of unlabeled antigen that was bound to the antibody by directly referencing the “standard 
curve” which is produced at the same time as the assay of samples by using set concentrations 
of the pure peptide. The assay detected changes of 2 pmol/l of plasma kisspeptin with a 95% 
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confidence limit. The intra- and inter-assay coeﬃcients of variation were 8.3% and 10.2%, 
respectively. 
2.3.6 Statistical methods  
Cumulative changes in hormone secretion were quantified by calculating area under curve 
(AUC) values using Prism (GraphPad Inc. La Jolla, CA, USA); mean AUC values for each 
peptide and dose were compared using two-way ANOVA with Bonferroni’s post-hoc analysis 
test. P<0.05 was considered statistically significant. Data is presented as mean +/- SEM.  
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2.4 Results 
Baseline characteristics including age, BMI and hormone levels are shown in Table 2.1 (in the 
methods 2.3.2): mean age 28.9 ± 2.02 years and mean BMI 23.61 ± 0.68.   
No participants reported any adverse effects. There were no changes in heart rate or blood 
pressure during the studies (results not shown). 
 
2.4.1 Levels of circulating kisspeptin  
Time-profiles for plasma kisspeptin-IR are presented for vehicle and each dose of kisspeptin-
10, kisspeptin-54 and GnRH in healthy men (Figure 2.2A-C), and cumulative levels of 
kisspeptin-IR (AUC) are also presented (Figure 2.2D-E). As expected, levels of plasma 
kisspeptin-IR were not elevated significantly during IV infusion of vehicle or any tested dose 
(0.1, 0.3 and 1.0nmol/kg/h) of GnRH in healthy men (Figure 2.2A-E). Dose-dependent 
elevations in plasma kisspeptin-IR were observed during infusions of kisspeptin-54, and to a 
lesser extent during kisspeptin-10 infusions. All doses of kisspeptin-54 achieved a highly 
significant rise in kisspeptin-IR compared with vehicle (p<0.001). 
At the highest dose (1.0nmol/kg/h), levels of AUC kisspeptin-IR were 37-fold higher during 
kisspeptin-54 infusion when compared with kisspeptin-10 and 170-fold higher when compared 
with vehicle (mean AUC plasma kisspeptin-IR during infusion in h.pmol/L: 40±5.8, vehicle; 
179±24, kisspeptin-10 1.0nmol/kg/h; 6650±397, kisspeptin-54 1.0nmol/kg/h, p<0.001 vs 
vehicle, p<0.001 vs. kisspeptin-10 1.0nmol/kg/h, p<0.001 vs GnRH; 48±3.6, GnRH 
1.0nmol/kg/h). 
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A 
B 
C 
Figure 2.2: Plasma kisspeptin immunoreactivity (kisspeptin-IR) during IV 
administration of kisspeptin-10, kisspeptin-54 and GnRH to healthy men. 
Time profiles of mean plasma kisspeptin-IR are presented during infusion of vehicle, 
kisspeptin-10 (A); kisspeptin-54 (B); GnRH (C), at the following doses: 0.1, 0.3 and 
1.0nmol/kg/h. The infusion period commenced at 60min. (D and E) Mean AUC plasma 
kisspeptin-IR is presented for each infusion group: graph D shows data as linear curves and 
graph E as bar graphs. Data are mean±SEM. N=5/group. ***, p<0.001, kisspeptin-10 vs 
kisspeptin-54 at all doses; ΦΦΦ, p<0.001, kisspeptin-54 vs GnRH at all doses. 
 
0 6 0 1 2 0 1 8 0 2 4 0
0
2 0
4 0
6 0
8 0
1 0 0
T im e  (m in u te s )
P
la
s
m
a
 k
is
s
p
e
p
ti
n
-I
R
(p
m
o
l/
L
)
V e h ic le
1 .0 n m o l/k g /h
0 .3 n m o l/k g /h
0 .1 n m o l/k g /h
0 6 0 1 2 0 1 8 0 2 4 0
0
1 0 0 0
2 0 0 0
3 0 0 0
T im e  (m in u te s )
P
la
s
m
a
 k
is
s
p
e
p
ti
n
-I
R
(p
m
o
l/
L
)
V e h ic le
1 .0 n m o l/k g /h
0 .3 n m o l/k g /h
0 .1 n m o l/k g /h
0 6 0 1 2 0 1 8 0 2 4 0
0
2 0
4 0
6 0
8 0
1 0 0
T im e  (m in u te s )
P
la
s
m
a
 k
is
s
p
e
p
ti
n
-I
R
(p
m
o
l/
L
)
V e h ic le
1 .0 n m o l/k g /h
0 .3 n m o l/k g /h
0 .1 n m o l/k g /h
Kisspeptin-10 
Kisspeptin-54 
GnRH 
 
 
105 
 
D 
E 
 
  
V e h ic le 0 .1 0 .3 1 .0
1 0
1 0 0
1 0 0 0
1 0 0 0 0 K is s p e p t in -1 0
K is s p e p t in -5 4
G n R H
  
* * *
D o s e  o f  k is s p e p tin -1 0 , -5 4
o r  G n R H  (n m o l/k g /h )
A
U
C
 k
is
s
p
e
p
ti
n
-I
R
 (
h
.p
m
o
l/
L
)
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
* * *
* * *
0 .1 0 .3 1 .0
V eh ic le
K is s p e p tin -1 0
K is s p e p tin -5 4
G n R H
V eh ic le
A
U
C
 k
is
s
p
e
p
ti
n
-I
R
 (
h
.p
m
o
l/
L
)
D o s e  o f  k is s p e p t in -1 0 , -5 4
o r  G n R H  (n m o l/k g /h )
  
  
  
* * *
 
 
106 
 
2.4.2 LH results   
Time-profiles for serum LH are presented for vehicle and each dose of kisspeptin-10, 
kisspeptin-54 and GnRH in healthy men (Figure 2.3A-C), and cumulative levels of AUC serum 
LH are also presented (Figure 2.3D-E). As expected, levels of serum LH were not elevated 
significantly during IV infusion of vehicle in healthy men (Figure 2.3A-E). Dose-dependent 
elevations in serum LH were observed during infusion of GnRH, and to a lesser extent during 
kisspeptin-10 and kisspeptin-54 infusions. There was no significant difference in LH between 
kisspeptin-10 and kisspeptin-54 at any dose tested, although levels were numerically higher in 
the kisspeptin-54 group.  
For all three hormones, peak levels of LH secretion were observed at the 0.3nmol/kg/h dose; 
at this dose, levels of AUC serum LH were 3-fold higher during GnRH infusion when 
compared with kisspeptin-10 and almost two-fold higher when compared with kisspeptin-54 
(mean AUC serum LH during infusion in h.IU/L: 1.65±0.5, vehicle; 12.53±1.49, kisspeptin-10 
0.3nmol/kg/h; 20.60±4.43, kisspeptin-54 0.3nmol/kg/h; 36.94±9.60, GnRH 0.3nmol/kg/h, 
p<0.001 vs. kisspeptin-10, p<0.01 vs. kisspeptin-54).   
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Figure 2.3: Serum LH levels during IV administration of kisspeptin-10, kisspeptin-54 and 
GnRH to healthy men. A-C.  
Time profiles of mean serum LH are presented during infusion of vehicle, kisspeptin-10 (A); 
kisspeptin-54 (B); GnRH (C), at the following doses: 0.1, 0.3 and 1.0nmol/kg/h. The infusion 
period commenced at 60min. (D and E) Mean AUC serum LH is presented for each infusion 
group: graph D shows data as linear curves and graph E as bar graphs. Data are mean±SEM. 
N=5/group. *, p<0.05 for GnRH vs. kisspeptin-54. **, p<0.01 for GnRH vs. kisspeptin-54. 
ΦΦΦ, p<0.001 for GnRH vs. kisspeptin-10. 
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2.4.3 FSH results  
Time-profiles for serum FSH are presented for vehicle and each dose of kisspeptin-10, 
kisspeptin-54 and GnRH in healthy men (Figure 2.4A-C), and cumulative levels of AUC serum 
FSH are also presented (Figure 2.4D-E). As expected, IV infusion of vehicle did not result in 
an elevation of serum FSH. A dose-dependent rise in serum FSH were observed during infusion 
of GnRH, and to a lesser extent during kisspeptin-10 and kisspeptin-54 infusions (Figure 2.4A-
E). There was no significant difference in FSH between kisspeptin-10 and kisspeptin-54 at any 
dose tested, although levels were numerically higher in the kisspeptin-54 group.  
Peak levels of FSH secretion during GnRH were observed at the 1.0nmol/kg/h dose; at this 
dose, levels of AUC serum FSH were over 3-fold higher during GnRH infusion when compared 
with kisspeptin-10 and over 2-fold higher when compared with kisspeptin-54 (mean AUC 
increase in serum FSH during infusion in h.IU/L: 0.19±0.05, vehicle; 1.43±0.24, kisspeptin-10 
1.0nmol/kg/h; 1.90±0.22, kisspeptin-54 1.0nmol/kg/h, p<0.01 vs. vehicle; 4.69±0.55, 
1.0nmol/kg/h GnRH, p<0.001 vs. vehicle, p<0.001 vs. kisspeptin-10 1.0nmol/kg/h, p<0.001 
vs. kisspeptin-54 1.0nmol/kg/h).  
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Figure 2.4: Change in serum FSH levels during IV administration of kisspeptin-10, 
kisspeptin-54 and GnRH to healthy men.  
Time profiles of mean change in serum FSH are presented during infusion of vehicle, 
kisspeptin-10 (A), kisspeptin-54 (B) and GnRH (C), at the following doses: 0.1, 0.3 and 1.0 
nmol/kg/h. The infusion period commenced at 60 min.  Mean change in AUC serum FSH is 
presented for each infusion group: graph D shows data as linear curves and graph E as bar 
graphs. Data are presented as the mean ± SEM. N = 5/group. ** p< 0.01 for GnRH vs 
kisspeptin-54. *** p< 0.001 for GnRH vs kisspeptin-54. ΦΦΦ p< 0. 001 for GnRH vs kisspeptin-
10.  
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2.4.4 Testosterone results 
Time-profiles for serum testosterone are presented for vehicle and each dose of kisspeptin-10, 
kisspeptin-54 and GnRH in healthy men (Figure 2.5A-C), and cumulative levels of AUC serum 
testosterone are also presented (Figure 2.5D-E). There were no significant differences in 
testosterone between any peptide at any dose, although, the middle dose of 0.3nmol/kg/h 
produced the highest numerical values in all three peptides (mean AUC serum testosterone in 
h.nmol/L at the 0.3nmol/kg/h dose: 72.85±7.50, vehicle; 77.40±10.24, kisspeptin-10; 
79.98±8.30 kisspeptin-54; 78.36±10.56, GnRH).  
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Figure 2.5: Serum testosterone levels during IV administration of kisspeptin-10, 
kisspeptin-54 and GnRH to healthy men.  
Time profiles of serum testosterone are presented during infusion of vehicle, kisspeptin-10 (A); 
kisspeptin-54 (B); GnRH (C), at the following doses: 0.1, 0.3 and 1.0nmol/kg/h. The infusion 
period commenced at 60min. Mean AUC serum testosterone is presented for each infusion 
group: graph D shows data as linear curves and graph E as bar graphs. Data are mean±SEM. 
N=5/group.  
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2.5 Discussion 
2.5.1 Overview 
Direct stimulation of the hypothalamus using kisspeptin administration offers an attractive 
novel potential avenue for treating patients with infertility, since it causes the release of an 
endogenous pool of GnRH, which in turn stimulates physiological levels of gonadotrophin 
secretion (Gottsch et al. 2004; Messager et al. 2005; Shahab et al. 2005). Kisspeptin stimulates 
the reproductive axis in a self-limiting manner, which is more physiological when compared 
with direct pituitary or gonadal stimulation with GnRH analogues or gonadotrophin 
preparations, respectively.  
We designed this study with the primary objective of directly comparing the responses of the 
same subjects to kisspeptin-10, kisspeptin-54 or GnRH at the same dose. However, ethical 
limitations on cumulative blood loss dictated that subjects could not undergo all three doses of 
any given peptide. I have shown that both kisspeptin-10 and kisspeptin-54 stimulate 
gonadotrophin secretion to similar levels and that GnRH is more potent than either kisspeptin 
isoform when administered at the same doses to the same individuals.  
 
2.5.2 Kisspeptin-10 vs kisspeptin-54 
This study showed that equimolar doses of IV kisspeptin-10 and -54 administered as a 3h 
infusion produced similar increases in serum LH and FSH, despite observing much higher 
levels of circulating kisspeptin-IR during kisspeptin-54 administration when compared with 
kisspeptin-10. The radioimmunoassay used to determine the levels of kisspeptin detects all 
fractions of kisspeptin and therefore the lower kisspeptin-IR achieved with the kisspeptin-10 
group may be due to the longer in vivo plasma half-life of kisspeptin-54 at 27.6min (Dhillo et 
al. 2005) compared with the in vivo half-life of kisspeptin-10 at 4-5min (Jayasena et al. 2011) 
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and in vitro half-life of 55 seconds (Seminara et al. 2003). This is likely to account for the rapid 
degradation of kisspeptin-10 in comparison to kisspeptin-54 and thus significantly higher 
levels of plasma kisspeptin-IR with kisspeptin-54. Also, as all the isoforms are detected in the 
assay, it is possible that kisspeptin-54 degraded to several smaller isoforms which were all 
detected in the assay thus elevating the kisspeptin-IR seen in the kisspeptin-54 group.   
Consistent with these previous studies, our results showed a greater rise in LH than FSH 
regardless of the peptide administered (Dhillo et al. 2005; Chan et al. 2011; George et al. 2011). 
In vitro studies have shown that both isoforms of kisspeptin have similar efficacy for the 
KISS1R (Kotani et al. 2001). However, in vivo the two isoforms have been compared in rodents 
and found that kisspeptin-54 more potently stimulates gonadotrophin secretion compared to 
kisspeptin-10. Tovar et al, administered IV bolus injections of 3.0nmol/kg kisspeptin-52 (the 
rodent homologue of kisspeptin-54) and kisspeptin-10 to male rats and found that kisspeptin-
52 stimulated approximately 30% more LH secretion than with an equimolar dose of 
kisspeptin-10 (Tovar et al. 2006). Although the peak LH was similar with both isoforms, the 
rise was more prolonged with kisspeptin-52 (Tovar et al. 2006). Therefore, we may have 
observed the prolonged effects of kisspeptin-54 on serum LH if the study had continued. 
Furthermore, SC bolus injection of 1 or 50nmol kisspeptin-54 stimulated approximately 9 and 
12 fold greater LH secretion respectively in male rats when compared with vehicle, however,  
an  equimolar dose of kisspeptin-10 showed no difference from vehicle (Thompson et al. 2006). 
In humans, SC bolus injections of kisspeptin-54 were able to stimulate gonadotrophins in 
women in the follicular phase, however, SC kisspeptin-10 showed no response despite 
increased doses (Dhillo et al. 2007; Jayasena et al. 2011). These results are from two different 
studies and therefore, the same individual did not receive both isoforms SC at the same dose to 
compare their potencies. SC administration is likely to rapidly degrade kisspeptin-10 and thus 
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lower levels are absorbed to stimulate gonadotrophin secretion and therefore, the SC results 
from the animal and human studies are likely to reflect this route of administration.   
However, in this study no differences in gonadotrophin secretion between the two isoforms 
when administered as 3h IV infusions were seen, although a longer study may have established 
differences. Therefore, my initial hypothesis that kisspeptin-54 would be more potent than 
kisspeptin-10 at stimulating gonadotrophins was disproved when both peptides were 
administered IV.  
 
2.5.3 The dose of kisspeptin  
In the current study, the greatest LH response of both kisspeptin isoforms was observed during 
infusions of 0.30nmol/kg/h; an approximately 30% lower LH response was observed during 
the 1.0nmol/kg/h dose of kisspeptin-54 compared with 0.3nmol/kg/h, although the reduction 
seen in the kisspeptin-10 group between the doses was marginal. This may be due to receptor 
desensitisation (tachyphylaxis) occurring at higher doses of kisspeptin-54. Dhillo et al, showed 
that at doses above 0.72nmol/kg of kisspeptin-54 when administered as an IV infusion to 
healthy men resulted in a lower increase in LH than at 0.72nmol/kg/h dose (Dhillo et al. 2005), 
suggesting tachyphylaxis occurred at the 1.0nmol/kg/h dose used in this study resulting in a 
lower rise in LH compared with the 0.3nmol/kg/h dose.  
 
2.5.4 Kisspeptin vs GnRH  
My data suggest for the first time that at the doses tested, GnRH stimulates gonadotrophins 
more potently when compared with either kisspeptin isoform in healthy men. This implies that 
endogenous GnRH released by kisspeptin administration may only be able to stimulate a 
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submaximal level of gonadotrophin secretion from the pituitary compared with direct pituitary 
stimulation by GnRH.  
Firstly, kisspeptin may only activate a proportion of GnRH neurons. The majority but not all 
GnRH neurons express the kisspeptin receptor (approximately 77% in adult male rats), which 
implies that a subset of GnRH neurons lack the receptor to respond to kisspeptin (Irwig et al. 
2004; Han et al. 2005), thus indicating that kisspeptin stimulation will not allow for the full 
capacity of GnRH secretion available. In keeping with this, GnRH antagonists lower LH levels 
considerably more than kisspeptin antagonists (Roseweir et al. 2009; Millar et al. 2010), 
indicating that there is a kisspeptin independent component of GnRH secretion.  
KISS1 and KISS1R knockout mice retain some degree of GnRH activity which is enough for 
the majority of female mutants to eventually go into oestrus and for some males to exhibit 
spermatogenesis (Chan et al. 2009). These effects were significantly reduced with GnRH 
antagonist administration and led to lower LH and FSH levels; further indicating a kisspeptin 
independent component of GnRH secretion (Chan et al. 2009).   
It would be very interesting to determine the GnRH levels after kisspeptin administration to 
see how this compared to the doses of exogenous GnRH administered, although this is not 
possible in humans. As discussed previously, kisspeptin does not have a great effect directly at 
the pituitary and thus we have been able to compare the hypothalamic response to kisspeptin 
with the pituitary response to GnRH, although this has been limited by the pool of endogenous 
GnRH secreted by kisspeptin as well as the availability of KISS1R on GnRH neurons to 
respond to kisspeptin.  
My findings indicate that GnRH is more potent than kisspeptin at stimulating gonadotrophin 
release this could confer a therapeutic advantage over exogenous GnRH, by stimulating a level 
of gonadotrophin secretion which does not exceed physiological levels. Future studies are 
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needed to determine if such an action could prevent adverse consequences of excessive 
gonadotrophin stimulation, such as ovarian hyper stimulation syndrome during in vitro 
fertilization therapy (Elchalal and Schenker 1997).  
Certain animal studies are also in agreement that GnRH at similar equimolar doses of 
kisspeptin-10, induced a greater LH secretory response in male rats and goats (Tovar et al. 
2006; Hashizume et al. 2010). However, only one study showed that in rats comparing SC 
kisspeptin-54 and GnRH at equimolar doses resulted in similar LH release (Thompson et al. 
2009).  
Kisspeptin-10 administered to male juvenile rhesus monkeys produced LH pulses similar in 
magnitude to the preceding GnRH priming, however, a 7.5 fold increase in kisspeptin dose was 
used compared with the GnRH priming dose (Plant et al. 2006). In a study of GnRH deficient 
men given exogenous GnRH, and healthy men given kisspeptin-10, the GnRH doses required 
to mimic a kisspeptin induced LH surge were much smaller than the pharmacological dose of 
kisspeptin-10 require to produce a similar rise in LH (Chan et al. 2011).  
Similar to the effects on LH, GnRH also more potently stimulated FSH release than kisspeptin 
in all dosing groups. There was a greater rise in LH compared with FSH in all GnRH treatment 
groups and previous studies have shown that IV infusions of GnRH stimulated LH 6-12 fold 
more potently when compared with FSH, in healthy men (Happ et al. 1976; Fauser et al. 1983), 
which has also been shown after kisspeptin administration (Dhillo et al. 2005).  
Taken together this evidence in animals and humans is largely in agreement with our current 
findings that GnRH is more potent than both kisspeptin isoforms at secreting gonadotrophins.  
2.5.5 Testosterone 
The testosterone results were not significantly different between any peptide and vehicle at any 
of the doses tested. It has been suggested from previous studies that sex steroids take at least 
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4h to peak after a SC bolus injection of kisspeptin-54 (Jayasena et al. 2009; Jayasena et al. 
2010), therefore, a longer period of blood sampling after the infusion may have shown 
differences in testosterone between the peptide groups.   
 
2.5.6 Limitations  
It is important to consider the weaknesses of this study. In the current study no participant 
received all three doses of each peptide due to the blood volume which would have been 
required and thus may have accounted for some of the variation in the data observed.   
We recognize that this was a small study primarily aimed to compare the potencies of two 
novel kisspeptin hormones with an established stimulator of LH secretion, GnRH. Extending 
the study to a larger number of subjects in each group would be useful to confirm the current 
findings. 
Whilst I observed no significant difference in gonadotrophin secretion between kisspeptin-10 
and kisspeptin-54 groups the gonadotrophin responses appeared higher with kisspeptin-54 
treatment. However, I would likely need a larger group of subjects to confirm this and ideally 
longer studies.  
2.6 Conclusion  
This study provides the first direct and objective comparison of kisspeptin-10 and kisspeptin-
54 administration in human subjects. Each kisspeptin isoform has relative advantages over the 
other isoform. For instance, kisspeptin-54 but not kisspeptin-10 can be administered SC due to 
its longer half-life; however, kisspeptin-10 is substantially cheaper to manufacture when 
compared with kisspeptin-54, due to its shorter amino acid sequence. Therefore, despite similar 
potencies, kisspeptin-54 seems the preferred isoform for therapeutic administration at home 
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which is likely to involve SC administration. If however, IV use is required then either isoform 
could be administered.  
Interestingly, GnRH at the same doses of kisspeptin is more potent at secreting gonadotrophins 
which highlights complex differences between kisspeptin and GnRH physiology in leading to 
gonadotrophin secretion. Kisspeptins ability to stimulate gonadotrophins is limited by a 
subject’s own GnRH reserve and this may confer an advantage over GnRH or gonadotrophin 
treatment. Therefore, this data provides important information for the future development of 
kisspeptin-based therapies to treat patients with infertility. 
2.7 Future work 
It would be interesting to conduct further studies to investigate the effects of SC administration 
of kisspeptin-10 and -54 in the same individual. Previously, SC kisspeptin-10 has not been able 
to stimulate gonadotrophins in women in the follicular phase of the menstrual cycle although 
different studies have shown SC kisspeptin-54 was able to. Therefore, by using the same 
protocol as this study but administering the peptides SC we would be able establish for certain 
if kisspeptin-10 is not a viable therapeutic option to be administered SC.  
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CHAPTER 3: THE EFFECTS OF 
SUBCUTANEOUS INFUSIONS OF KISSPEPTIN 
IN HEALTHY WOMEN AND EFFECTS OF 
BASELINE OESTRADIOL ON LH RESPONSE 
TO KISSPEPTIN   
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3.1 Introduction  
Kisspeptin is emerging as a novel therapeutic agent and may confer an advantage over current 
treatments as it is limited by a patient’s endogenous GnRH reserve (Irwig et al. 2004; Messager 
et al. 2005) and thus may be more physiological. Current treatments for infertility include 
GnRH and gonadotrophin replacement (Santoro, Wierman, et al. 1986), however, there is 
potential for overstimulation of the HPG axis (Elchalal and Schenker 1997).  
Kisspeptin has been used successfully in IVF clinical trials to replace hCG (LH activity) to 
trigger oocyte maturation and resulted in fewer complications of ovarian hyper stimulation 
syndrome (Abbara et al. 2015; Jayasena, Abbara, Comninos, et al. 2014).  
A number of recent studies have administered kisspeptin to humans either intravenously (IV) 
or subcutaneously (SC) (Skorupskaite, George, and Anderson 2014). However, if kisspeptin is 
to be administered at home as a potential therapeutic to patients then either SC bolus injections 
or SC infusion via a pump device are possible routes of administration. Insulin pumps are now 
used routinely for the treatment of patients with type 1 diabetes (Pickup 2012a) and therefore,  
may provide an alternative route of administration of kisspeptin in the future. The rate of 
infusion of peptide can be changed rapidly through a pump device which is an important feature 
in view of the high risk of tachyphylaxis with kisspeptin administration in very responsive 
women with reproductive disorders (Jayasena et al. 2009).   
However, no previous study has investigated the gonadotrophin response to SC infusion of 
kisspeptin in humans and therefore, I wanted to investigate for the first time in humans, the 
gonadotrophin response to SC infusions of kisspeptin-54 in healthy women. If this resulted in 
potent gonadotrophin stimulation then pump administration would be a viable route of 
administration in the future.  
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Although from chapter 2 we showed that kisspeptin-10 has the same potency as kisspeptin-54, 
this was administered IV and previous studies administering SC kisspeptin-10 found no 
gonadotrophin stimulation in women in the follicular phase of the menstrual cycle (Jayasena 
et al. 2011), which may be due to the difference in half-lives (28min for kisspeptin-54 and 4min 
for kisspeptin-10 (Dhillo et al. 2005; Jayasena et al. 2011)) and time taken for peptide 
absorption. Therefore, in order to optimise gonadotrophin stimulation when administering 
kisspeptin via a SC infusion, I chose to use kisspeptin-54.    
Women are markedly more responsive to kisspeptin during the pre-ovulatory phase of the 
menstrual cycle compared with the early follicular phase (Dhillo et al. 2007; Chan et al. 2012). 
High oestradiol levels are observed in the pre-ovulatory phase compared with the early 
follicular phase and this could be a contributing factor to the differences seen in gonadotrophin 
response to exogenous kisspeptin in different phases of the menstrual cycle.  
Studies in vitro and in vivo have shown that GnRH stimulation by kisspeptin in the presence 
of oestradiol is important and lack of oestradiol reduces the secretion of kisspeptin-induced 
GnRH and subsequent gonadotrophins (Tonsfeldt et al. 2011; Guerriero et al. 2012).  
Chan et al, showed that women are least responsive to kisspeptin in the early follicular phase 
when oestradiol is at its lowest and despite increasing the dose of kisspeptin the LH pulse 
response did not alter (Chan et al. 2012). We proposed to further examine the role of oestradiol 
in the LH response to kisspeptin by investigating whether a participant’s individual baseline 
oestradiol level correlated with their LH response to kisspeptin administration.  
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3.2 Aims and hypothesis  
3.2.1 Aim  
 
To determine whether subcutaneous infusion of kisspeptin could be a viable mode of 
administration and whether baseline oestradiol correlates with LH response to kisspeptin.  
 
3.2.2 Hypothesis  
I hypothesise that kisspeptin administered via subcutaneous infusions will result in a significant 
rise in gonadotrophins and that baseline oestradiol will correlate with gonadotrophin response 
to kisspeptin, such that the higher the baseline oestradiol the greater the LH response to 
kisspeptin.  
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3.3 Materials and methods 
 
3.3.1 Ethical approval 
Ethical approval was granted by the Hammersmith, Queen Charlotte’s and Chelsea Hospitals 
Research Ethics Committee, London. The study was performed in accordance with the 
Declaration of Helsinki.  
 
3.3.2 Subjects 
Healthy female volunteers aged between 18-40 years old were recruited from local newspaper 
advertisements. They underwent a detailed medical evaluation as part of the pre-study 
screening to assess their suitability.  The screening visit involved obtaining informed consent, 
a medical history, medication history, clinical examination, electrocardiogram and blood tests 
to test the following: full blood count; renal profile; liver profile; bone profile; random glucose; 
thyroid profile; prolactin; LH; FSH; oestradiol; testosterone and SHBG. Participants were 
recruited who fulfilled the following criteria: regular menstrual cycles, no known medical 
problems or allergies, no medication use, no oral contraceptive use in the preceding 4 months, 
no recreational drug use and no previous research study or blood donation in the last 3 months. 
Clinical examination, electrocardiogram and blood testing were all normal. Four participants 
were recruited into the study. Their ages, weight, BMI, mean baseline oestradiol and mean 
menstrual cycle length are given in table 3.1.  
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Table 3.1: Baseline characteristics of the participants.   
The demographics of the participants are shown. The weight and baseline hormone levels from 
all the 4 studies were averaged for each participant and presented below. All mean results are 
presented as data ± SEM.  
 
Subject Age 
(yrs) 
Mean 
weight 
(kg) 
BMI Mean 
baseline 
LH 
(IU/L) 
Mean 
baseline 
FSH 
(IU/L) 
Mean  
baseline 
oestradiol 
(pmol/L) 
 
Mean 
menstrual 
cycle length 
(days) 
1 34.9 64.6 23.4 5.69 
± 0.64 
2.53 
± 0.22 
 
580.9 ± 132.7 32.3 ± 1.0 
2 37.7 65.4 21.4 2.10 
± 0.61 
4.32 
± 0.76 
 
90.3 ± 25.5 26.6 ± 1.9 
3 20.5 67.4 23.3 5.88 
± 0.88 
6.20 
± 0.91 
 
208.6 ± 35.7 24.8 ± 0.9 
4 22.1 74.6 23.5 4.88 
± 0.70 
4.64 
± 0.33 
 
115.5 ± 21.9 36 ± 0.4 
Mean 28.8 
± 4.7 
68.0  
± 2.3 
22.9 
± 0.5 
4.64 
±0.51 
4.42  
± 0.44 
 
249.0 ± 59.8 29.9 ± 2.8 
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3.3.3 Study protocol 
The subjects were blinded but not the investigators. The studies were conducted during the 
early follicular phase (day 2-6) of the subject’s menstrual cycle. Each participant attended for 
a total of 4 study visits (each study day was carried out in a separate menstrual cycle) and 
received a different treatment at each visit (saline or kisspeptin-54 at one of three doses tested) 
Subjects were asked to refrain from strenuous exercise, sexual activity and alcohol 
consumption for the 24h period preceding each study visit.  
Studies were conducted in our clinical investigation unit and figure 3.1 shows a summary of 
the protocol for each study visit. Subjects arrived in the morning and were cannulated in both 
forearms and asked to lie supine. Baseline blood sampling was performed and 30min later an 
infusion of vehicle (0.9% saline) or SC kisspeptin-54 was started and continued for 8h. Ten 
minutely blood sampling was then commenced for the duration of the 8h infusion until 480min 
to measure gonadotrophins and oestradiol. Blood samples were collected in plain serum 
vacutainer tubes and were allowed to clot prior to centrifugation and separation of the serum. 
The samples were centrifuged at 3000 rpm for 10min, separated and then frozen at -20 degrees 
centigrade until analysed.  
Three doses of kisspeptin-54 were investigated: 0.1, 0.3 and 1.0nmol/kg/h. The doses chosen 
have been previously shown to cause a rise in LH in healthy women following a single SC 
injection (Dhillo et al. 2007). Kisspeptin was administered SC into the abdomen and the 
infusion rate of peptide was doubled in the first 30min in order to achieve steady-state plasma 
levels during the infusion period (Edwards et al. 1999). Therefore, total doses of 0.85, 2.55 or 
8.50nmol/kg peptide were administered during 8h infusions with maintenance administration 
rates of 0.10, 0.30 or 1.00nmol/kg/h, respectively. Participants had their blood pressure and 
pulse recorded on arrival and at regular intervals throughout the study.  
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Figure 3.1. Protocol diagram for the study. 
Healthy women (n=4) received a single 8h infusion of saline or SC kisspeptin-54 0.1, 0.3, or 
1.0nmol/kg/h in the early follicular phase (day 2-6 of the menstrual cycle) of 4 separate 
menstrual cycles in random order. Each participant underwent a baseline blood sample 30min 
prior to the kisspeptin infusion or vehicle. The infusion was started at t=0h and continued for 
8h. Blood samples were taken every 10 minutes (upward arrows) for the duration of the 8h 
study to measure LH, FSH and oestradiol. 
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3.3.4 Peptide 
Human kisspeptin-54 was synthesized by the Advanced Biotechnology Centre, Imperial 
College London and further purified and tested as previously described in chapter 2 section 
2.3.3 entitled peptides. Vials of freeze-dried kisspeptin-54 were stored at -20 degrees 
centigrade and then reconstituted with 0.9% saline. The rate of infusion was calculated as per 
the weight. A set amount of the peptide solution from the reconstituted vial was transferred 
into the 50ml syringe containing 0.9% saline.  
 
3.3.5 Analytical methods 
Frozen samples were defrosted and analysed for measurement of LH, FSH and oestradiol using 
automated chemiluminescent immunoassays (Abbott Diagnostics, Maidenhead, UK). 
Reference ranges for females were as follows: LH 2–10 IU/L (follicular), FSH 1.5–8 IU/L 
(follicular and luteal) and oestradiol <300pmol/L (early follicular). The respective intra-assay 
and inter-assay coefficients of variation for each assay were: 4.1 and 3.4% (LH); 4.1 and 3.5% 
(FSH); 3.3% and 3.0% (oestradiol). Limits of detectability for each assay were: 0.07 IU/L (LH), 
0.05 IU/L (FSH); 37 pmol/L (oestradiol).   
 
3.3.6 Statistical methods 
The data was analysed in collaboration with a statistician, P.B. To allow for the repeat 
measurements over time and multiple comparisons between groups, the analysis was 
performed using multilevel linear regression with Bonferroni adjustment. Linear regression 
analysis was also used to investigate any correlation between baseline oestradiol levels and LH 
response to kisspeptin-54 at the different doses. In all cases p<0.05 was considered statistically 
significant and data is presented as mean +/- SEM. J.D.V. used a previously described, blinded 
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deconvolution method with 93% sensitivity and specificity to analyze LH pulsatility (Veldhuis, 
Keenan, and Pincus 2008).  
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3.4 Results 
Table 3.1 on page 126 shows the participant’s characteristics; mean age 28.86 ± 4.7yrs and 
mean BMI 22.9 ± 0.5. No participants reported any adverse effects. There were no changes in 
heart rate or blood pressure during the studies (results not shown). 
3.4.1 LH results  
At all doses tested in this study, kisspeptin-54 caused a rise in serum LH. Figure 3.2A shows a 
time profile of the 8h study, presenting the mean LH results at each time point from the 4 
participants’ receiving the same treatment (vehicle or SC kisspeptin-54 0.1, 0.3, 1.0nmol/kg/h 
doses). The 0.1nmol/kg/h group had slight increases in LH values over time but this did not 
reach statistical significance compared with vehicle (p=0.32, 0.1nmol/kg/h vs vehicle). The 
increase in LH was much greater for the 0.3 and 1.0nmol/kg/h groups and this was found to be 
highly statistically significant when compared with vehicle for both the 0.3 and 1.0nmol/kg/h 
groups (p<0.001). 
Figure 3.2B shows a graphical representation of the mean LH over the study period from the 
data presented in figure 3.2A.  
LH pulsatility was formally analysed by a deconvolution method and although the number of 
LH pulses increases with increasing doses of kisspeptin-54 (Figure 3.3A), this difference did 
not reach statistical significance (number of LH pulses per 8h: 4.3 ± 1.1, vehicle; 5.5 ± 1.8 
kisspeptin-54 0.1nmol/kg/h; 6.0 ± 1.3 kisspeptin-54 0.3nmol/kg/h; 6.0 ± 0.7 kisspeptin-54 
1.0nmol/kg/h). The LH pulse amplitude (Figure 3.3B), did not show any difference between 
the dosing groups (LH pulse amplitude in IU/L of LH pulses per 8h: 5.41 ± 0.89, vehicle; 8.10 
± 2.11 kisspeptin-54 0.1nmol/kg/h; 7.31 ± 1.67 kisspeptin-54 0.3nmol/kg/h; 6.92 ± 1.76 
kisspeptin-54 1.0nmol/kg/h). 
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B 
A 
Figure 3.2. Effects on serum LH during vehicle and SC infusions of kisspeptin-54 in 
healthy women during the early follicular phase of the menstrual cycle.  
Collated results from all participants in response to 8h infusions of vehicle and SC kisspeptin-
54 at 0.1, 0.3 and 1.0nmol/kg/h doses. Figure A shows the mean serum LH results for each 
time point (from all 4 participants) during the 8h study presented as a time profile. Figure 2B 
is a graphical representation of the mean LH over the study period as shown in Figure 2A. Data 
are mean ± SEM. N=4/group. Blue***, P<0.001 for SC kisspeptin-54 0.3nmol/kg/h vs vehicle; 
red ***, P<0.001 for SC kisspeptin-54 1.0nmol/kg/h vs vehicle. 
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A 
B 
Figure 3.3: Effects of SC infusions of kisspeptin-54 over 8h on LH pulsatility in healthy 
women.   
Healthy women received 8h SC infusions of kisspeptin-54 at 3 doses (0.1, 0.3 and 
1.0nmol/kg/h) and vehicle, 10 minutely blood samples were taken for the duration of the study 
and the LH pulses were analysed by using a blinded deconvolution method. Graph A shows 
LH pulses and graph B LH pulse amplitude.  
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3.4.2 FSH results  
Figure 3.4A shows the time profile of the study with mean FSH values for each time point from 
the 4 participants receiving the same treatment. There is a significant increase in serum FSH 
with all doses of SC kisspeptin-54 when compared with vehicle (p<0.05, 0.1nmol/kg/h vs 
vehicle; p<0.001, 0.3nmol/kg/h vs vehicle; p<0.001, 1.0nmol/kg/h vs vehicle). Figure 3.4B is 
a graphical representation of the mean FSH over the study period as shown in Figure 3.4A.  
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A 
B 
Figure 3.4: Effects on serum FSH during infusions of vehicle and SC kisspeptin-54 in 
healthy women during the early follicular phase of the menstrual cycle.  
Mean serum FSH was collated from all participants at each time point during an 8h infusion of 
either vehicle or SC kisspeptin-54 at 0.1, 0.3 and 1.0nmol/kg/h doses. Graph A shows the mean 
serum FSH results during the 8h study presented as a time profile. Graph B is a graphical 
representation of the mean serum FSH shown in Figure 3.5A. Data are mean ± SEM. 
N=4/group. Green *, P<0.05 for SC 0.1nmol/kg/h kisspeptin-54 vs vehicle; blue ***, P<0.001 
for SC kisspeptin-54 0.3nmol/kg/h vs vehicle; red ***, P<0.001 for SC kisspeptin-54 
1.0nmol/kg/h vs vehicle.  
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3.4.3 Oestradiol results  
Figure 3.5A shows the mean oestradiol values for each time point over the 8h study from the 4 
participants receiving the same treatment. There was a significant change in oestradiol with 
kisspeptin administration at the two highest doses of 0.3 and 1.0nmol/kg/h compared with 
vehicle (p<0.001, 0.3nmol/kg/h vs vehicle; p<0.001, 1.0nmol/kg/h vs vehicle). Figure 3.5B is 
a graphical representation of the mean oestradiol over the study period as shown in Figure 
3.5A.  
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B 
A 
Figure 3.5: Effects on serum oestradiol during infusions of vehicle and SC kisspeptin-54 
in healthy women during the early follicular phase of the menstrual cycle.  
Mean serum oestradiol was collated from all participants at each time point during an 8h 
infusion of either vehicle or SC kisspeptin-54 at 0.1, 0.3 and 1.0nmol/kg/h doses. Graph A 
shows the mean serum oestradiol results during the 8h study presented as a time profile. Graph 
B is a graphical representation of the mean serum FSH shown in graph A. Data are mean ± 
SEM. N=4/group.  
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3.4.4 Baseline oestradiol vs LH response to kisspeptin administration 
Using regression analysis, the baseline oestradiol levels of each woman was correlated with 
her serum LH response to SC kisspeptin-54 at the 3 doses tested. The results suggest there was 
a highly significant relationship between baseline oestradiol and mean LH for the 0.3 and 
1.0nmol/kg/h groups as shown in Table 3.2 and pictorially in Figure 3.7 (regression coefficients 
and p-value: -0.25, p=0.26, vehicle; -1.75, p=0.24, 0.1nmol/kg/h; 0.83, p=0.03, 0.3nmol/kg/h; 
1.00, p=0.03, 1.0nmol/kg/h). The positive regression coefficients implies that higher values of 
baseline oestradiol were associated with higher LH values in the 2 highest doses tested. For the 
1.0nmol/kg/h group a 100pmol/L rise in baseline oestradiol was associated with a 1.0 IU/L 
increase in LH. 
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Table 3.2: Effects of baseline oestradiol on LH response to kisspeptin-54 administration. 
Linear regression analysis was used to determine whether there was an association between 
baseline oestradiol and the LH response to SC kisspeptin-54 at 3 doses (0.1, 0.3 and 
1.0nmol/kg/h) and vehicle, when administered to healthy women in the early follicular phase 
of the menstrual cycle. The regression coefficients and confidence intervals presented represent 
the change in mean LH for a 100pmol/L increase in baseline oestradiol.  
 
Group Coefficient (95% CI) P-value 
Vehicle -0.25 (-0.72, 0.23) 0.26 
0.1nmol/kg/h kisspeptin-54 -1.75 (-4.85, 1.36) 0.24 
0.3nmol/kg/h kisspeptin-54 0.83 (0.12, 1.53) 0.03 
1.0nmol/kg/h kisspeptin-54 1.00 (0.11, 1.89) 0.03 
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Figure 3.6: Effects of baseline oestradiol on LH response to kisspeptin-54 administration.  
4 healthy women in the early follicular phase underwent 8h infusions of SC kisspeptin-54 at 3 
doses (0.1, 0.3 and 1.0nmol/kg/h) and vehicle in random order in separate menstrual cycles. 
The participant’s baseline oestradiol levels from the beginning of each study were plotted 
against their mean LH response to kisspeptin-54 or vehicle from that study, for the 3 doses 
tested and vehicle.   
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3.5 Discussion 
3.5.1 SC administration of kisspeptin 
This proof of concept study shows that SC administration of kisspeptin is a viable option for 
future administration to stimulate gonadotrophin release in women. I have shown that 
gonadotrophins rise with all doses of kisspeptin-54 tested, however the highest two doses of 
0.3 and 1.0nmol/kg/h result in a significant rise in both LH and FSH.  Testing higher doses of 
SC infusion of kisspeptin in the future would be useful to establish the full dosing range and 
efficacy of this approach for therapeutic potential.   
Administration of kisspeptin continuously via a SC infusion in a pump device could result in 
desensitization of kisspeptin receptors (tachyphylaxis) and hence a reduction in 
gonadotrophins. Thus, prolonged studies to determine when tachyphylaxis may occur, if at all, 
would be useful for future therapeutic regimens.  
Twice daily SC injections of kisspeptin-54 to women with hypothalamic amenorrhoea resulted 
in tachyphylaxis (Jayasena et al. 2009). However, IV infusions of kisspeptin-54 resulted in a 
rise in LH pulsatility over the 8h infusion period (Jayasena, Abbara, Veldhuis, et al. 2014). 
Important factors in determining the gonadotrophin response to kisspeptin include dose, 
duration and route of administration, thus perhaps administering smaller doses of kisspeptin 
over a prolonged period may be effective in achieving a sustained and meaningful rise in 
gonadotrophins but avoiding tachyphylaxis. 
In this study kisspeptin had a greater effect on LH compared to FSH release at the doses tested. 
This is consistent with previous studies in humans and in animals which show that kisspeptin 
administration has greatest effects on LH release compared with FSH release (Dhillo et al. 
2005; Navarro, Castellano, Fernandez-Fernandez, Tovar, Roa, Mayen, Barreiro, et al. 2005).  
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3.5.2 Baseline oestradiol and LH response to SC kisspeptin  
The second part of my study was to investigate whether baseline oestradiol levels affected the 
LH response to kisspeptin. We know that the gonadotrophin response to kisspeptin varies over 
the ovulatory cycle in animals (Roa et al. 2006; Smith et al. 2009) and in humans (Dhillo et al. 
2007; Jayasena et al. 2011; Chan et al. 2012), with greater response in the pre-ovulatory phase 
compared with the follicular phase. This may be closely related to oestradiol levels which are 
higher in the pre-ovulatory phase and lower in the follicular phase. Oestradiol can both 
negatively and positively affect the axis depending on the phase of the oestrous cycle (Smith, 
Clifton, and Steiner 2006).  
We compared baseline oestradiol levels with the LH response to SC kisspeptin infusion at 3 
different doses. We showed that a kisspeptin infusion given at the two highest doses of 0.3 and 
1.0nmol/kg/h showed the greatest correlation between baseline oestradiol and LH response to 
kisspeptin. This suggested that at these doses the higher the baseline oestradiol the better the 
response to kisspeptin. Interestingly, we have shown that a 100pmol/L rise in baseline 
oestradiol resulted in a 1.0 IU/L rise in LH in response to a SC infusion of 1.0nmol/kg/h 
kisspeptin-54. 
In vitro and in vivo animal studies have also shown that oestradiol is an important determinant 
of LH response to kisspeptin. GnRH neuronal cell lines showed an enhanced GnRH secretion 
in response to kisspeptin administration when treated with oestradiol (Tonsfeldt et al. 2011). 
In hypothalamic ERα positive GT1-7 cells it was shown that oestradiol upregulated the 
expression of the kisspeptin gene (Li et al. 2007) and in mice enhanced  kisspeptin induced 
GnRH neuronal activity (Pielecka-Fortuna, Chu, and Moenter 2008). Guerriero et al, 
administered kisspeptin-10 into the hypothalamus of pubertal female rhesus monkeys and 
directly measured GnRH secretion. They showed that in ovariectomised pubertal rhesus 
monkeys, kisspeptin did not enhance GnRH secretion, however, on replacing with oestradiol 
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this restored kisspeptin stimulation of GnRH (Guerriero et al. 2012). Roa et al, showed that in 
rats the maximum gonadotrophin response to kisspeptin was only achieved after oestradiol 
replacement (Roa et al. 2006). Indicating that the GnRH neuronal response to kisspeptin is 
modulated by oestradiol. 
We know that sex steroids are involved in feedback regulation of GnRH secretion mediated 
mostly likely via kisspeptin neurons. Oestradiol is remarkable in that it can cause both positive 
and negative feedback effects on GnRH secretion, thus interpreting its effects is not 
straightforward. It is clear from the studies presented above that there must be an adequate 
level of oestradiol for kisspeptin to stimulate gonadotrophins via GnRH. If we consider 
ovariectomy, there is a loss of oestradiol and a rise in hypothalamic KISS1 mRNA (likely due 
to the loss of oestradiol negative feedback), which reduces after the replacement of oestradiol 
(Smith, Cunningham, et al. 2005). One could speculate that in the low oestradiol state with 
higher KISS1 expression that there is also a higher level of kisspeptin and therefore, would not 
be responsive to exogenous kisspeptin. On restoring oestradiol and reducing the hypothalamic 
KISS1 mRNA expression this restored normal GnRH functioning which is responsive to 
kisspeptin.  
Clomiphene (oestradiol antagonist), administered to healthy women in different phases of the 
menstrual cycle found that in the follicular phase the response to GnRH was abolished (Wang 
and Yen 1975), suggesting that not only oestradiol but another factor intrinsic to the follicular 
phase resulted in no response to GnRH administration in this phase of the menstrual cycle. This 
would be in keeping with the theory that in the follicular phase there is already a high level of 
kisspeptin and GnRH functioning in view of negative feedback effects of the low oestradiol 
and therefore, little capacity to further respond to exogenous GnRH (Wang and Yen 1975) and 
kisspeptin administration (Dhillo et al. 2007; Chan et al. 2012).  
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George et al, showed that post-menopausal women were much more responsive to IV 
kisspeptin-10 than those taking steroid contraception or those in the follicular phase of the 
menstrual cycle, indicating that perhaps there is a difference in women with cyclically higher 
or lower sex steroids compared with exogenous sex steroids or post-menopausal low sex 
steroids (George, Anderson, and Millar 2012), but this should be interpreted with caution in 
view of the markedly different gonadotrophin levels which were elevated in the post-
menopausal group and suppressed in the oral contraceptive group.   
Interestingly, despite the variation in gonadotrophin response to kisspeptin over the menstrual 
cycle there is little change in mean daily LH and LH half-life  over the cycle (Sollenberger et 
al. 1990), thus perhaps in low oestradiol states there is a change in GnRH neuronal sensitivity 
to kisspeptin or pituitary sensitivity to GnRH, thus requiring greater levels of kisspeptin and 
GnRH to secrete the same amount of LH. Clearly these mechanisms guiding the differences in 
follicular response need to be further elucidated.    
Of note subject 1 had higher than average baseline oestradiol levels than would be expected 
for the early follicular phase of the menstrual cycle and are more in keeping with late follicular 
phase levels. However, she did not have an exaggerated gonadotrophin response to kisspeptin-
54 that is usually seen in the late follicular, pre ovulatory phase of the menstrual cycle (Dhillo 
et al. 2007). Therefore, her oestradiol levels are likely to represent individual variation rather 
than another phase of the menstrual cycle. 
3.6 Conclusions  
My data shows that SC administration of kisspeptin is a potential option for future 
administration to stimulate gonadotrophin release in women to treat reproductive disorders. In 
addition the data indicates that baseline oestradiol levels may be an important determinant of 
the gonadotropin response to kisspeptin administration in women in the follicular phase of the 
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menstrual cycle. Thus suggesting that if kisspeptin is to be used therapeutically that it may be 
beneficial to replace the low oestradiol levels of the patient in order to obtain the optimal 
response from kisspeptin administration.  
3.7 Future work 
Further studies are required to establish the correct dose and duration of treatment using SC 
kisspeptin infusions that cause a rise in gonadotrophins but avoid tachyphylaxis. A dosing 
range would be the first step in determining optimal dosing regimens for the future. The 
duration of treatment would also need to be investigated and conducting prolonged studies 
would be ideal, although may be difficult to recruit for. Pump administration would be the most 
convenient way to conduct further SC infusion studies in the future as they could be used for 
prolonged periods and easily allow for dose adjustments.  
Also, further clinical studies are needed to confirm whether oestradiol supplementation 
improves the gonadotrophin response to kisspeptin. This would likely involve women 
receiving oestradiol supplementation several days prior to kisspeptin administration. If this did 
show significant effects then it would further indicate that the low oestradiol levels seen in 
women with infertility disorders should be optimised in order to gain the maximum benefit 
from kisspeptin administration.  
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CHAPTER 4: THE INTERACTIONS OF 
KISSPEPTIN, NKB AND DYNORPHIN (KNDy) 
ON GONADOTROPHIN SECRETION IN 
HEALTHY MEN   
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4.1 Introduction 
Recent evidence suggests that kisspeptin may not work alone, but in combination with 2 other 
neuropeptides, neurokinin B (NKB) and dynorphin collectively termed KNDy neurons (Cheng 
et al. 2010) to affect GnRH release and pulsatility. They co-localise in the ARC of many species 
studied to date (Navarro et al. 2009; Burke et al. 2006; Goodman et al. 2007; Ramaswamy et 
al. 2010; Wakabayashi et al. 2010; True, Kirigiti, Ciofi, et al. 2011) and have been implicated 
in forming the GnRH pulse generator.  
These peptides individually have been studied and affect gonadotrophin secretion and also 
mutations in the genes encoding kisspeptin, NKB and their receptors result in HH (de Roux et 
al. 2003; Seminara et al. 2003; Topaloglu et al. 2009). Since the discovery of KNDy neurons, 
numerous research has investigated how these peptides interact to regulate GnRH secretion 
and in doing so has resulted in the KNDy hypothesis for pulsatile GnRH secretion. 
KNDy neurons form a dense network of interconnected neurons that project to GnRH neurons 
and are found in close opposition to GnRH nerve terminals (Burke et al. 2006; Navarro et al. 
2009; Krajewski et al. 2010; Wakabayashi et al. 2013). It has been proposed that NKB 
produced by KNDy neurons acts on other KNDy neurons as well as autosynaptically at its 
receptor, NK3R, to stimulate kisspeptin secretion (Burke et al. 2006; Navarro et al. 2009; 
Navarro, Gottsch, et al. 2011; Amstalden et al. 2010). Kisspeptin is unlikely to act directly on 
KNDy neurons as there is no KISS1R expression on KNDy neurons (Smith et al. 2011). 
Instead, kisspeptin acts on GnRH neurons and terminals to secrete GnRH and thus stimulation 
of the HPG axis (Irwig et al. 2004; Han et al. 2005; Dhillo et al. 2005; Herbison et al. 2010; 
Smith et al. 2011). 
After sufficient GnRH has been released it has been proposed that dynorphin (an opioid) is 
secreted by KNDy neurons and acts via intermediary neurons (as there is low expression of its 
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receptor, KOR, on both GnRH and KNDy neurons) to switch off GnRH pulses (Mitchell et al. 
1997; Sannella and Petersen 1997; Navarro et al. 2009; Navarro, Gottsch, et al. 2011; Chavkin, 
James, and Goldstein 1982).  
Dynorphin and agonists of its receptor, KOR, have been shown to inhibit LH secretion 
(Kinoshita et al. 1982; Navarro et al. 2009; Wakabayashi et al. 2010). Conversely, opioid 
receptor antagonists and specific KOR antagonists have been shown to increase MUA activity 
in the ARC as well as LH (Kimura et al. 1991; Kinsey-Jones et al. 2008; Mostari et al. 2013; 
Goodman et al. 2013). Thus, opioid antagonists may be used to indirectly assess the actions of 
dynorphin on GnRH and subsequently gonadotrophin secretion. Naltrexone is a non-specific 
opioid receptor antagonist that can be administered as an oral tablet and has been shown to 
increase LH in humans (Ellingboe et al. 1982; Mendelson et al. 1986). 
There have been a number of difficulties in investigating the interactions between these 
peptides, most importantly because of the variability of NKB effects depending on the animal 
model studied. It is now clear that sex steroid milieu, pubertal status and gender are important 
factors that govern the effects of NKB on gonadotrophin release (Grachev, Millar, and O'Byrne 
2014). 
In order to investigate the KNDy hypothesis in humans we co-administered kisspeptin-54, 
NKB and naltrexone to healthy men and assessed their gonadotrophin response and LH 
pulsatility (surrogate marker of GnRH pulsatility).  
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4.2 Aims and hypothesis 
 
4.2.1 Aim 
To investigate the KNDy hypothesis in humans, by assessing the effects of co-administration 
of kisspeptin-54, NKB and an opioid receptor antagonist, naltrexone on LH pulsatility 
(surrogate marker for GnRH pulsatility in humans) and gonadotrophin release.  
 
4.2.2 Hypothesis 
I hypothesise that naltrexone will remove opioid inhibition on GnRH regulation and thus co-
administration with kisspeptin and NKB will potentiate gonadotrophin secretion.  
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4.3 Materials and methods 
 
4.3.1 Ethical approval  
Ethical approval was granted by the UK National Research Ethics Committee (REC number 
14/LO/1098). The study was performed in accordance with the Declaration of Helsinki. 
Written informed consent was obtained from all participants.  
 
4.3.2 Subjects 
Healthy male volunteers aged between 18-46 years old were recruited from local newspaper 
advertisements. They underwent a detailed medical evaluation as part of the pre-study 
screening to assess their suitability including clinical examination, electrocardiogram and 
blood testing which were all normal. Participants had no known medical problems or allergies, 
no medication use, no recreational drug use and no previous research study participation or 
blood donation in the last three months.  
 
4.3.3 Peptides 
Human kisspeptin-54 was synthesized by the Advanced Biotechnology Centre, Imperial 
College London and further purified and tested as previously described in chapter 2, section 
2.3.3.  
NKB was synthesised by Bachem (Liverpool, UK), and purified by reverse-phase high 
performance liquid chromatography (HPLC). Electrospray mass spectroscopy and amino acid 
analysis confirmed identity of the peptide. The Limulus amoebocyte lysate test detected no 
endotoxin (Associates of Cape Cod, Liverpool, UK), and bacterial culture was sterile 
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(Department of Microbiology, Hammersmith Hospital, London, UK) in samples of NKB 
peptide.  
Vials of freeze-dried kisspeptin-54 and NKB were stored at -20 degrees and then reconstituted 
with 0.9% saline and water for injection respectively. The rate of infusion was calculated taking 
into account the bodyweight of each volunteer. A set amount of the peptide solution from the 
reconstituted vial was transferred into a 50ml syringe containing gelofusin (5% vol/vol) 
(B.Braun Medical, Sheffield, UK) to minimise peptide adsorption (Kraegen et al. 1975).   
Kisspeptin-54 was administered at 0.1nmol/kg/h as this dose has been shown to cause a rise in 
LH in healthy men (Dhillo et al. 2005). NKB was administered at 2.56nmol/kg/h as this dose 
was biologically active and well tolerated in previous studies (Jayasena, Comninos, De Silva, 
et al. 2014). The infusion rate of peptides was doubled in the first 30min in order to achieve 
steady-state plasma levels during the infusion period (Edwards et al. 1999). Therefore, total 
doses of 0.85nmol/kg kisspeptin-54 and 21.76nmol/kg NKB were administered during 8h 
infusions with maintenance administration rates of 0.10nmol/kg/h kisspeptin-54 and 
2.56nmol/kg/h NKB. Participants had their blood pressure and pulse recorded on arrival and at 
regular intervals throughout the study.  
Naltrexone hydrochloride (a non-selective opioid receptor antagonist) was purchased from 
Bristol-Myers Squibb and administered as an oral tablet with water. Oral naltrexone is rapidly 
absorbed with peak plasma levels achieved after 1h (similar peak levels seen with IV 
administration) (Perez-Reyes and Wall 1981) and the active metabolite has a half-life of 12h, 
thus stable levels were achieved for the majority of the study period (Perez-Reyes and Wall 
1981; Wall, Brine, and Perez-Reyes 1981). Oral naltrexone 50mg was chosen as it has been 
shown in other human studies to cause a rise in LH at this dose (Ellingboe et al. 1982; 
Mendelson et al. 1986; Gindoff et al. 1988).  
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4.3.4 Study protocol 
 
Studies were conducted in our clinical investigation unit and participants were asked to refrain 
from strenuous exercise, sexual activity and alcohol consumption for the 24h period preceding 
each study visit. The subjects were blinded but not the investigators. Subjects arrived in the 
morning, were cannulated in both forearms and asked to lie supine.  
The participants attended 8 study visits at least a week apart and received a different treatment 
at each visit in random order. Figure 4.1 shows a summary of the protocol for each study visit 
and the treatments received (A-H). After 1h baseline blood sampling, participants received 
either a naltrexone 50mg tablet to swallow with water (NAL) or IV infusions of vehicle 
(gelofusin), 2.56nmol/kg/h NKB (NKB) or 0.1nmol/kg/h kisspeptin-54 (KP) for 8h alone or in 
combination as outlined further in Table 4.1, in random order. Ten minutely blood sampling 
was commenced and continued for 8h to measure gonadotrophins and testosterone.  
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Figure 4.1: Study protocol diagram.  
5 healthy male participants attended for 8 study visits at least a week apart and received a 
different treatment combination (A-H) in random order at each visit. After 1h baseline blood 
sampling every 15 minutes, the treatments were initiated at t=0h: naltrexone (single 50mg 
tablet) swallowed with water or 8h infusions of vehicle, 2.56nmol/kg/h NKB or 0.1nmol/kg/h 
kisspeptin-54 administered alone or in combinations (A-H below) in random order. Ten 
minutely blood sampling for gonadotrophins and testosterone was commenced from the start 
of the treatment at t=0h and continued for the duration of the 8h study period (upward black 
arrows), after which the infusions were stopped and the study ended.  
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Table 4.1: Treatments received.  
5 healthy male participants attended for 8 separate study visits at least a week apart and received 
treatments A-H in random order.  
Study 
Treatments 
Abbreviation Treatments 
A Vehicle Vehicle. IV infusion of gelofusin.   
B NAL Naltrexone only. A 50mg oral tablet of naltrexone 
swallowed with water.  
C NKB Neurokinin B only. IV infusion of 2.56nmol/kg/h NKB for 
8h. 
D KP Kisspeptin-54 only. IV infusion of 0.1nmol/kg/h kisspeptin-
54. 
E NAL+NKB Naltrexone plus NKB. 50mg oral tablet of naltrexone 
swallowed with water and simultaneously an IV infusion of 
2.56nmol/kg/h NKB was started and continued for 8h. 
F NAL+KP Naltrexone plus kisspeptin-54. 50mg oral tablet of 
naltrexone swallowed with water and simultaneously an IV 
infusion of 0.1nmol/kg/h kisspeptin-54 was started and 
continued for 8h. 
G NKB+KP NKB plus kisspeptin-54. Simultaneously, IV infusions of 
2.56nmol/kg/h NKB and 0.1nmol/kg/h kisspeptin-54 was 
started and continued for 8h. 
H NAL+NKB+KP Naltrexone, NKB and kisspeptin-54. 50mg oral tablet of 
naltrexone swallowed with water, whilst simultaneously IV 
infusions of 2.56nmol/kg/h NKB and 0.1nmol/kg/h 
kisspeptin-54 were started and continued for 8h. 
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4.3.5 Hormone analysis 
Samples were analysed for measurement of LH, FSH and testosterone using automated 
chemiluminescent immunoassays (Abbott Diagnostics, Maidenhead, UK). Reference ranges 
were as follows: LH 4-14 IU/L, FSH 1.5–8 IU/L and testosterone 10-28 nmol/L. The respective 
intra-assay and inter-assay coefficients of variation for each assay were: 4.1 and 3.4% (LH); 
4.1 and 3.5% (FSH); 4.2 and 2.8% (total testosterone). Analytical sensitivities were: 0.5 IU/L 
(LH), 0.05 IU/L (FSH) and 2 nmol/L (total testosterone). Limits of detectability for each assay 
were: LH, 0.07 IU/L; FSH, 0.05 IU/L; testosterone, 4.9nmol/L.  
 
4.3.6 Statistical methods 
Statistical analysis of the data was performed in collaboration with a statistician, P.B. For the 
purposes of analysis the eight treatment combinations were considered as eight different 
groups, rather than splitting into the three constituent peptides. Due to the relatively large 
number of combinations between pairs of groups, only comparisons with a p-value of <0.001 
were considered statistically significant.  
J.D.V. used a previously described, blinded deconvolution method with 93% sensitivity and 
specificity to analyse LH pulsatility (Veldhuis, Keenan, and Pincus 2008). 
 
4.3.6.1 LH, FSH and testosterone statistical analysis 
The analyses were performed by modelling the response of LH, FSH and testosterone over 
time for each treatment group. To allow for the repeat measurements over time, multilevel 
linear regression analysis was used. LH and FSH were found to have positively skewed 
distributions, and thus were analysed on the log scale. No data transformation was performed 
for testosterone, which was found to be approximately normally distributed.  
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4.3.6.2 LH pulse number, amplitude and ApEn analysis 
J.D.V calculated the LH pulse number, amplitude of each pulse and the approximate entropy 
(ApEn) for each study visit. ApEn is a measure of orderliness of LH pulses (the lower the 
number the more ordered the pulses in the time series with zero denoting perfect orderliness) 
(Veldhuis, Keenan, and Pincus 2008). To allow for repeat measurements, statistical analysis 
was performed using multilevel linear regression.   
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4.4. Results 
 
Table 2 shows the participant’s characteristics; mean age ± SEM 32.9 ± 3.9 yrs, mean BMI 
23.8 ± 1.0 and baseline LH, FSH and testosterone. No participants reported any adverse effects. 
 
Table 4.2: Participant’s demographics. 
Age, mean weight, BMI for the volunteers is shown below. Mean weight is an average of the 
weight from the 8 study visits. The age at the final study visit was recorded as the age below. 
The baseline LH, FSH and testosterone are an average of the baseline period from the vehicle 
study. Mean data is presented as mean +/- SEM. 
Participant Age Mean 
weight  
(kg) 
Height 
(m) 
Mean 
BMI 
Baseline 
LH 
(IU/L) 
Baseline 
FSH 
(IU/L) 
Baseline 
total 
testosterone 
(nmol/L) 
1 31.2 88.7 ± 
0.7 
1.85 25.9  3.8 2.9 14.9 
2 27.7 78.0 ± 
0.3 
1.73 26.1 4.1 1.6 22.9 
3 45.8 76.2 ± 
0.8 
1.85 22.3 2.3 2.7 14.3 
4 23.4 73.6 ± 
0.3 
1.76 23.8 2.1 1.4 18.7 
5 36.3 64.0 ± 
0.7 
1.75 20.9 2.9 2.9 20.5 
Mean  32.9 ± 
3.9 
76.1 ± 
4.0 
1.79 ± 
0.02 
23.8 ± 
1.0 
3.0 ± 1.9 2.3 ± 0.3 18.3 ± 1.6 
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4.4.1 LH results 
 
The results suggested a very distinct pattern dividing into two groups: those containing 
kisspeptin and those without. Treatment combinations containing kisspeptin (KP, NAL+KP, 
NKB+KP, NAL+NKB+KP) showed a highly significant rise in LH compared with vehicle 
(p<0.001) over time up to around 360 minutes, after which the values levelled off (Figure 4.2).  
In treatment combinations not containing kisspeptin there was a marginal rise in LH over time 
compared with vehicle but this was highly significant in the NAL (p<0.001 vs vehicle) and 
NAL+NKB (p<0.001 vs vehicle) group. The NKB group did not show a statistically significant 
rise in LH over time compared with vehicle (p=0.75). Figure 4.3 shows the individual LH 
results from participant 1-5 for the 8 treatment interventions.  
Given the sharp difference in LH depending on whether kisspeptin was given, the focus of 
further analysis was on the difference between the kisspeptin only group and the groups 
containing kisspeptin. There was no significant difference in LH with the NAL+KP (p=0.08) 
or NAL+NKB+KP (p=0.62) groups when compared with kisspeptin alone. However, there was 
significantly lower increases in LH with the NKB+KP group (p=0.006) compared with 
kisspeptin alone.  
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Figure 4.2: Effects of naltrexone, NKB and kisspeptin on serum LH.  
5 healthy male participants attended for 8 separate study visits at least a week apart and received 
vehicle, naltrexone, NKB and kisspeptin alone and in combination in random order. 1h baseline 
blood sampling was conducted prior to starting the treatment. Ten minutely blood sampling 
was continued from the start of the treatment for 8h to measure gonadotrophins and 
testosterone. The lines of best fit are presented below for each treatment.  
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Figure 4.3: Individual LH effects of naltrexone, NKB and kisspeptin alone and in 
combination.  
5 healthy male participants attended for 8 separate study visits at least a week apart and received 
vehicle, naltrexone (NAL), NKB and kisspeptin (KP) alone and in combination (NAL+NKB, 
NAL+KP, NKB+KP, NAL+NKB+KP) in random order. 1h baseline blood sampling was 
conducted prior to starting the treatment. Ten minutely blood sampling was continued from the 
start of the treatment for 8h to measure gonadotrophins. Individual LH results from participant 
1-5 are shown for the 8 different treatments are shown.  
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4.4.2 LH pulsatility 
  
4.4.2.1 Number of LH pulses 
Figure 4.4 shows a boxplot illustration of the number of LH pulses for each treatment group. 
All treatment combinations with the exception of NKB showed a significant increase in LH 
pulse number compared with vehicle (p<0.001 for all, except p=0.007 KP only and NKB 
p=0.55). There was no significant difference in comparing the kisspeptin containing groups 
with kisspeptin alone, NAL+KP (p=0.23), NKB+KP (p=0.04) and NAL+NKB+KP (p=0.37). 
As NAL alone significantly increased LH pulses (p<0.001 vs vehicle), a further comparison 
was made between NAL containing groups compared with NAL alone, however, there was no 
significant change in LH pulse number compared with NAL alone (p=0.99, NAL+NKB vs 
NAL; p=0.77, NAL+KP vs NAL; p=0.99, NAL+NKB+KP vs NAL).  
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Figure 4.4: Effects of naltrexone, NKB and kisspeptin on number of LH pulses.  
5 healthy male participants attended for 8 separate study visits at least a week apart and received 
vehicle, naltrexone, NKB and kisspeptin alone and in combination in random order. 1h baseline 
blood sampling was conducted prior to starting the treatment. Ten minutely blood sampling 
was continued from the start of the treatment for 8h to measure gonadotrophins. Deconvolution 
analysis was used to determine the number of LH pulses.  
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4.4.2.2 LH pulse amplitude 
Figure 4.5 shows the pulse amplitude for each treatment group. Specific comparisons between 
each group and vehicle were examined and showed that only the LH pulse amplitude in the 
NAL+KP group increased significantly compared with vehicle (p=0.001).  
 
Figure 4.5: Effects of naltrexone, NKB and kisspeptin on LH pulse amplitude.  
5 healthy male participants attended for 8 separate study visits at least a week apart and received 
vehicle, naltrexone, NKB and kisspeptin alone and in combination in random order. 1h baseline 
blood sampling was conducted prior to starting the treatment. Ten minutely blood sampling 
was continued from the start of the treatment for 8h to measure gonadotrophins. Deconvolution 
analysis was used to determine the LH pulses amplitude for each study.  
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4.4.2.3 Approximate entropy (ApEn) 
Figure 4.6 shows the ApEn for each treatment group. ApEn is a measure of orderliness of LH 
pulses (the lower the number the more ordered the pulses) (Veldhuis, Keenan, and Pincus 
2008). All kisspeptin containing groups had a trend towards lower ApEn values, indicating 
more ordered pulses, but this only reached the 1% significance level for the NAL+NKB+KP 
group (p<0.001, NAL+NKB+KP vs vehicle; p=0.02, KP vs vehicle; p=0.02, NAL+KP vs 
vehicle; p=0.04, NKB+KP vs vehicle). In contrast naltrexone containing groups not containing 
kisspeptin had significantly higher ApEn compared with vehicle (p<0.001, NAL vs vehicle; 
p<0.001, NAL+NKB vs vehicle), indicating less ordered pulses. NKB alone had no significant 
effects on ApEn (p=0.28, NKB vs vehicle). 
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Figure 4.6: Effects of naltrexone, NKB and kisspeptin on approximate entropy (ApEn). 
5 healthy male participants attended for 8 separate study visits at least a week apart and received 
vehicle, naltrexone, NKB and kisspeptin alone and in combination in random order. 1h baseline 
blood sampling was conducted prior to starting the treatment. Ten minutely blood sampling 
was continued from the start of the treatment for 8h to measure gonadotrophins. Deconvolution 
analysis was used to determine ApEn for each study. The ApEn is a measure of orderliness of 
LH pulses (the lower the number the more ordered the pulses in the time series).  
 
 
 
 
  
0 .2 .4 .6 .8
ApEn
NAL+NKB+KP
NKB+KP
NAL+KP
NAL+NKB
KP
NKB
NAL
Vehicle
 
 
167 
 
4.4.3 FSH results 
Similar to the LH results, any group containing kisspeptin (KP, NAL+KP, NKB+KP, 
NAL+NKB+KP) resulted in a highly significant rise in FSH compared with vehicle (p<0.001) 
(Figure 4.7). In the non-kisspeptin containing groups, only NAL+NKB showed a significant 
rise in FSH compared with vehicle; the NAL alone group showed a trend towards a rise in FSH 
but this did not reach the 1% significance level  (p=0.002, NAL+NKB vs vehicle; p=0.03, NAL 
vs vehicle).   NKB alone had no significant effects on FSH release (p=0.99, NKB vs vehicle).   
Figure 4.8 shows the individual FSH results from participant 1-5 for the 8 treatment 
interventions. 
Specific comparisons between the kisspeptin containing groups showed no significant 
difference with NAL+KP (p=0.44) or NAL+NKB+KP (p=0.62) compared with kisspeptin 
alone. However, similarly to LH, there was significantly lower increases in FSH with the 
NKB+KP group compared with kisspeptin alone (p=0.003).  
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Figure 4.7: Effects of naltrexone, NKB and kisspeptin on serum FSH.  
5 healthy male participants attended for 8 separate study visits at least a week apart and received 
vehicle, naltrexone, NKB and kisspeptin alone and in combination in random order. 1h baseline 
blood sampling was conducted prior to starting the treatment. Ten minutely blood sampling 
was continued from the start of the treatment for 8h to measure gonadotrophins and 
testosterone. The lines of best fit are presented below for each treatment. 
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Figure 4.8: Individual FSH effects of naltrexone, NKB and kisspeptin alone and in 
combination.  
5 healthy male participants attended for 8 separate study visits at least a week apart and received 
vehicle, naltrexone (NAL), NKB and kisspeptin (KP) alone and in combination (NAL+NKB, 
NAL+KP, NKB+KP, NAL+NKB+KP) in random order. 1h baseline blood sampling was 
conducted prior to starting the treatment. Ten minutely blood sampling was continued from the 
start of the treatment for 8h to measure gonadotrophins. Individual LH results from participant 
1-5 are shown for the 8 different treatments are shown.  
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4.4.4 Testosterone  
The effects on testosterone were less consistent than the gonadotrophins as shown in Figure 
4.9 and the individual testosterone results from participants 1-5 for the 8 interventions is shown 
in  Figure 4.10.  
Some groups showed a significant rise in testosterone compared with vehicle (p<0.001), NAL, 
KP and NAL+KP. However, some groups did not reach the 1% significance level but were 
significant at the 5% level (p=0.01, NAL+NKB vs vehicle; p=0.01, NKB+KP vs vehicle). No 
significant difference was seen between vehicle and NKB alone (p=0.35) and NAL+NKB+KP 
(p=0.23) groups. A higher testosterone was seen in the NAL+KP group compared with KP 
only (p=0.02), but no difference was seen between NKB+KP and KP only (p=0.08).  
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Figure 4.9: Effects of naltrexone, NKB and kisspeptin on serum testosterone.  
5 healthy male participants attended for 8 separate study visits at least a week apart and received 
vehicle, naltrexone, NKB and kisspeptin alone and in combination in random order. 1h baseline 
blood sampling was conducted prior to starting the treatment. Ten minutely blood sampling 
was continued from the start of the treatment for 8h to measure gonadotrophins and 
testosterone. The lines of best fit are presented below for each treatment. 
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Participant 4 
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Figure 4.10: Individual testosterone effects of naltrexone, NKB and kisspeptin alone and 
in combination.  
5 healthy male participants attended for 8 separate study visits at least a week apart and received 
vehicle, naltrexone (NAL), NKB and kisspeptin (KP) alone and in combination (NAL+NKB, 
NAL+KP, NKB+KP, NAL+NKB+KP) in random order. 1h baseline blood sampling was 
conducted prior to starting the treatment. Ten minutely blood sampling was continued from the 
start of the treatment for 8h to measure gonadotrophins. Individual LH results from participant 
1-5 are shown for the 8 different treatments are shown.  
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4.5 Discussion  
I investigated the KNDy hypothesis in humans by co-administering kisspeptin, NKB and an 
opioid receptor antagonist, naltrexone and evaluated their combined effects on gonadotrophin 
release and LH pulsatility in healthy male volunteers.  
Kisspeptin and naltrexone when administered alone increased LH secretion and LH pulsatility 
in keeping with previous studies (Ellingboe et al. 1982; Mendelson et al. 1986; Gindoff et al. 
1988; Dhillo et al. 2005). Kisspeptin is a potent stimulator of LH (via GnRH secretion) and all 
kisspeptin containing groups showed a substantial rise in LH. Naltrexone acting via opioid 
receptor inhibition also increased LH but to a lesser degree when compared to the effects of 
kisspeptin.  
Although both kisspeptin and naltrexone administered alone increased LH, their combined 
administration did not significantly increase LH secretion or LH pulsatility above that of 
kisspeptin alone. It is possible that kisspeptin alone had maximally stimulated LH release and 
hence no further increase occurred with co-administration of NAL+KP. However, only the 
NAL+KP group caused a significant rise in LH pulse amplitude, implicating opioid inhibition 
in limiting the kisspeptin induced rise in LH pulse amplitude.  Thus, NAL+KP may provide a 
therapeutic advantage over kisspeptin alone by stimulating robustly not only LH secretion and 
LH pulse frequency but also LH pulse amplitude.   
NKB did not significantly affect LH secretion or LH pulsatility when given in isolation, in 
keeping with our previous studies in healthy men and women (Jayasena, Comninos, De Silva, 
et al. 2014; Jayasena et al. 2015). Animal studies have previously shown that pre-treatment 
with a KOR antagonist unmasked the LH effects of senktide (NK3R agonist) (Grachev, Li, 
Kinsey-Jones, et al. 2012; Kinsey-Jones et al. 2012). In my study, there were no effects of co-
administration of an opioid antagonist with NKB above that of naltrexone alone. 
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The data from volunteers who received combined NKB+KP revealed a novel interaction 
between NKB and KP in humans. There were significantly lower increases in LH when 
volunteers were co-administered NKB+KP compared with kisspeptin treatment alone. This 
suggests that co-administration of NKB limited the ability of kisspeptin to stimulate a rise in 
LH. Similar to the LH results, there were significantly lower increases in FSH when volunteers 
were co-administered NKB+KP compared with kisspeptin treatment alone. Therefore, my 
results strongly suggest that in healthy male volunteers NKB administration reduces the ability 
of exogenous kisspeptin to stimulate gonadotrophin release in healthy male volunteers.  
It is interesting to speculate about the mechanism by which co-administration of NKB may 
have limited the ability of kisspeptin to stimulate a rise in LH in this human study. It is 
obviously not possible to determine changes in hypothalamic expression of neuropeptides 
following acute hormone infusion in humans. However, studies in rats show that intra-ARC 
administration of senktide to ovariectomised and oestradiol treated rats resulted in a reduction 
in GnRH1 and KISS1R mRNA expression in the medial POA (Grachev, Li, Kinsey-Jones, et 
al. 2012). This suggests that ARC NKB may suppress GnRH secretion directly by reducing 
GnRH transcription but also indirectly by reducing KISS1R (Grachev, Li, Kinsey-Jones, et al. 
2012). Therefore, one could tentatively propose a mechanism in which NKB in the presence 
of an abundance of kisspeptin acts to inhibit GnRH secretion by affecting GnRH and KISS1R 
transcription to reduce the actions of kisspeptin on gonadotrophin release.  
NKB and kisspeptin have never been co-infused in humans previously and relatively few 
animal studies have investigated the effects of peripheral co-administration of NKB+KP. One 
previous study in male mice showed that intraperitoneal co-administration of NKB+KP 
resulted in an approximately 20% lower rise in LH compared to when intraperitoneal KP was 
administered alone (Corander et al. 2010). Consistent with this in the same study the authors 
investigated the interaction between NKB+KP in hypothalamic explants. They showed that 
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NKB caused no increase in GnRH whilst kisspeptin increased GnRH; however, co-
administration of NKB+KP resulted in no increase in GnRH above basal state (Corander et al. 
2010), indicating that NKB inhibited the kisspeptin induced rise in GnRH. This is similar to 
our findings where co-administration of NKB+KP led to a lower rise of LH and FSH when 
compared with kisspeptin administration alone.  
Ramaswamy et al, investigated the combined effects of senktide (a NK3R agonist) and 
kisspeptin in GnRH primed juvenile rhesus monkeys and showed that a continuous IV infusion 
of senktide or vehicle for 48h followed by IV kisspeptin-10 resulted in a similar rise in LH 
(Ramaswamy, Seminara, and Plant 2011). Thereby, indicating that senktide did not affect the 
rise in gonadotrophins with kisspeptin administration. However, this protocol was different to 
my study as a 48h infusion of high dose senktide was administered to cause NK3R 
desensitisation prior to kisspeptin treatment unlike in our study where NKB+KP were co-
administered acutely over an 8h study period.  
Another important consideration is sex steroid negative feedback and whether this could have 
influenced our results. KNDy neurons in the ARC mediate sex steroid negative feedback 
effects on GnRH and subsequently gonadotrophin secretion (Smith, Cunningham, et al. 2005; 
Smith, Clifton, and Steiner 2006). In the current study, testosterone increased in most 
kisspeptin and naltrexone containing groups (at the 5% significance level), however, there was 
no significant difference in testosterone between the NKB+KP and KP alone group (p=0.08), 
therefore, the important differences seen in gonadotrophins between these groups cannot be 
explained by sex steroid negative feedback effects as both groups had similar levels.   
In this study we were also able to investigate the orderliness of the LH pulses (ApEn) and found 
that all kisspeptin containing groups had a trend towards more ordered pulses (lower ApEn 
values) although this only reached the 1% significance level for the NAL+NKB+KP group. 
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Interestingly, the remaining two naltrexone containing groups which did not contain kisspeptin 
(NAL and NAL+NKB) caused significantly disordered pulses compared with vehicle (higher 
ApEn). This suggests that kisspeptin administration results in more ordered pulses whereas 
opioid blockade results in more disordered pulses. In addition, kisspeptin may have a more 
dominant role in determining the orderliness of LH pulses as when kisspeptin is co-
administered with naltrexone the effects are to produce more ordered pulses (and the ability of 
naltrexone to generate less ordered LH pulses is not observed). 
My data reveals interesting and novel interactions following co-administration of kisspeptin, 
NKB and naltrexone in healthy men. Many animal studies testing the KNDy hypothesis have 
used ICV administration of peptides directly into the central nervous system, however, this is 
obviously not possible in humans and we have used peripheral administration of peptides which 
may not have full access to the central nervous system, although the ARC is close to areas with 
incomplete blood brain barrier, so it is reassuring that kisspeptin and naltrexone were able to 
potently stimulate LH pulsatility and gonadotrophin release.   
In this study, there has been cautious interpretation of the results by using a 1% significance 
level (rather than the traditional 5% significance level) to define statistical significance. This 
was used on the advice the statistician (P.B.) in order to account for the relatively large number 
of combinations between pairs of groups. A limitation of this approach is that subtle 
interactions may have not been identified. However, the advantage of this approach is that the 
statistically significant findings presented in this study are robust.  
 
4.6 Conclusions 
I have shown for the first time in humans some important interactions of KNDy signalling in 
regulating GnRH release and pulsatility (using LH as a surrogate marker). This has important 
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implications not only for improving our understanding of GnRH pulse generation in humans 
but also in optimising novel hormonal therapeutic agents to treat reproductive disorders. 
Kisspeptin and naltrexone in combination confer the greater output of gonadotrophins, LH 
pulsatility and LH pulse amplitude and therefore, could offer an advantage over kisspeptin 
alone.  
4.7 Future work and therapeutic implications. 
This research has identified important interactions between KNDy neuropeptides in humans 
and will form the basis of future studies.  Several questions have been raised from this research 
including why NKB alone has no effect but NKB+KP resulted in a lower rise of 
gonadotrophins. NKB administration is not straightforward in humans as doses above those 
administered here produce flushing although short lived (Jayasena et al. 2015). Animal studies 
may shed further light on this interaction especially in view of the ability to administer these 
peptides centrally.  
Further human studies could be directed towards reviewing a dosing range for NKB+KP at 
which this reduction in gonadotrophins occurs, as it may be a result of tachyphylaxis, which 
would further add to our understanding of KNDy interactions in regulating GnRH secretion. 
Also the interaction of dynorphin needs further investigation. There are only few KOR on 
GnRH and KNDy neurons and therefore, it is important to decipher how it acts to inhibit GnRH 
secretion by identifying these unknown intermediary neurons.   
Therapeutically, from this study the optimum gonadotrophin rise as well as LH pulsatility and 
amplitude was with NAL+KP, thus humans studies in the future could involve establishing a 
dosing range for this combination and also whether kisspeptin administered as a pump with 
naltrexone orally could be a viable therapeutic option in the future. 
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CHAPTER 5: GENERAL DISCUSSION   
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5.1 General discussion 
The incidence of infertility is growing globally, attributed to improvements in diagnostics and 
familiarity with treatments such as IVF, but also in part to couples seeking fertility at an older 
age (Mascarenhas et al. 2012). More couples are undergoing IVF treatment however, the 
success rate has remained similar for many years on average 20% (HFEA 2013). The failure 
to reproduce can cause devastating social and psychological consequences and therefore, there 
is a pressing need to develop newer treatments.  
There are many causes of infertility affecting both males and females, however, in 25% of 
cases no cause can be found (HFEA 2013). Hormonal treatments such as gonadotrophins and 
GnRH are only suitable for a proportion of patients with specific causes of infertility. However, 
hormonal treatments can also be used to induce puberty in those with delayed puberty. GnRH 
treatment requires both functional pituitary gonadotrophs and gonads in order to restore 
gonadotrophin and sex steroid levels to normal and initiate spermatogenesis and ovarian 
follicular growth. Gonadotrophin treatments act directly on the gonads to stimulate them. 
Although GnRH administration is possible, it is not widely available in the UK. It must be 
administered in regular pulses and thus has not been pursued. Gonadotrophins on the other 
hand are much easier to administer as SC injections. Although testosterone and oestradiol could 
also be replaced, however would not promote spermatogenesis or ovarian follicular growth as 
FSH is required for this.  
Kisspeptin offers another viable treatment option for certain reproductive disorders in patients 
with functional GnRH neuron circuitry and gonads that are able to respond once properly 
stimulated by gonadotrophins. I have shown from my research that both isoforms of kisspeptin 
which have been commonly used in clinical studies have the same potency when administered 
IV and thus either could be used as therapy. Kisspeptin-10 is a smaller peptide and therefore, 
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less expensive to manufacture therefore, this isoform may be most cost effective to administer 
IV in the future. However, IV administration is not a feasible long term treatment and more 
studies are needed to compare kisspeptin-54 and kisspeptin-10 administered SC in the same 
individuals. Patients with infertility are very sensitive to kisspeptin (Jayasena et al. 2009) and 
therefore, perhaps kisspeptin-10 administered to these patients SC will be effective at 
stimulating gonadotrophins.  
We have also shown that kisspeptin is less potent than GnRH, which is physiologically very 
interesting and may confer and advantage to kisspeptin treatment. One complication of the 
current treatments is excess stimulation of the gonads. As kisspeptin treatment is limited by the 
patient’s own GnRH reserve it prevents over stimulation which is an advantage particularly in 
IVF treatment. Recently we have conducted two clinical IVF trials where kisspeptin was 
substituted for hCG (LH like action) and this resulted in no cases of ovarian hyper stimulation 
syndrome (OHSS)  and even in women at high risk of OHSS with polycystic ovarian syndrome 
no severe cases of OHSS were seen (Jayasena, Abbara, Comninos, et al. 2014; Abbara et al. 
2015).  
SC administration of kisspeptin-54 stimulates gonadotropins in men and women as well as 
those with reproductive disorders such as HA. SC kisspeptin was also used in the IVF trials 
and therefore, is a viable route of administration, which also can be managed at home by the 
patient. The dosing and frequency of injections would need further investigation, however, 
newer methods of administering peptides are emerging and the pump device is a novel route. 
Patients may prefer a pump device to twice weekly or daily injections.  
Hormonal treatments to stimulate spermatogenesis can take up to a year or longer to produce 
the quality sperm needed for fertility, although with better surgical strategies now small 
numbers of sperm can be retrieved from the testes and directly injected into the ovum.  
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Intermittent gonadotrophin replacement regimens result in peaks and troughs of gonadotrophin 
levels.  Therefore, continuous or intermittent kisspeptin administration at low doses via a pump 
device could eliminate the peaks and troughs in gonadotrophin levels more in keeping with 
physiological levels, which could then lead to more sustained effects and perhaps even quicker 
actions on spermatogenesis.  
My research has shown that SC infusions of kisspeptin produced significant elevations in 
gonadotrophins at the two higher doses tested and therefore, pump administration is a viable 
option of administration. More work is needed to investigate the use of a kisspeptin 
administered via a SC pump device and whether the gonadotrophin response could be sustained 
and in male patients with infertility whether spermatogenesis could be restored.  
My research has also shown that baseline oestradiol correlates with LH response to kisspeptin. 
This is an extremely important correlation as women with infertility invariably have low 
oestradiol levels and therefore, in the future sex steroids may need to be improved in order to 
gain the optimum benefit from kisspeptin administration. Although it is not known at what 
level of oestradiol the best response to kisspeptin is achieved. By conducting further studies in 
healthy women replaced with different levels of oestradiol a dosing range could be established.  
The KNDy hypothesis is of great research interest at present however, these interactions have 
not been directly assessed in humans previously. By co-administering kisspeptin, NKB and an 
opioid receptor antagonist, naltrexone, I have been able to highlight some interesting 
interactions. I was only able to administer these agents peripherally and therefore, they may 
have not been able to act centrally. However, both kisspeptin and naltrexone caused a rise in 
gonadotrophins. The actions of NKB administered peripherally are unclear, however, on 
combination with kisspeptin resulted in a reduction of gonadotrophins compared with 
kisspeptin alone. This is a profound interaction and therefore, NKB must be having an effect 
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even though it was administered peripherally. Another study in monkeys administered NKB 
peripherally and showed NKB did affect gonadotrophin secretion although this was in pre-
pubertal animals where studies have shown consistent effects with NKB (Ramaswamy et al. 
2010).  
I speculate that in adults, NKB agonism may be already maximally active and therefore has 
little capacity for exogenous stimulation, however, on administering high doses of exogenous 
kisspeptin, NKB acts to inhibit further GnRH secretion, possibly through opioid inhibition.  
Interestingly, perhaps when kisspeptin is administered alone, endogenous NKB is also limiting 
the rise in kisspeptin and therefore, future use of NK3R antagonists in combination with 
kisspeptin will be interesting to see if this is the case.  
The combination of NAL+KP produced the greatest rise in gonadotrophins as well as LH 
pulsatility and LH pulse amplitude, suggesting that this would be the treatment combination of 
choice to maximise the KNDy interactions on gonadotrophin secretion. Future studies could 
investigate how NAL with SC kisspeptin-54 would impact on gonadotrophin secretion in 
patients with infertility.  
 
5.2 Conclusion  
Kisspeptin-54 administered via a SC infusion (like a pump device) may be a viable alternative 
to current hormonal treatments for infertility. The manipulation of KNDy peptides has shown 
important interactions between them, in particular between kisspeptin and NKB. Kisspeptin 
and naltrexone in combination not only increases gonadotrophins but significantly affects LH 
pulsatility, therefore, could also be potentially used as therapy for reproductive disorders.  
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5.3 Future work 
Building on my research work, we have now received ethical approval to administer kisspeptin 
via a pump device and future work will investigate its effects in patients with reproductive 
disorders to establish whether this confers an advantage over current therapies.  
Further manipulation of KNDy neuropeptides is planned to establish the dosing range at which 
the combination of naltrexone and kisspeptin provide the optimum gonadotrophin response.  
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APPENDICES 
 
 1: PRINCIPLES OF RADIOIMMUNOASSAY  
Radioimmunoassay (RIA) is a technique used to measure the concentration of an unknown 
quantity of peptide (in this case kisspeptin) in plasma. 
Unlabeled antigen on the peptide in the plasma sample and radiolabeled (using I-125) antigen 
compete for an antibody binding site: 
 Ag* + Ab + Ag ↔ Ag*Ab + AgAb 
Ag*= radiolabeled antigen 
Ag= unlabeled antigen (from plasma sample) 
Ab= antibody 
The specificity of the antibody is dependent on its ability to recognise structural features of the 
antigen on the peptide and bind to it. The antibody for kisspeptin in my assay was produced by 
immunising rabbits with kisspeptin.  
In the RIA both the radiolabeled peptide and antibody are at specific, constant concentrations, 
with the concentration of antibody being limiting. The known amount of radiolabeled antigen 
will compete with unlabeled antigen (in the plasma sample) for antibody binding, with the 
amount of radiolabeled antigen bound to the antibody being inversely proportional to the 
amount of unlabeled antigen in the plasma sample being assayed. 
A ‘standard curve’ is produced at the same time as assay of samples. This ‘standard curve’ uses 
known concentrations of pure peptide to calculate the percentage of labelled peptide bound for 
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each concentration of unlabeled pure peptide. Separation of the unbound radiolabeled antigen 
from the radiolabeled antigen-antibody complex and counting the proportion of radiolabel 
present in the two fractions enables direct measurement of the amount of unlabeled antigen that 
has bound to the antibody. By directly referencing the ‘standard curve’, the unknown 
concentrations of peptide in the plasma sample can be deduced by interpolation. 
To distinguish antibody-bound antigen from free antigen, and to determine the distribution of 
radioactive antigen between the two fractions, the method of charcoal separation is used as 
detailed below. 
Dextran is added to a charcoal suspension to block the larger holes in porous charcoal. The 
suspension is then added to the RIA tubes, where it traps the free (unbound) radiolabeled 
antigen. The tubes are then centrifuged and the supernatant (containing antibody-antigen 
complex) and charcoal pellet (free radiolabeled antigen) are separated by aspiration with a 
pipette. The bound and free labels are counted in a gamma counter.  
All samples are added in duplicate. ‘Non-specific binding’ tubes (without antibody) are added 
at the beginning of the assay rack. Tubes containing half and twice the standard volume of 
added labelled antigen are also included so as to confirm label quality. Tubes with no plasma 
sample (‘zero’ tubes) are placed at regular intervals throughout the assay, and ‘standard curves’ 
(containing known quantities of unlabeled antigen) are placed at the beginning and end of each 
assay, in order to calibrate the assay. The analytical sensitivity of the assay is determined by 
the smallest change in hormone concentration that can be reliably detected. This is governed 
by the steepness of the standard curve, and the error of a known value on the curve. The 
analytical sensitivity is calculated as two standard deviations from the mean concentration of 
antigen measured in the zero standards (which contain no unlabeled peptide).  
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